


























	•	 The	 sequencing	 experiments	 presented	 in	 Chapter	 6	 were	 performed	 at	 Source	 Biosciences,	
Nottingham.		Bioinformatics	analyses	of	these	datasets	were	performed	by	Dr	Ai	Nagano.		
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The	 PI3K/mTOR	 signalling	 pathway	 plays	 a	major	 role	 in	 biology	 and	 disease.	 Therefore,	 effective	
inhibitors	that	target	proteins	of	this	pathway	have	been	developed.	However,	acquired	resistance	of	
cancer	cells	is	a	prevalent	phenomenon	that	limits	the	durable	response	of	these	compounds.	
				It	 is	 becoming	 apparent	 that	 experimental	 approaches	 for	 comprehensive	 biochemical	 analysis	
contribute	to	understand	the	complex	mechanisms	that	confer	drug	resistance,	and	advances	in	large-
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PI3K/AKT/mTOR	 is	 a	 signalling	 pathway	 that	 regulates	 multiple	 biological	 processes,	 such	 as	
proliferation,	migration,	vesicular	transport,	and	metabolism.	The	major	biological	functions	of	this	
signalling	axis	occur	because	of	the	lipid	kinase	activity	of	phosphoinositide	3-kinases	(PI3Ks),	which	
mediates	 the	membrane	 distribution	 of	 phosphatidylinositol	 lipids	 to	which	 downstream	 proteins	
bind	specifically	and	get	activated.	







Figure	 1.1	 Synthesis	 of	 phosphoinositides	 from	 phosphatidylinositol.	Phosphatidylinositol	 is	
a	glycerophospholipid	 that	 has	 a	 glycerol	backbone	 and	 a	 phosphate	 group	 binding	 two	 fatty	 acid	tails.	
Metabolic	reactions	that	lead	to	the	synthesis	of	phosphatidylinositol	and	seven	phosphoinositides	are	shown	
in	 this	 figure.	 	 Seven	 phosphoinositides	 are	 synthesised	 and	 have	 important	 signalling	 roles	 in	 different	
subcellular	compartments.	Reactions	catalysed	by	the	different	classes	of	PI3K	are	shown.	Reactions	pointed	
out	with	dashed	arrows	have	been	shown	 in	vitro,	but	their	relevance	 in	vivo	remains	unclear.	CDP,	cytosine	
diphosphate;	 CMP,	 cytosine	 monophosphate;	 DAG,	 diacylglycerol;	 IP3,	 inositol	 phosphate;	 PI,	
phosphatidylinositol;	 PI3K,	 phosphoinositide	 3-kinase;	 PI4K,	 phosphoinositide	 4-kinase;	 PIPK	 I/II,	
































or	 Ras	 proteins,	 class	 I	 PI3Ks	 are	 recruited	 to	 the	 plasma	 membrane,	 where	 they	 phosphorylate	
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plants,	 and	 yeast	 [3].	 Vps34	 constitutes	 a	 heterodimer	 with	 its	 regulatory	 membrane-associated	

















the	 dimerisation	 and	 auto-phosphorylation	 of	 particular	 intracellular	 tyrosine	residues	 of	 the	














transactivate	 RTKs,	 and	 this	 cross-talk	 between	 receptors	 integrates	 signalling	 that	 can	modulate	
PI3K	activity	[20].		
				Finally,	 several	 class	 I	 PI3K	 isoforms	 can	be	activated	by	Ras	 family	of	GTPases	 (including	HRAS,	
NRAS,	and	KRAS),	whose	genes	are	recurrently	mutated	in	different	human	cancers	types	[21].	Active,	
GTP-bounded		Ras	mediates	the	activation	of		p110a/γ/d	via	the	small	domain	Ras-binding	domain	
present	 in	 the	kinase	 [3].	 In	vivo	 studies	suggest	 that	selective	regulation	of	Ras	on	different	p110	





polyphosphate	 4-phosphatase	 (INPP4B)	 [23]	 (Fig	 1.2).	 As	 mentioned	 previously,	 PTEN	 hydrolyses	
PI(3,4,5)P3	 to	 PI(3,4)P2	 [5],	 and	 its	 activity	 influences	 cell	 survival,	 metabolism	 and	 motility	 [24].	
Interestingly,	PTEN	activity	 is	controlled	by	the	PI3K	pathway,	as	demonstrated	by	decreased	PTEN	

































and	 implicated	 in	multiple	cellular	roles	 including	survival,	metabolism,	growth	and	migration	[31].	
There	are	three	highly	conserved	AKT	isoforms,	namely	AKT1/2/3:	AKT1/2	are	ubiquitously	expressed,	
whereas	the	expression	of	the	AKT3	enzyme	is	restricted	to	certain	tissues	(e.g.	brain).	AKT	activity	is	



























sites	 can	 stimulate	 or	 hinder	 its	 activity,	 and	 the	 overall	 AKT’s	 output	 is	 believed	 to	 support	 cell	
viability.	 
				AKT	 negatively	 regulates	 proteins	 involved	 in	 apoptosis.	 For	 instance,	 AKT-mediated	
phosphorylation	of	the	BCL-2	protein	family	member	BAD	at	Ser136	leads	to	its	cytosolic	capture	and	




of	 and	 translocation	 into	 the	 nucleus	 of	 MDM2,	 a	 negative	 regulator	 of	 p53	 [35].	 In	 addition,	













whereas	 mTORC2	 comprises	 mTOR,	 mSIN1,	 rictor,	 protor	 and	 mLST8.	 These	 two	 complexes	
coordinate	different	activating	upstream	signals	 (including	growth	factors	and	nutrients)	to	control	
key	biological	processes,	such	as	cell	survival,	metabolism	and	migration.	mTORC1’s	biology	is	better	
understood	 due	 to	 studies	 with	 rapamycin	 and	 its	 derivatives	 (a	 macrolide	 produced	 by	
the	bacterium	Streptomyces	 hygroscopicus).	 These	 compounds	 physically	 interact	 with	 the	 FK506-
binding	 protein	 of	 12	 kDa	 (FKBP12)	 constituting	 the	 complex	 FKBP12-rapamycin	 that	 impedes	




inhibition	 of	 mTORC2	 has	 been	 observed	 in	 some	 cells	 chronically	 exposed	 to	 rapamycin	 [42].	
Although	the	mechanisms	that	lead	to	mTORC2’s	activation	are	not	as	well	understood,	some	studies	
involving	the	genetic	inhibition	of	mTORC2	suggested	that	mTORC2	is	a	growth-factor-sensitive	but	





conditions,	 mTORC1	 is	 activated	 to	 drive	 the	 anabolic	 conversion	 of	 nutrients	 and	 energy	 into	
macromolecules	— namely	proteins,	lipids,	and	nucleic	acids	[44].	Active	mTORC1	promotes	protein	
synthesis	both	through	the	specific	5ʹ-cap-dependent	mRNA	translation	and	by	enhancing	the	protein	
synthesis	 machinery	 capacity.	 Thus,	 mTORC1	 specifically	 phosphorylates	 two	 downstream	 target	
regulators	 of	 translation:	 eIF4E	 binding	 proteins	 1	 and	 2	 (4E-BP1/2)	 at	 Thr37	 and	 Thr46	 and	 the	
ribosomal	S6	kinases	1	and	2	(RPS6KB1/2)	at	Ser394	and	Thr412	[45,	46].	On	one	hand,	phosphorylated	
4E-BPs	are	released	from	eIF4E,	allowing	the	assembly	of	the	complete	translation	initiation	complex.	
On	 the	 other	 hand,	 activated	 RPS6KBs	 phosphorylate	 several	 proteins,	 including	 the	 RPS6	 (40S	
ribosomal	protein	S6	—	this	being	an	activating	phosphorylation),	eEF2K	(Eukaryotic	elongation	factor	
2	kinase	—		this	being	an	inhibitory	phosphorylation)	and	PDCD4	(programmed	cell	death	4	protein	—	
this	 being	 an	 inhibitory	 phosphorylation)	 to	 enhance	 protein	 translation	 efficiency	 [45].	 mTORC1	
promotes	the	protein	synthesis	on	a	global	scale	by	facilitating	ribosomal	RNA	transcription	through	
the	 direct	 phosphorylation	 and	 deactivation	 of	 MAF1,	a	 main	 repressor	 of	 RNA	 polymerase	 III	
transcription	[47].	
				mTORC1	 also	 stimulates	 nucleotide	 synthesis	 to	 regulate	 cell	 proliferation.	 For	 example,	 active	
RPS6KB1	 phosphorylates	 and	 activates	 carbamoyl-phosphate	 synthase	 2	 (CAD),	 the	 rate-limiting	
enzyme	for	de	novo	synthesis	of	pyrimidines,	increasing	the	nucleotides	pool	for	DNA/RNA	synthesis,	
as	 observed	 in	 in	 vitro	 and	 in	 vivo	 systems	 [48,	 49].	mTORC1’s	 activity	 can	 stimulate	 glycolysis	 to	
generate	biosynthetic	precursors	and	the	production	of	 the	redox	capacity	–	 in	 form	of	NAPDH	—	
required	for	cellular	anabolic	processes	and	to	maintain	the	de	novo	lipids	and	nucleic	acids	synthesis.	
One	of	the	mechanism	used	by	mTORC1	to	regulate	glycolysis	 is	by	driving	the	synthesis	of	HIF-1α	







known	 to	 activate	 the	 expression	 of	 over	 30	 genes	 for	 enzymes	 that	 regulate	 the	 de	 novo	 lipid	





SBREP,	 and	 thus	mTORC1	 coordinates	 the	 demand	 of	NAPDH	—	obtained	 in	 the	 PPP	—	with	 the	
SREBPs	synthesis.		
				In	 addition	 to	 contributing	 to	 the	 production	 of	 cellular	 building	 blocks,	 mTORC1	 also	 inhibits	




the	 initial	 steps	 of	 autophagosome	 formation	 [56]	 ;	 and	 (ii)	 through	 the	 phosphorylation	 and	































that	 is	 dosage-	 and	 cellular	 compartment-dependent.	 Experiments	 have	 demonstrated	 that	 ROS	
inactivate	TSC2	by	direct	oxidation	of	its	cysteines,	contributing	to	mTORC1	activity	[70].	In	contrast,	
it	has	been	shown	that	peroxisome-located	TSC2	reduces	mTORC1	activity	in	response	to	ROS	[71],	





amino	acids	 is	mediated	by	an	additional	protein	complex,	nicknamed	the	 ragulator.	This	 complex	
comprises	a	class	of	G	proteins,	the	RagA-D	GTPases	and	five	regulatory	subunits	LAMTOR1–5	(late	
endosomal/lysosomal	 adaptor	 and	 MAPK	 and	 mTOR	 activator	 1).	 Ragulator	 subunits	 recruit	 Rag	
GTPases	to	the	 lysosomal	membrane,	where	the	complete	ragulator	complex	can	sense	the	amino	
acids	 levels	 and	 activate	 Rheb	 accordingly	 [74].	 Under	 energy	 depletion,	 the	 ATP-dependent	 TTT-

















phosphorylated	 Grb10	 and	 IRS-1	 (by	 p70S6K)	 that	 prevents	 growth	 factor-promoted	 mTORC2’s	 activity.	
GRB10	(Growth	Factor	Receptor	Bound	Protein	10);	Insulin	receptor	substrate	1	(IRS-1);	PKC	(protein	kinase	C);	
SGK1	(Serum/Glucocorticoid	 Regulated	 Kinase	 1);	 AMPK,	 AMP-activated	 protein	 kinase;	 TSC1/2,	 tuberous	
sclerosis	protein	1/2;	REDD1,	regulated	in	development	and	DNA	damage	responses	1;	HIF,	Hypoxia-inducible	
factor	1;	ATF4,	Activating	Transcription	Factor	4;	p38β,	mitogen-activated	protein	kinases	MAPK11;	PRAK,	p38-
regulated/activated	protein	kinase;	 TTT,	Tel2–Tti1–Tti2	 	 4E-BP1,	 eIF4E-binding	 protein-1;	 p70S6K,	 70	 kDa	















































































				mTORC2,	 on	 the	 other	 hand,	 is	 responsive	 to	 growth	 factor	 molecules,	 and	 phosphorylates	
hydrophobic	motif	sequences	of	the	 large	family	of	AGC	kinases	—		 including	AKT,	PKCα	and	SGK1	
[76].	 For	 example,	 AKT	 phosphorylation	 at	 Ser473	 by	 mTORC2	 enables	 its	 complete	 activation	




				The	 molecular	 mechanisms	 that	 trigger	 mTORC2’s	 activity	 are	 starting	 to	 be	 understood.	 A	
cofounding	 factor	 in	 the	 regulation	 of	 mTORC2	 is	 its	 cellular	 localisation.	 One	 mechanism	 that				
engages	mTORC2	activation	is	through	the	specific	interaction	of	PI(3,4,5)P3	with	the	PH	domain	of	
the	mSIN1	subunit;	this	interaction	releases	the	suppression	of	mSIN1	from	mTORC2’s	kinase	activity	
[79].	 Other	 studies	 indicated	 that	 activation	 of	mTORC2	 requires	 its	 physical	 association	with	 the	
ribosome;	when	located	in	that	organelle,	mTORC2	eases	the	stabilisation	of	nascent	AKT	proteins	by	
the	 co-translational	 phosphorylation	 of	 AKT	 at	 Thr450,	 preventing	 AKT	 ubiquitination	 [80].	 When	
mTORC2	 locates	 in	 a	 sub-compartment	of	 the	 endoplasmic	 reticulum	 and	 associates	 with	
mitochondria	 it	 activates	 AKT	 upon	 growth	 factor	 stimulation	 and	 decreases	 mitochondrial	
inner	membrane	 potential	 measured	 in	 vitro	 [81].	 mTORC2’s	 activity	 is	 further	 regulated	 by	
mechanisms	 upstream	 and	 downstream	 of	 PI3K	 signalling.	 For	 instance,	 mTORC1/S6K-mediated	
phosphorylation	of	 IRS-1	and	the	adaptor	protein	GRB10	blocks	the	 interaction	with	the	p85	PI3K-









kinase	 activity;	 (iii)	 loss	 of	 PI3K	 tumour	 suppressors	 (e.g.	 PTEN);	 (iv)	 over-activity	 of	 AKT	 (due	 to	
amplifications	of	AKT	 isoforms	or	activating	mutations	 in	AKT’s	PH	domains);	 (v)	over-activation	of	





phosphorylation	of	4E-BPs	and	p70S6K	or	activating	mutations	 in	V-ATPase);	 and	 (vi)	 activation	of	
mTORC2	(due	to	aberrant	EGFR	signalling	and	loss	of	PTEN).	







The	 adaptation	 of	 cellular	 metabolism	 supplies	 the	 macromolecules	 and	 cofactors	 required	 to	
maintain	the	high	rates	of	proliferation	of	cancer	cells	[86,	87].	Metabolic	networks	evolve	driven	by	
external	 and	 internal	 factors	 that	 select	 the	 malignant	 phenotype	 [88].	 Hence,	 during	 tumour	
progression,	 cancer	 cells	 are	 selected	 based	 on	 their	 capacity	 to	 use	 the	 scarce	 nutrients	 usually	
present	 in	 the	 tumour	microenvironment	 to	 produce	 biomass	 and	maintain	 cellular	 proliferation.	
Metabolic	remodelling	not	only	allows	cancer	cell	growth,	but	also	substantially	adapts	the	tumour	





flavin	 adenine	 dinucleotide	 (FADH2);	 those	 factors	 are	 shuttled	 to	 the	 mitochondria	 where	 they	
produce	 an	 electrochemical	 gradient	 that	 ultimately	 results	 in	 the	 production	 of	 ATP	 through	 the	
ATPase	complex.	Cancer	cells,	similarly	to	genetically	normal	proliferating	cells	[89]	and	cells	infected	
by	 some	 viruses	 [90],	 divert	 metabolic	 intermediates	 of	 the	 central	 carbon	 metabolism	 to	 the	
synthesis	of	diverse	biomolecules,	the	generation	of	sufficient	redox	potential	in	form	of	nicotinamide	
adenine	dinucleotide	phosphate	(NADPH),	and	the	production	of	lactic	acid	by	the	activity	of	lactate	







be	 enhanced	by	 an	 increase	 of	 the	 side-reaction	 from	 fructose-6-phosphate	 (F6P),	 the	 product	 of	
glycolysis-second	reaction.	As	an	example	of	this	metabolic	channelling	in	cancer	cells,	in	an	oncogenic	
mutant	KrasG12D	pancreatic	 cancer	mouse	model,	 the	biosynthesis	of	 ribose	 to	both	maintain	DNA	






of	 nucleotides,	 methyl	 donor	 groups	 and	 NADPH,	 and	 contributes	 to	 the	 TCA	 anaplerosis	 (i.e.	
replenishment	of	TCA	intermediates).	The	gene	that	encodes	for	the	first	committed	enzyme	of	the	
de	 novo	 serine	 biosynthesis,	 3-phosphoglycerate	 dehydrogenase	 (PHGDH),	 locates	 in	 the	
chromosome	 locus	1p12,	a	genetic	 region	 that	 is	 recurrently	amplified	 in	diverse	cancer	 subtypes,	






different	 tissues	 and	 their	 regulation	 depends	 on	 extracellular	 and	 intracellular	 stimuli	 [96].	 The	
expression	and	plasma	membrane	 translocation	of	 these	 transporters,	 as	previously	mentioned	 in	
Section	1.1.3,	can	be	mediated	by	the	activity	of	PI3K/AKT/mTOR	pathway	[97].	In	addition,	the	levels	









microenvironment.	 In	 addition,	 cancer	 cells	 increase	 the	 expression	of	metabolic	 enzymes	 such	 as	 LDH	 and	









































































insulating	 organ	 predominantly	 composed	 of	 adipocytes,	 where	 the	 up-regulation	 of	 the	
transporter	FABP4	(fatty-acid-binding	protein	4)	in	omental	and	ovarian	cancer	cells	facilitates	fatty	
acids	acquisition	of	the	latter	[102].	This	helps	to	compensate	the	deficit	of	certain	fatty	acid	species	
in	 ovarian	 cancer	 cells,	 such	 as	 unsaturated	 fatty	 acids,	 which	 synthesis	 is	 obviated	 in	 hypoxic	
conditions.			
				In	 addition	 to	enhanced	nutrient	acquisition,	 the	metabolic	 reprogramming	of	malignant	 cancer	





ketoglutarate	 into	 2-hydroxyglutarate	 (2-HG),	 instead	 of	 usual	 conversion	 isocitrate	 to	 α-
ketoglutarate.	In	patients	suffering	from	acute	myeloid	leukaemia	(AML),	mutations	in	IDH1/2	genes	






and	 the	 resulting	metabolites,	govern	 the	phenotypic	 characteristics	of	 cancer	 cells;	 the	 impact	of	
metabolic	modulators	on	cell	physiology	may	be	dictated	by	the	tumour	genotype	and	tissue	of	origin.	
For	example,	experiments	have	demonstrated	that	c-MYC	induces	diverse	metabolic	phenotypes	in	
murine	 lung	and	 liver	 tumours:	 lung	 tumours	 induced	by	 c-MYC	 tended	 to	 accumulate	 glutamine,	
whereas	 liver	 tumours	 induced	 by	c-MYC	 increased	 their	 lactate	 production	 [105].	 The	 genetic	









nutrients	 between	 non-malignant	 cells	 (e.g.	 omental	 adipocytes)	 and	malignant	 cancer	 cells	 (e.g.	
ovarian	metastatic	cells).	Another	example	of	metabolite	exchange	across	tumour	cells	is	the	lactate	
shuttle	 between	 catabolic	 stromal	 cells	 and	 anabolic	 malignant	 cancer	 cells	 [107].	 Although	 the	
mechanisms	for	cell-cell	communication	and	the	topological	features	of	metabolic	pathways	may	be	






(e.g.	monocarboxylate	 transporters	[MCTs]	 to	 control	 the	 flux	 of	monocarboxylates,	 such	 as	 lactic	




mMol/L	 [108].	 Lactate	 is	 transported	 through	 the	 plasma	 membrane	 via	 MCTs.	 MCTs	 family	 is	





function	 [109].	 Four	 members	 of	 the	 MCT	 family	 (MCT1-4)	 locate	 in	 the	 plasma	 membrane	 and	
perform	 a	 proton-mediated	 transport	 of	metabolites	 [109].	MCT1	 is	 expressed	 in	 the	majority	 of	
tissues	of	species	studied	and	participates	in	lactate	influx	and	efflux	[110].	MCT2	is	less	ubiquitously	
expressed	 and	 is	 thought	 to	 play	 key	 roles	 in	 neurons	 at	 the	 postsynaptic	 density	 [109].	 MCT3	



















						To	 deal	 with	 greater	 acid	 concentration,	 cells	 rely	 on	 the	 activity	 of	 acid-ejecting/converting	
proteins.	These	 include	Na+/H+	exchangers	 (NHE1,	also	known	as	SLC9A1),	Na+/HCO3−	(NBCn1,	also	
known	 as	 SLC4A7)	 and	 carbonic	 anhydrases	 (CAs)	 [113].	 Cells	 can	 also	 sense	 and	 respond	 to	
Lactate
















































ROS	products	 [118].	 	As	mentioned	 in	Section	1.1.5,	 the	 functional	effects	of	ROS	are	dosage-	and	
context-dependent.	 ROS	 are	 constantly	 created,	 transformed	 and	 eliminated	 by	 multiple	 cellular	






				ROS	attain	fundamental	 functions	 in	 living	organisms.	The	signalling	properties	of	ROS	were	first	
recognised	 in	 seminal	 experiments	 that	 demonstrated	 that	 ROS	 stimulation	 caused	 the	








interacting	partners	 [121,	 122].	 For	 example,	 the	 activity	 of	 PI3K/AKT/mTOR	pathway	 increases	 in	
response	to	ROS	due	to	the	inactivation	of	PTEN	upon	its	oxidation	at	Cys124,	a	residue	essential	for	
PTEN	 catalytic	 activity	 [123],	 and	 due	 to	 the	 inactivation	 of	 phosphatase	 2A	 (PP2A)	 and	 protein	
tyrosine	phosphatase	1B	(PTP1B)	upon	oxidation	of	cysteines	present	in	their	active	sites	[124].	
				Among	 the	 regulators	 of	 the	 expression	of	 antioxidant	 genes,	NRF2	 (nuclear	 factor	 erythroid	 2-
related	 factor	 2)	 is	 arguably	 the	 most	 important	 transcription	 factor	 involved	 in	 the	 control	 of	
transcription	of	many	of	 antioxidant	genes	 [125].	Under	unstressed	 conditions,	NFR2	 is	negatively	
regulated	via	its	binding	to	KEAP1	(Kelch	ECH	associating	protein	1),	an	adaptor	protein	that	targets	
NRF2	for	its	degradation	by	the	ubiquitin	proteome	system.	NRF2,	through	the	recognition	and	binding	
to	DNA	 antioxidant	 response	 elements	 (AREs),	 promotes	 the	 expression	 of	 over	 100	 genes	which	
protein	 products	 carry	 antioxidant	 function,	 including	 glutathione	 and	 catalase	 (see	 below).	 The	
bound	complex	between	NRF2	and	the	very-rich	Cys	protein	KEAP1	 is	disrupted	upon	oxidation	of	





p16INK4A/Rb	 [127].	 In	 addition	 to	 cell	 cycle,	 ROS	 impact	 on	 the	 stability	 of	 cellular	 lipids.	 Non-
enzymatic	 peroxidation	 of	 membrane-abundant	 polyunsaturated	 fatty	 acids	 triggers	 downstream	
reactions	 that	 generate	 highly-reactive	 lipid	 electrophiles.	 These	 lipid-radicals	 avidly	 form	 adducts	
with	nucleic	acids,	proteins,	and	lipids	by	creating	covalent	bonds	with	their	nucleophilic	moieties.	The	















reduction	 at	 the	 complex	 IV	 to	 generate	 water.	 (B)	 The	 mitochondrial	 sites	 where	 O2
-	 is	 created	 by	 the	
acceptance	 of	 O2	 of	 leaking	 electrons	 from	 in	 the	 mitochondria	 are	 shown.	 Drugs	 that	 interfere	 with	
mitochondrial	complexes	are	shown	in	red.	Superoxide	can	be	converted	by	superoxide	dismutase	2	(SOD2)	to	
H2O2,	 which	 is	 exported	 outside	 the	 mitochondria	 to	 be	 further	 reduced.	 SOD1	 converts	 the	 cytoplasmic	
superoxide	 derived	 from	 peroxisomes	 and	 ER.	 Catalase	 reduces	 H2O2	 to	 H2O	 and	 O2.	 Glutathione	 (GSH)	 is	
synthesised	from	glutamate	and	cysteine	by	glutamate	cysteine	ligase	(GCL).	The	GSH	redox	cycle	is	comprised	
by	 GSH	 and	 glutathione	 disulphide	 (GSSG)	 and	 it	 is	 maintained	 by	 the	 reducing	 equivalents	 from	 NADPH.	
Similarly,	thioredoxin	(TRX)	and	glutaredoxin	(GRX)	transfer	electrons	from	NADPH	to	their	oxidised	substrates.	
Nitric	oxide	(NO)	derived	from	arginine	and	this	reactive	radical	can	be	eliminated	 in	the	cytoplasm	by	nitric	
oxide	 synthase	 (NOS).	Nuclear	 factor	 erythroid	 2-related	 factor	 2	 (NRF2)	 (shown	 in	 yellow)	 controls	 various	
antioxidants	pathways	 including	 the	production	of	GSH,	 TRX	and	NADPH.	Generation	of	NADPH	arises	 from	
reactions	 involving	 glucose-6-phosphate	dehydrogenase	 (G6PD),	phosphoglycerate	dehydrogenase	 (PHGDH),	
isocitrate	dehydrogenase	1	 (IDH1)	and	malic	enzyme	1	 (ME1)	 (data	not	 shown).	Cyt	C,	 cytochrome	C;	FCCP,	
Carbonyl	 cyanide	 4-(trifluoromethoxy)	 phenylhydrazone;	 PDH,	 glycerol-3-phosphate	 dehydrogenase;	 Q,	
quinone.	ΔΨM,	membrane	potential.	
	
				The	 source	 of	 ROS	 can	 be	 extracellular	 —	 such	 as	 radiation,	 iron	 salts,	 and	 aerosols	 —	 or	
intracellular.	 The	 major	 intracellular	 contributors	 of	 ROS	 are	 the	 mitochondria,	 the	 endoplasmic	
reticulum	(ER),	peroxisomes	and	oxidases	and	oxygenases	enzymes	that	generate	ROS	as	part	of	their	
enzymatic	reaction	cycles	(Fig	1.6B)	[130].	Mitochondria	are	by	far	the	largest	source	of	intracellular	
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energetic-favourable	 enzymatic	 electron-exchange	 reactions	 between	 electron	 donor/acceptor	
complexes	 located	 in	 the	 inner	 membrane,	 and	 electrons	 are	 used	 to	 pump	 protons	 into	 the	
mitochondrial	 intermembrane	 space.	 The	 series	 of	 consecutive	 reactions	 comprise	 the	 electron	
transport	chain	(ETC)	and	the	electrochemical	gradient	of	protons	 is	transferred	via	chemiosmotic-




contribute	 to	 the	 pool	 of	 mitochondrial	 superoxide.	 As	 an	 example,	 the	 inner-membrane	
mitochondrial	glycerol-3-phosphate	dehydrogenase	(GPDH)	is	able	to	couple	electron	transport	and	
can	generate	superoxide	[130].	Peroxisomes	also	contribute	to	the	net	amount	of	cellular	ROS.	Thus,	
whilst	 the	 activity	 of	 peroxisome	 proliferator-activated	 receptor	 alpha	 (PPARα)	 –	 member	 of	 the	
peroxisomal	 β-oxidation	 system	 –	 increases	 the	 amount	 of	 ROS,	 the	 activity	 of	 mammalian	
peroxisomes	enzymes	(e.g.	catalase,	superoxide	dismutase	1,	and	peroxiredoxin	5)	and	non-enzymatic	


















cells	 more	 dependent	 to	 those	 cascades	 than	 other	 healthy	 cells.	 Examples	 include	 the	 human	
epidermal	growth	 factor	 receptor	2	 (HER2/ERBB2),	which	 is	 frequently	overactive	 in	breast	cancer	
cells,	the	activation	of	kinase	BRAF	that	increases	the	activity	of	MAPK	pathway	in	melanoma,	the	BCR-
Abl	 fusion	 kinase	 that	 causes	 the	 constitutive	 activation	 of	 receptor-downstream	 pathways	 in	
leukaemia	and	PTEN	loss	and	PI3K	over-activation	 in	prostate	cancer	cells	[87].	Molecular	targeted	










1.7).	 It	 is	 important	 to	 note	 that	 the	 specific	 inhibition	 of	 p100δ	 isoform,	 highly	 expressed	 in	




pharmacotherapy,	 and	 in	 fact	 several	 small	 molecule	 kinase	 inhibitors	 and	macrocyclic	 inhibitors	
specific	against	nodes	of	this	pathway	have	been	approved	by	the	FDA	for	their	clinical	use	[135].		
				However,	the	effectiveness	of	targeted	therapeutics	 is	 limited	by	the	confined	knowledge	of	the	
cancer	 nature	 as	 well	 as	 by	 intrinsic	 characteristics	 of	 cancer	 cells	 including:	 (i)	 the	 inter-tumour	
heterogeneity,	evidenced	by	differential	responses	of	patients	suffering	from	cancer	with	the	same	























[140].	 Such	 compounds	 can	 interfere	with:	 (i)	 pathways	 that	 supply	 nutrients/produce	 energy;	 (ii)	










































[146],	 chemotherapeutic	 agents	 that	 block	 nucleic	 acids	 synthesis	 and	 DNA	 repair	 (e.g.	





combination	 with	 all-trans	 retinoic	 acid	 (ATRA)	 in	 patients	 suffering	 from	 acute	
promyelocytic	leukaemia	(APL)	 [148].	 Other	mitochondrial	 enzymes	 are	 also	 targets	 in	 anti-cancer	







and	 reduced	xenografts	 tumour	 size,	which	can	be	 rescued	by	 the	glutathione	precursor	N-acetyl-















inhibits	 HIF	 transcriptional	 activities	 by	 precluding	 the	 HIF-interacting	 domain	 with	 the	 p300	
















				In	 summary,	 during	 the	 treatment	 of	 cancer	 cells	 with	 targeting	 agents	 that	 modulate	 protein	
activity	it	is	important	to:	(i)	elucidate	which	biological	pathways	are	altered	in	cancer	cells	at	the	time	




































clinical	 observations	 demonstrated	 that	 the	 clinical	 benefit	 rate	 (defined	 as	 absence	 of	 disease	
progression	≥6	months)	of	 ER+	breast	 cancer	 cell	 after	 treatment	with	BYL719	was	44%	 for	 those	
patients	with	PIK3CA-mutated	tumours	and	20%	for	those	with	the	PIK3CA	wild-type	[158].	 Indeed,	
chemosensitive	 responses	 to	 kinase-targeted	 therapies	 rated	 only	 up	 to	 75%	 in	 EGFR	 mutated	




				There	 are	 at	 least	 three	mechanisms	 that	 account	 for	 the	existence	of	 drug	 intrinsic	 resistance,	
namely:	(i)	relief	of	negative	feedback	loops;	(ii)	activity	of	cooperative	signalling	pathways;	and	(iii)	
aberrant	mutations	in	apoptotic	genes.	The	inhibition	of	feedback	regulation	is	a	common	mean	of	
intrinsic	 resistance	 described	 for	 some	 small-molecules	 targeting	 the	 PI3K	 and	 MAPK	 signalling	
pathways,	 whereby	 membrane	 receptors	 are	 permanently	 activated.	 For	 example,	 inhibition	 of	
mTORC1	 with	 rapamycin	 reduces	 the	 phosphorylation	 of	 S6K1-mediated	 feedback	 loop	 to	 IRS-1,	
enhancing	the	activity	of	the	latter	and	raising	the	activation	of	MAPK	signalling	[160].	The	activity	of	






















[167].	 Loss	 of	 phosphatases	 that	 counteract	 the	 activity	 of	 the	 targeted	 kinase	 can	 explain	 the	





over-expressed	 in	 resistant	 melanoma	 cells	 to	 compensate	 for	 the	 inhibition	 of	 BRAF	 [169].	 By	
contrast,	 the	 activation	 of	 alternative	 kinases	 that	 make	 up	 for	 the	 inhibited	 activity	 of	 targeted	
kinases	is	an	alternative	mechanism	used	by	cancer	cells	to	reactivate	the	targeted	signalling	pathway.	
For	 instance,	 the	activity	of	p110b	 isoform	can	rebound	PIP3	 levels	mediating	resistance	to	p110a	
inhibitors	 [170].	 Cancer	 cells	 that	 have	 common	 point-mutation	 BRAF	 (V600E)	 in	 melanoma,	 can	
overcome	MAPK	inhibition	via	mutational	activation	or	over-expression	of	pathway	activators	(such	
as	NRAS,	CRAF),	splicing	of	alternative	BRAF	isoform	immune	to	inhibitors	(e.g.	p61	BRAF-V600E)	or	
through	 mutation	 of	 kinases	 downstream	 of	 BRAF	 (e.g.	 COT,	 MEK1,	 and	 MEK2)	 [169].	 Lastly,	









				Overall,	 these	 examples	 serve	 to	 emphasise	 that	 profiling	 of	 somatic	 mutations	 may	 not	 be	
sufficient	 to	 infer	 the	 sensitivity	 of	 cancer	 cells	 to	 a	 given	 treatment,	 and	 this	 may	 have	 direct	
implication	in	the	design	of	lines	of	chemotherapy.		
    
 
Figure	 1.9	Mechanisms	 of	 acquired	 resistance.	Within	 population	 of	 patients	 suffering	 from	 cancer,	 some	





of-function	mutations	or	deletions	of	phosphatases	 that	 counteract	 the	 kinase	 activity	 lead	 to	 resistance	 to	
kinases	 inhibitors	 (2).	Mutations	 or	 over-expression	 of	 kinases	 able	 to	 compensate	 the	 signalling	 activation	
rescue	the	pathway	activity	(3).	Activation	of	downstream	components	of	the	signalling	pathway	also	restore	
the	signalling	activity	(4).	Hyperactivation	of	parallel	signalling	cascades	(usually	mediated	by	up-regulation	of	





In	 the	 clinic	 parlance	 “drug	 resistance”	 is	 frequently	 used	 almost	 interchangeably	 to	 “progressive	
disease”	[174].	The	usual	procedure	in	cancer	treatment	after	disease	progression	is	to	commence	an	
alternative	therapy	by	the	administration	of	drugs	which	cancer	cells	are	non-cross-resistant	to	(Fig	
Mechanism of acquired resistance Example disease [proteins]
1 Mutations on target kinase impedes drug binding CML  [BCR-ABL]
NSCL [EGFR]
2 Loss of phosphatase Metastatic breast cancer
[PTEN-null phenotype]
3 Upregulation of compensatory kinase Melanoma (BRAF(V600E))
[NRAS, CRAF,+BRAF, alternative splicing]
4 Activation of downstream kinase Melanoma (BRAF(V600E))
[+MAP3K8, activating mutation in MEK1/2]
5 Emergence of parallel pathways Melanoma (BRAF(V600E))
[+PI3K/AKT/mTOR signalling]
6 Amplification of membrane receptor Melanoma (BRAF(V600E))
[+EGFR, IGF-1R, and PDGFR]
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to	patients	 that	 switch	 to	 lapatinib	 (i.e.	51.6	weeks	 for	 treatment	beyond	progression	versus	39.0	














two	 melanoma	 patients	 were	 re-sensitised	 to	 BRAF-selective	 inhibitors	 after	 rechallenge	 [188].	









with	an	alternative	drug,	which	may	 improve	 the	 response	 rate	of	 the	alternatives	agents.	The	 lower	 image	
shows	the	traditional	approach	to	determine	the	optimal	response	dose	tolerable	based	on	drugs	toxicities.	(C)	
An	 alternative	 dosing	 strategy	 consists	 in	 scheduling	 intermittent	 drug	 administrations.	 A	 gap	 in	 therapy	 1,	















has	 an	 unbiased	 nature	 and	 high	 information	 content.	 These	 facts,	 coupled	 with	 adequate	
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peptide	 mass	 fingerprinting,	 but	 this	 ionisation	 technique	 is	 not	 suitable	 for	 high-throughput	
proteomic	 analysis	 given	 that	 it	 is	 difficult	 to	 couple	 to	 liquid-chromatography	 and	 that	 its	
reproducibility	depends	on	the	efficiency	of	matrix-to-analyte	proton	transfer,	which	is	often	variable.	
In	fact,	the	ionisation	method	of	choice	for	proteomic	analysis	is	nano-ESI,	a	variant	of	ESI	performed	













trapped	 ions	 are	 subject	 to	 be	 fragmented	 (CID	 fragmentation,	 see	 Section	 1.4.4).	 A	 hyphenated	
variation	of	this	is	the	triple	stage	quadrupole	(TSQ),	which,	as	the	name	suggests,	has	three	sequential	
quadrupoles	(Fig	1.11).	When	quadrupole	ion	traps	are	in	selection	mode,	they	have	high	sensitivity	
and	 therefore	 are	 efficient	 instruments	 for	 the	 quantification	 of	 known	 component	 fragments.	






a	 charge	 on	 the	 detection	 electrodes	 (the	 image	 current),	 which	 can	 be	 converted	 into	 a	 mass	
spectrum	 using	 a	 Fourier	 transformation.	 Therefore,	 this	 technique	 is	 often	 referred	 as	 Fourier	
transform	ion	cyclotron	resonance	(FT-ICR).	
				Lastly,	the	orbitrap	consists	of	an	axial	inner	electrode	surrounded	by	a	barrel-shape	outer	electrode	
[197].	Orbitrap	 instruments	 trap	 ions	 using	 an	 electric	 field	 and	 subsequently	 eject	 them	 into	 the	
orbitrap,	where	 ions	 oscillate	 around	 the	 central	 electrode	 according	 to	 their	m/z.	 Like	 for	 FT-ICR	
analysers,	 the	 image	 current	 induced	 by	 the	 oscillating	 ions	 on	 the	 detection	 electrodes	 can	 be	
















[198].	 The	 first	 consideration	 is	 the	 method	 used	 for	 protein	 extraction;	 as	 such,	 tissue-derived	
samples	are	subject	to	vortexing	and	liquid	nitrogen	treatment	in	order	to	achieve	complete	tissue	
disruption.	Otherwise,	cells	are	usually	 lysed	with	buffers	 that	contain	denaturing	chaotropes	 (e.g.	
urea)	 to	 increase	protein	 solubility.	However,	 chaotropes	can	 interfere	with	 the	enzymatic	activity	
required	for	protein	digestion.	One	strategy	to	remove	those	blocking	agents	is	to	immobilise	proteins	
in	a	solid	support,	either	in	a	gel	in	the	case	of	polyacrylamide	gel	electrophoresis	(PAGE),	using	a	filter	
for	 detergent	 removal	 in	 the	 case	 of	 filter-assisted	 sample	 preparation	 (FASP)	 [199],	 or	 the	more	
advanced	 pipette-based	 filters	 that	 remove	 interfering	 agents	 while	 minimizing	 sample	 loss	 and	
contamination	[200].	Another	strategy	 is	 to	perform	an	 in-solution	protein	enzymatic	digestion,	so	
that	 the	 disrupting	 substances	 are	 diluted	 and	 their	 negative	 impact	 on	 the	 proteolytic	 yield	 is	
reduced.	Solubilised	and	denatured	proteins	are	consequently	reduced	and	alkylated	with	agents	such	

















hydrophobicity,	 and	 charge	 can	be	exploited	 to	 fractionate	entire	proteomes	 into	more	 simplified	
formats.	 Among	 the	 separation	 techniques	 integrated	 with	 mass	 spectrometry,	 liquid	
chromatography	(LC)	is	a	widely	used	online	method	(i.e.	the	complex	sample	fractionation	is	directly	
coupled	 to	 the	 mass	 spectrometer).	 In	 the	 LC-MS/MS,	 compounds	 are	 separated	 based	 on	 their	
hydrophobicity:	the	liquid-phase	analyte	in	the	organic	carrier	solvent	(mobile	phase)	is	separated	on	
its	moving	through	the	silica-bead-filled	hydrophobic	chromatography	column	(the	stationary	phase,	






Alternative	 offline	 methods	 such	 as	 immunological/inorganic	 affinity	 purification	 or	 1D/2D	
electrophoresis/chromatography	 also	 reduce	 sample	 complexity,	 but	 the	 integration	with	 the	MS	
analysis	 is	 not	 fully	 automated	 (see	 Section	 1.4.6).	 Although	 tandem	 LC-MS/MS	 requires	 longer	
















are	 measured	 in	 the	 first	 MS	 scan.	 A	 given	 precursor	 is	 selected	 and	 isolated	 for	 fragmentation	 and	 the	
intensities	of	fragmented	ions	are	measured	in	the	second	MS/MS	scan.	The	sequence	of	the	precursor	ion	is	
inferred	from	the	MS2	data	by	manual	sequence	assembly	or	by	comparison	with	a	database.	(C)	Ions	can	also	
be	directed	 into	a	 triple	quadrupole	mass	 spectrometer.	 This	 instrument	allows	high	 sensitivity	quantitative	
detection	 of	 peptides	 and	 small	 molecules,	 such	 as	 metabolites	 and	 drugs.	 Each	 quadrupole	 contains	 four	
cylindrical,	metal	 parallel	 rods	 connected	 electrically,	 which	 allow	 the	 ions	 travelling	 through	 the	 centre	 of	
quadrupole	analyser.	 Ions	are	guided	 into	the	 first	quadrupole	 (Q1),	which	acts	as	a	mass	 filter	allowing	the	
streaming	of	 ions	of	certain	m/z.	 Ions	with	a	stable	trajectory	arrive	to	the	middle	quadrupole	(Q2),	which	is	






with	 high	 precision	 the	 amount	 of	 known	 proteins	 within	 a	 sample.	 Untargeted	 proteomics,	






































































is	 possible	 due	 to	 the	 existence	 of	 tandem	 mass	 spectrometry	 (MS/MS	 or	 MS2)	 analysis,	 which	
separates	and	fragments	ions	in	a	multiple-step	process.	In	the	first	step,	peptide	ions	are	selected	for	
their	 further	 fragmentation	 (i.e.	chemical	dissociation	of	energetically	unstable	 ions)	 in	 the	second	
step.	There	are	two	ways	how	mass	spectrometers	select	sample	peptides	for	fragmentation,	namely	
data	dependent	 acquisition	 (DDA)	 and	data	 independent	 acquisition	 (DIA).	During	DDA	mode,	 the	
instrument	is	automated	so	that	only	a	specific	number	of	peptide	ions	—	for	example,	20	in	a	“top	
20”	experiment	—	that	generate	the	most	intense	MS	signal	are	selected	for	fragmentation.	The	DDA	
approach	 has	 the	 significant	 limitation	 that	 its	 performance	 deteriorates	 as	 sample	 complexity	
increases	because	the	less	abundant	ions	are	usually	not	selected	for	fragmentation;	this	limits	further	
peptide	 identification	 and	 quantification	 (the	 so	 called	 under-sampling	 problem).	 Development	 of	
more	sensitive	instruments	with	lower	duty	cycle	(the	operating	time	of	the	mass	spectrometer)	have	
greatly	 ameliorated	 the	 output	 of	 this	 approach.	 Optimised	 algorithms	 for	 protein/peptide	







generated	 using	DDA	methods.	 Among	 the	 benefits	 of	 DIA	 are	 broader	 dynamic	 range	 of	 signals,	





in	 a	 proteomics	 experiment.	 In	 fact,	 ion-source	 fragmentation	 is	 technically	 not	 a	 tandem	MS/MS	
technique	because	 some	 ions	 (i.e.	metastable	 ions)	 dissociate	 before	 being	 selected,	 contrarily	 to	
post-source	fragmentation,	whereby	energy	is	added	to	the	ions	after	MS	analysis.	Ion	fragmentation	









the	 instrument	 of	 analysis	 and	 the	 analyte,	 as	 different	 types	 of	 fragment	 ions	 can	 be	 generated	
depending	 on	 the	 fragmentation	 method.	 For	 example,	 during	 CID	—	 the	 most	 popular	 form	 of	





prior	 knowledge,	 using	 the	 so	 called	 de	 novo	 sequencing,	 where	 the	mass	 of	 each	 amino	 acid	 is	














extremely	 advantageous	 given	 the	 relatively	 fast,	 high	 throughput	 identification	 of	 peptides.	 In	











Large-scale	 quantification	 of	 proteomes	 has	 made	 possible	 to	 address	 fundamental	 questions	 of	
biological	systems	[206,	207].	There	are	two	main	methods	applied	in	quantitative	proteomics:	label-









limitations,	 including	 large	 tags	 interfering	with	 the	 subsequent	 fragmentation,	and	 it	 is	 limited	 to	
label	cysteine-containing	proteins.	Moreover,	hydrophobic	proteins	are	underrepresented	in	ICAT	due	
to	poor	recovery	of	peptides	from	avidin.	Isobaric	labelling		with	tandem	mass	tag	(TMT)	[216]	and	
isobaric	 tags	 for	 relative	 and	 absolute	 quantitation	(iTRAQ)	 [217]	 aim	 to	 amend	 some	 of	 these	
limitations,	 by	 the	 usage	 of	 reporters	 ions	 that	 are	 released	 during	 MS2	 step,	 which	 permit	 the	
identification	and	quantification	of	reporter	groups	of	known	mass	[217].	Although	these	methods	
have	been	used	in	multiple	studies,	isobaric	tagging	approaches	present	various	drawbacks,	including	
variability	 in	 the	 labelling	 efficiency	 —	 and	 therefore	 variability	 in	 the	 quantification	 —	 and	
limited/erroneous	quantification	due	to	co-isolation	and	fragmentation	of	precursors	that	have	similar	
mass	[218].	
				Proteins	 can	also	be	 labelled	 in	 vivo	 during	protein	 synthesis	using	 the	well-established	method	
called	stable	isotope-labelled	amino	acids	in	cell	culture	(SILAC)	[219].	SILAC	involves	the	incorporation	





peptide	 ions	 to	 their	 unlabelled	 counterparts.	 In	 this	 manner,	 proteins	 are	 labelled	 as	 they	 are	
synthesised,	which	ameliorates	purification	 issues	and	 issues	with	 labelling	kinetics	 [219].	The	 two	




straightforward	 and	 that	 only	 a	 limited	 number	 of	 comparisons	 is	 possible	 within	 an	 experiment	
(usually	between	2-3	samples).		
				In	 sum,	 label-based	 approaches	 offer	 several	 possibilities	 to	 successfully	 perform	 quantitative	
proteomics	 analysis,	 allowing	 multiplexing	 to	 improve	 quantitative	 precision.	 However,	 there	 are	
crucial	limitations	including	increased	complexity	and	time	for	sample	preparation,	limited	number	of	
comparisons,	 relatively	 high	 cost	 of	 reagents	 and	 constrains	 for	 clinical	 samples,	which	 ultimately	
restrict	the	application	of	these	approaches	to	answer	many	biological	questions.	
				On	the	other	hand,	the	label-free	methods	rely	neither	on	chemical	derivatisation	nor	on	metabolic	





peptide	 [221].	 After	 counting	 the	MS2	 events	 for	 all	 peptides,	 the	 abundance	 of	 each	 protein	 is	
calculated	by	averaging	the	spectral	counts	of	all	peptides	belonging	to	each	protein.	This	method	is	























the	 quantification	 of	 peptide/proteins	 of	 complex	 samples	 [205].	 Initially,	 a	 database	 of	 peptides	
identified	in	the	MS/MS	data	is	populated	with	peptides	m/z,	charge	state	(z),	tR	and	name	of	sample	
where	 the	 peptide	 was	 identified.	 The	 tR	 of	 common	 peptides	 are	 calculated	 across	 samples	 to	
compensate	for	chromatography	variability.	The	tR	used	to	calculate	the	XICs	(with	windows	of	±	7-10	
ppm),	however,	is	specific	for	each	sample	and	is	a	result	of	extrapolation	with	linear	models	formed	
between	standards	present	 in	 the	sample.	To	 increase	 the	quantification	accuracy	of	 this	method,	
peaks	must	contain	a	minimum	number	of	data	points	to	be	considered	for	quantification.	Moreover,	
the	ratios	of	second	and	third	isotopes	of	each	peptide	are	correlated	with	the	theoretical	distribution	
and	used	 in	 the	quantification,	which	 improves	 the	 robustness	of	 the	peak-picking,	 increasing	 the	
correct	assignation	of	isobaric	peptides	[205].		
				Among	the	advantages	of	the	PESCAL	method,	stands	the	fact	that	the	number	of	possible	samples	








Performing	 data	 replicates	 has	 proved	 to	 enhance	 the	 quality	 of	 quantitative	 data	 [225],	 despite	







Figure	1.12	Representation	of	 label-based	and	 label-free	methods	used	 for	quantitative	proteomics.	 (A)	 In	






isotopes	 is	 calculated	 from	 the	MS	 data.	 (B)	 Quantitation	 strategies	 based	 on	 label-free	methods	 included	
spectral	 counting	 and	 extracted	 ion	 chromatograms	 (XICs).	 Samples	 are	 lysed,	 proteins	 are	 digested	 and	
peptides	are	independently	run	on	an	LC-MS/MS	system.	In	this	example,	the	blue	proteins	are	more	abundant	
than	the	purple	proteins	and	the	relative	abundance	of	 the	peptides	 is	 reflected	by	 the	number	of	 the	MS2	
spectra	(in	spectral	counting)	or	by	the	area	under	the	XIC.	ICAT,	isotope-coded	affinity	tagging;	iTRAQ,	isobaric	
tags	 for	 relative	and	absolute	quantification;	 SILAC,	 stable	 isotope-labelled	amino	acids	 in	 cell	 culture;	 TMT,	
tandem	mass	tagging.	
1.4.6	Phosphoproteomics	
Phosphoproteomics	 is	 the	 study	 of	 the	 global	 dynamic	 post-translational	 modification	 (PTM)	 of	
proteins	whereby	phosphate	is	added	via	a	covalent	bound.	Phosphorylation	of	proteins	is	catalysed	
by	 kinases,	 removed	 by	 phosphatases,	 and	 often	 causes	 protein	 conformational	 changes.	 Protein	








































































Identification and quantification 































Identification at the MS2 level 





























































5%)	 [237].	 Phosphorylation	 at	 histidine	 residues	 has	 also	 been	 reported	 [238].	 Protein	
phosphorylation	 is	 one	of	 the	most	 studied	 regulatory	 processes	 in	 cellular	 physiology,	 and	 faulty	
signalling	transduction	has	been	associated	to	pathological	conditions	including	cancer	[239],	diabetes	
[240],	 and	 neurodegenerative	 disorders	 [241].	 Deregulation	 of	 signalling	 pathways	 can	 arise	 from	
mutations	 on	 kinases/phosphatases	 or	 by	 alteration	 in	 epigenetic	 modulators	 of	 the	







				To	perform	 comprehensive	 analyses	of	 phosphorylation	events,	 it	 is	 critical	 to	 acknowledge	 the	
dynamic	nature	of	the	phosphate	bound,	unstable	at	high	temperature	and	high	pH,	and	the	rapid	
kinetics	of	phosphatases	compared	to	kinases	[243].	Hence,	to	preserve	phosphorylation	states,	it	is	
essential	 to	maintain	 cold	 and	non-alkaline	 pH	 conditions	 and	use	 compounds	 to	maintain	 inhibit	
phosphatase	activity.		
				Moreover,	it	is	important	to	note	that	phosphorylated	peptides	are	usually	less	abundant	compared	














				Immunological-based	 affinity	 purification	 relies	 on	 the	 selective	 recognition	 of	 phosphorylated	
residues	 by	 specific	 antibodies	 raised	 against	 pSer,	 pThr	 or	 pTyr	 [246]	 (Fig	 1.13B).	 Although	 it	 is	
believed	 that	 Tyr	 kinases	 evolved	 after	 Ser/Thr	 kinases,	 and	 phosphorylation	 in	 tyrosines	 the	 less	
frequent	 modification	 in	 phosphoproteome	 of	 higher	 eukaryotes	 [237],	 the	 number	 of	 specific	
antibodies	that	recognise	pTyr	residues	is	by	far	greater	than	those	for	pSer	or	pThr,	possibly	given	
the	 higher	 immunogenicity	 of	 the	 Tyr	 aromatic	 ring	 [247].	 Antibody	 purification	 of	 pTyr	 has	 been	
successfully	used	 for	 the	 study	of	pTyr	 residues,	primarily	due	 to	 the	absence	of	 alternative	pTyr-





approaches	 exploit	 the	 charge-difference	 between	 phosphorylated	 and	 non-phosphorylated	





improves	 when	 in	 combination	 with	 other	 methods,	 particularly	 when	 the	 amount	 of	
phosphopeptides	in	the	sample	is	limited	[253].	Additional	chromatography	fractionation	techniques	
based	 on	 hydrogen-bonding	 are	 used	 to	 retain	 charged	 or	 polar	 ions	 in	 a	 stationary	 phase.	 For	
example,	 electrostatic	 repulsion-hydrophilic	 interaction	 chromatography	 (ERLIC)	 causes	 the	





of	 analytes	 (e.g.	 phosphopeptides)	 with	 the	 hydrophilic	 stationary	 phase	 [255].	 Phosphorylated	
peptides	are	retained	in	ERLIC	and	HILIC	columns	based	on	the	number	of	negatively-charged	groups.	





methods	based	on	 this	principle	are	 immobilised	metal	 ion	affinity	chromatography	 (IMAC),	metal	
oxide	 affinity	 chromatography	 (MOAC),	 or	 combinations	 of	 both	 (Fig	 1.13D).	 IMAC	 resins	 chelate	
metal	ions	such	as	Fe3+,	Ni2+,	Cu2+,	Zn2+,	Al3+,	Ga2+	and	Ti4+,	which	in	turn	form	ion-pair	interactions	with	
phosphate	 groups.	 Although	 Fe3+-IMAC	was	 the	 first	 developed	 and	 has	 been	 frequently	 used	 for	
phosphopeptide	 enrichment,	 Ti4+-IMAC	 has	 proved	 greater	 reproducibility	 and	 in-depth	
phosphoproteome	screening	due	to	the	high	affinity	of	the	titanium	ions	for	phosphate	groups	[257].	










of	 acidic	 non-phosphorylated	 peptides,	 improving	 the	 selectivity	 for	 phosphate	 groups	 [260].	
Although	 multiply-phosphorylated	 peptides	 tend	 to	 tightly	 bind	 to	 TiO2,	 efficient	 elution	 of	
phosphopeptides	from	TiO2-MOAC	is	usually	achieved	using	basic	eluents,	such	as	NH4OH	[261],	and	
through	the	use	of	multiple	round	of	elution	steps	[262].	A	robust	and	sensitive	single-shot	TiO2-MOAC	












be	 taken	 during	 the	 mass	 spectrometry	 and	 bioinformatics	 analysis	 of	 phosphoproteomics	 data.		
Given	 the	 negative	 charge	 of	 phosphate,	 phosphopeptides	 are	 less	 well	 fragmented	 than	 non-
phosphorylated	peptides.	Therefore,	fragmentation	methods	can	be	optimised	for	the	sequencing	of	




[263].	 In	 the	multistage	 fragmentation	method	 termed	 Pseudo	MS(n)	 [264],	 CID	 fragmentation	 is	
applied	and	the	neutral	losses	are	subject	to	further	fragmentation,	generating	a	composite	spectrum	
containing	informative	spectra	of	all	ion	series.	Improved	CID-based	activation	methods	contribute	to	
reducing	the	prevalence	of	neutral	 loss	 ions	 in	 the	MS2	spectra.	For	example,	 	HCD	fragmentation	





that	 phosphate	 groups	 in	 gas	 phase	 are	 potentially	 capable	 of	 switching	 between	 side	 groups	







(e.g. NaOH, BaOH) 
Nucleophile attack



































therefore	rendering	artificial	pairs	of	 isomeric	phosphopeptides	(i.e.	peptides	 identical	 in	sequence	
but	 carrying	 the	 phosphate	 group	 in	 different	 amino	 acids)	 [267].	 The	 development	 of	 computer	
programs	such	as	Mascot	or	Sequest	has	contributed	to	correct	phosphopeptide	site	assignments.	The	
effectiveness	of	the	Mascot	delta	score	used	by	Mascot	and	the	A	score	used	by	Sequest	to	calculate	
the	most	 likely	phosphorylation	site	 location	providing	a	 false	 location	rate	(FLR)	associated	to	the	
probability	 of	 correct	 location	 of	 the	 phosphorylation	 was	 studied	 Savitski	 et	 al.	 [268],	 and	
demonstrated	their	efficacy	to	report	phosphopeptide	sites	likelihood.	
				As	 mentioned	 before,	 computational	 methods	 to	 investigate	 cellular	 signalling	 by	
phosphoproteomics	have	been	developed	in	the	last	years	[227].	One	approach	to	estimate	the	kinase	
activity	 called	 kinase	 substrate	 enrichment	 analysis	 (KSEA),	 which	 is	 based	 on	 changes	 on	 known	
kinase	 substrates,	 was	 developed	 in	 the	 Cutillas	 group	 [161],	 and	 was	 used	 in	 the	 experiments	
performed	in	the	studies	presented	this	thesis	(see	methods	Section	2.10.3	for	detailed	description).	
This	 method	 assumes	 that	 the	 activity	 status	 of	 a	 given	 kinase	 can	 be	 inferred	 from	 the	
phosphorylation	 of	 its	 known	 substrates.	 It	 should	 be	 noted	 that	 this	 method	 does	 not	 directly	
measure	kinase	activity,	as	opposed	to	other	techniques	[269],	but	uses	phosphoproteomic	targets	
and	 kinase-substrate	 annotations	 (e.g.	 those	 included	 in	 PhosphoSitePlus	 [33])	 to	 predict	 kinase	
activities.	The	performance	of	the	KSEA	method	and	similar	predictive	algorithms	has	been	recently	
benchmarked	by	Hernandez-Armenta	and	co-workers	 that	demonstrated	the	good	performance	of	
















Following	 the	 same	 principle,	Oroborus	 instruments	 permit	measurements	 of	O2	 perturbations	 of	
tissue-derived	samples	or	even	direct	measurements	on	isolated	mitochondria	[272].	Methods	based	
on	fluorescence	such	as	MitoSOX	and	MitoXpress	measure	the	amount	of	mitochondrial	superoxide	
and	 extracellular	 O2,	 respectively.	 Finally,	 extracellular	 flux	 analysers	 (XF)	 developed	 by	 Seahorse	
Bioscience	are	fully	integrated	24	or	96-well	instruments	that	quantify,	in	real	time	and	simultaneously	




surrounding	 attached	 cells.	 Each	 Seahorse	 experiment	 comprises	 a	 disposable	 sensor	 cartridge,	
integrated	 with	 pairs	 of	 fluorescent	 biosensors	 for	 oxygen	 and	 protons	 coupled	 to	 a	 fibre-optic	
waveguide.	 The	 excitation	 wavelength	 values	 for	 oxygen	 and	 protons	 are	 532	 nm	 and	 470	 nm,	
respectively	 and	 fluorescent	 transmission	 signals	 are	 650	nm	 for	 oxygen	 and	530	nm	 for	 protons.	
Oxygen	consumption	and	proton	extrusion	result	 in	 rapid	real-time	measurable	changes	 in	oxygen	
tension	and	pH	within	a	microchamber	generated	by	the	sensor	cartridge	in	each	of	the	microplate	
wells	 and	 after	 treatments	with	 a	 series	 of	 drugs	 that	 interfere	with	 different	 components	 of	 the	
mitochondrial	oxidative	chain.	Usually,	the	baseline	OCR	and	ECAR	readings	are	established	before	
the	 injection	 of	 mitochondrial	 drugs.	 Optimal	 confluency	 (number	 of	 seeding	 cells)	 is	 a	 critical	
parameter	that	needs	to	be	optimised	for	Seahorse	experiments	in	order	to	minimise	measurements	






by	 the	 Seahorse	 technology.	 Nevertheless,	 this	 method	 comes	 with	 some	 limitations	 including	




















No	 Yes Yes Yes Yes
Disposable	plates Yes Yes Yes No	 No
High-throughput Yes Yes Yes No	 No
Real	time Yes Yes Yes Yes Yes
Label-free Yes No No Yes Yes
Time	 ~2.5	h ~2h	 ~2h Long Long








Price	of	consumables High Medium High	 Low	 Low	
Information Seahorse MitoXpress MitoSOX Ouroboros
Clark	
electrode
Basal	Respiration Yes	 Yes	 No	 Yes Yes
ATP	Production Yes	 No	 No	 Yes Yes
Proton	Leak Yes	 No	 No	 Yes Yes
Maximal	Respiration Yes	 Yes No	 Yes Yes
Spare	Respiratory	Capacity Yes	 Yes No	 Yes Yes
Oxygen	consumption	 Yes	 Yes	 No	 Yes Yes	
Mitochondria	content	 No	 Yes	 No	 No	 No	
ROS	production	 No	 No	 Yes Yes No	
Glycolytic	capacity	 Yes No	 No	 Yes No	








its	 environment.	 Because	 each	 metabolite	 is,	 by	 definition,	 the	 result	 of	 a	 metabolic	 reaction,	
metabolites	 are	 direct	 fingerprints	 of	 the	 cellular	 metabolic	 activity.	 Profiling	 the	 metabolites	 of	
cellular	 system	contributes	 to	 greater	understanding	of	 the	metabolic	 status	of	biological	 systems	
[274],	and	can	help	to	identifying	biomarkers	of	disease	aggressiveness	[275].	
				As	for	LC-MS	proteomics,	correct	sample	preparation	is	paramount	for	ensuring	good	sensitivity	and	
reproducibility	 of	metabolomics	 results.	 There	 are	 two	main	 categories	 employed	 for	metabolites	
quantification	depending	whether	one	metabolite	or	all	the	metabolites	of	a	given	biological	system	
are	to	be	measured.	The	approaches	used	to	analyse	a	selected	metabolite	are	hypothesis-driven,	and	
the	 chemical	 properties	 of	 the	 compound	 to	 be	 investigated	 are	 known	 and	 used	 to	 guide	 the	
customisation	of	sample	preparation	to	minimise	matrix	effects.	Perhaps	the	most	commonly	used	
extraction	 technique	 to	 isolate	 metabolites	 is	 liquid-liquid	 extraction,	 which	 relies	 on	 differential	
solvents	 solubility	 [276].	Most	 of	 the	 LC-MS	platforms	 used	 for	metabolites	 analyses	 can	 perform	




















Genomics	 is	 the	 study	 of	 the	 complete	 genetic	material	 of	 a	 biological	 entity.	 The	 genome	 of	 an	
organism	includes	both	the	genes	(i.e.	the	coding	regions)	and	the	non-coding	regions	of	the	DNA	(e.g.	



































The	 aim	 of	 this	 thesis	 is	 to	 understand	 the	 molecular	 adaptations	 that	 allow	 cancer	 cells	 to	
compensate	for	chronic	PI3K	inhibition.	The	specific	objectives	to	cover	this	aim	are	the	following:	




based	proteomics	 and	phosphoproteomics	 approaches.	 This	project	 also	 seeks	 to	 characterise	 the	
biochemistry	of	PI3Ki-resistant	cells	when	these	cells	are	treated	with	the	PI3Ki	or	on	its	absence.	
	
3)	 To	 explore	 the	metabolic	 characteristics	 of	 sensitive	 and	 resistant	 cells.	 For	 this	 objective,	 the	
Seahorse	metabolic	 flux	 analyser	 is	 to	 be	 used	 to	 study	 the	 energy	 phenotype	 of	 such	 cells,	 the	










































Name Manufacturer Reference Glucose		[mM] Glutamine [mM] Sodium	
pyruvate [mM]











102365-100 25 2 1












Name Manufacturer Reference Dilution Concentration Primary	target
GDC-0941 Chemdea CD0245 DMSO 1	μM PI3K α/δ
BYL719 Selleckchem 2814 DMSO 1	μM PI3Kα
Ku-0063794 Chemdea CD0274 DMSO 1	μM mTORC1/2
MK-2206 Selleckchem S1078 DMSO 1	μM AKT	1/2/3
A-VII Cayman 14870 DMSO 1	μM AKT	1/2
Everolimus Selleckchem S1120 DMSO 20	nM mTORC1
10058-F4 Sigma F3680 DMSO 25	μM c-MYC
10074-G5 Sigma G3798 DMSO 20	μM c-MYC
Chetomin Sigma C9623 DMSO 10	nM HIF-1/2α
GSK-650394 Sigma 650394 DMSO 0.5	μM SGK
Trametinib Selleckchem S2673 DMSO 0-20	μM MEK
KN-93 Tocris 139298 DMSO 0-200	μM CAMKII	α/β/γ/δ
N-acetylcysteine Sigma A0737 Water 200	μM Freeradicals




Sigma C2920 DMSO 2	μM Mitochondria	uncoupler
AntimycinA Sigma A8674 DMSO 1	μM Mitochondria	CII
Rotenone Sigma R8875 DMSO 1	μM Mitochondria	CoQ10
(±)-α-Tocopherol Sigma T3251 DMSO 0-20	μM Free	radicals
H2O2 Sigma 216763 Water 130	μM Free	radicals
L-lactic	acid Alfa	Aesar L13242 Water 0-30	mM























Name Manufacturer Reference Information
2ʹ,7ʹ-Dichlorofluorescin	diacetate(DCFH-DA) Sigma D6883 Non- fluorescent dye	used	to	visualized	
intracellular	oxidative	species
4%	paraformaldehyde Santa	Cruz Sc-281692 Reagent	used	to	fix	cells













Thermo 160454 Trap	column	used	for	Q	Exactive +	LC	
separations
Bicinchoninic acid	(BCA)	protein	assay Thermo 23225 Assay	used	for	protein	quantification
Crystal	violet	 Sigma C3886 Cell	proliferation
CellTiter 96	AQueousOne	solution	reagent Promega G3580 Reagent	used	to	determine	celularmetabolic	
activity
DNeasyBlood	&	Tissue	Kit Quiagen 69504 DNA	isolation
Dual	luciferase reporter	assay Promega E1910 Luciferase reporter
EDTA-trypsin (0.05%/0.02%) Sigma L11-004/T4299 Cell	detacher
Empty	spin	filter-tips	TF2EMT Glygen TF2EMT Empty	tips	with	filter	used	to	prepared	TiO2
phosphoenrichement columns
Eppendorf LoBindmicrocentrifugetubes Sigma Z666505 Low	binding	microcentrifuge tubes	used	to	
collect	samples	for	protein	analysis
FujiFilm X100	FUJI	RX	X-RAY	FILM	(18	X	24	cm) Fisher 12715325 X-ray	film	for	western	blot
Guava	Cell	Cycle	Reagent	for	Flow	Citometry Millipore 4500-0220 Reagent	used	to	determine	cell	cycle	
distribution






Thermo 20230 In-solution	trypsin used	to	digest	peptides
Interferin transfection reagent		 Polyplus 40901 Reagent	used	to	transfect	cells	with	siRNA
Nano-Glo	Luciferase	assay Promega N1110 Reagent	used	to	determine	luciferase	activity
Oasis-HLB	1cc	cartridges		 Waters WAT094225 Cartridges	used	to	desalt	and	extract	peptides
ONE-Glo EX	Luciferase assay Promega E8110 Reagent	used	to	measure	luminesce
Passive	Lysis Buffer	5X Promega E1941 Reagent	used	to	lyse cells	transfectedwith	DNA
Penicillin/streptomycin Sigma P4333 Antibiotics
Phenylmethylsulfonyl fluoride	(PMSF) Sigma 93482 Serine	protease	inhibitor	used	in	Western	blot
Ponceau S	solution Sigma P7170 Reagent	used	to	visualized	protein	bands
Poly-L-lysine	solution Sigma P8920 Polymer	used	to	assist	cell	adhesion	to	solid	
surphaces
PolysineAdhesion	Slides	(25	mm	X	75	mm	X	1mm) Thermo 10143265 Slides	used	to	visualize	microscope	samples
PVDF	transfer	membrane Millipore IPVH00010 Transfer	membrane	for	western	blot
SuperSignal	West	Pico	ECL	substrate Pierce 34080 Horsereadishperoxidase (HRP)	reagent	for	
western	blot
siRNAagainst	HIF-1α(4082	bp) Sigma NM_001530 Sequence	used	to	transiently	inhibit	HIF-1-α
Titansphere TiO2 (Titanium	Dioxide,	TiO2) GL	Science 502075010 Method	used	to	perform	phosphoenrichement
method











MCF7	 cells	 were	 obtained	 from	 the	 ATCC	 (HTB-22).	 PI3Ki-resistant	 cells	 were	 previously	 made	
resistant	to	1	μM	GDC-0941	or	1	μM	Ku-0063794	[226].	MCF7	sensitive	and	resistant	cells	were	grown	
siRNA against GPR81 Quiagen 3124607 Sequences used to transiently inhibitsGPR81
Mounting medium with Vector 
laboratories
DAPI H-1200 Staining for DNA
Alexa Fluor® 488 Phalloidin Thermo A12379 Staining for F-actin
Name Manufacturer Reference Concentration Procedure
p-AKT	Ser473 Cell	Signalling		Technologies 4058 1/1000 Western	blot
p-PRAS40	Ser246 Cell	Signalling		Technologies 2640 1/2000 Western	blot
p-4EBP1	Thr37/Thr46 Cell	Signalling		Technologies 2855 1/1000 Western	blot
FASN Cell	Signalling		Technologies 3189 1/1000 Western	blot
LDHB Abcam ab53292 1/1000 Western	blot
c-MYC Cell	Signalling		Technologies 5605 1/1000 Western	blot
HIF-1α Cell	Signalling		Technologies 3716 1/500 Western	blot
HIF-1α	(siRNA	 experiments) BD	Transduction Laboratories 610959 1/500 Western	blot
MCT1 Astrazeneca MCT1 1/100 Western	blot
MCT2 Astrazeneca MCT2 1/100 Western	blot
MCT2 Astrazeneca MCT2 1/100 Western	blot
GPR81 Santa	Cruz sc-32647 1/100 Western	blot
α-Tubulin Cell	Signalling		Technologies 2144 1/1000 Western	blot





















































transferred	 into	 2	 mL	 sterilised	 eppendorf	 tubes.	 Interferin	 reagent	 (2	 mL)	 was	 added	 into	 the	
eppendorf	tubes	that	were	then	vortex	for	10	s.	Mixtures	were	spinned	down	for	approximately	10	s	
and	incubated	at	room	temperature	for	10	min.	Fresh	media	was	replaced	and	mixtures	containing	






































				For	apoptosis	measurements,	2,000	cells/well	 resuspended	 in	100	µL	were	plated	 into	a	96-well	
plate.	Cells	were	washed	once	with	PBS	before	 the	addition	and	 resuspension	of	150	μL	of	Guava	
Nexin	 reagent	 containing	 Annexin	 V	 and	 7-aminoactinomycin	 D	 (7-AAD)	 dyes.	 Annexin	 V	 stains	
extracellular	phosphatidylserine	and	is	an	indicator	of	plasma	membrane	integrity,	whereas	7-AAD	is	
a	 plasma	 membrane	 impermeable	 compound	 that	 exclusively	 labels	 unviable	 cells.	 Cells	 were	




























mixed	 thoroughly	 and	 subsequently	 deprotonated	 with	 600	 μL	 of	 a	 cold	 mixture	 of	 methanol:	
acetonitrile	 (1:1,	by	volume)	and	centrifuged	at	 room	temperature	 for	10	min	at	14,000	 rpm.	The	
supernatant	was	pipetted	 into	a	reaction	vial	and	evaporated	to	dryness	under	a	gentle	stream	of	
nitrogen	at	a	temperature	of	50°C.	The	derivatised	residue	was	reconstituted	with	150	μL	acetonitrile:	
















the	 Seahorse	 XF	Extracellular	 Flux	Analyser	 for	 30	min,	 prior	 to	 evaluation.	After	 establishing	 four	
baseline	OCR	and	ECAR	readings,	mitochondrial	inhibitors	were	injected.	
Figure	2.1	Overview	of	the	Seahorse	plate	design	and	experimental	output.	(A)	Seahorse	XF	analysers	use	a	
microchamber	created	between	the	sensors	and	 the	cells	 to	measure	 their	bioenergetic	profile	 in	a	precise,	
sensitive	and	relatively	non-destructive	manner.	Up	to	four	compounds	can	sequentially	be	added	per	well.	(B)	
Real	time	OCR	(upper	panel)	and	ECAR	(lower	panel)	measurements	are	obtained	in	response	to	compounds	
that	 interfere	with	mitochondrial	 ETC	 constituents:	 oligomycin,	 FCCP	 [carbonyl	 cyanide	 4-(trifluoromethoxy)	
phenylhydrazone],	antymycin	(A),	and	rotenone	(R).	
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the	appropriated	 treatment	 time,	 the	 fluorescent	dye	dichlorodihydrofluorescein	diacetate	 (DCFH-
DA)	10	μM	was	added	and	incubated	for	30	min.	Upon	transfusion	into	the	cells,	cellular	esterases	
oxidise	 the	 DCFH-DA	 compound	 into	 DCFH,	 which	 is	 further	 oxidised	 by	 nitrate	 species	 (NO2-),	
carbonate	species	(CO2-)	and	oxygen	species	(OH-)	into	the	highly	fluorescence	molecule	DCF	[285].	
Coverslips	were	 collected	 using	 forceps,	washed	with	 ice	 cold	 PBS	 and	 transferred	 to	microscope	

















mL	 low	 protein	 binding	 eppendorfs	 and	 centrifuged	 at	 4°C	 at	 13,000	 rpm	 for	 10	 min.	 Protein	
quantification	was	performed	using	the	BCA	assay	and	30-45	μg	of	protein	were	loaded	into	4-15%	
precast	 polyacrylamide	 gradient	 gels	 (Mini-PROTEAN	 TGX™,	 Biorad);	 runs	 were	 set	 at	 100	 V	 and	
proteins	were	transferred	to	PVDF	membranes	(Millipore).	Before	the	addition	of	primary	antibody,	
membranes	were	blocked	with	 5%	milk	 in	 TBS-Tween	 for	 1	 h.	 Primary	 antibodies	were	 incubated	
overnight	in	the	cold	room	and	the	appropriate	secondary	antibody	were	incubated	for	1	h	at	room	











lysis	 buffer	 (8	M	Urea	 in	 20	mM	HEPES	pH	8.0)	 supplemented	with	 phosphatase	 inhibitors	 (1mM	




After	 transferring	 the	 supernatants	 to	 fresh	 low	 protein	 binding	 eppendorf	 tubes,	 protein	
concentration	was	quantified	by	BCA	assay.		
2.9.2	Protein	digestion	and	peptide	desalting	for	proteomics	and	phosphoproteomics	
A	 total	of	450	µg	proteins	per	 sample	was	used	 for	 the	phosphoproteomics	experiments	of	MCF7	
























centrifugation	 with	 100	 µL	 glycolic	 acid	 solution,	 100	 µL	 ammonium	 acetate	 solution	 (100	 mM	
ammonium	 acetate;	 25%	 ACN)	 and	 100	 µL	 of	 10%	 ACN	 for	 3	 min	 at	 1,500	 x	 g.	 To	 recover	
phosphopeptides	 from	 the	 columns	 four	 consecutive	 elution	 steps	 of	 50	 μL	 of	 elution	 buffer	 (5%	























LTQ-Orbitrap	 XL	 ions	 are	 directed	 into	 the	 linear	 trap	 quadrupole	 (LTQ),	 which	 comprises	 three-
dimensional	 rod	quadrupoles	where	 selected	 voltages	 are	 applied	 to	 trap	 ions.	 The	 ion	 frequency	
given	by	their	m/z	determined	the	ion	motion	within	the	trap	[286].	Thus,	the	function	of	the	LTQ	is	
to	 accumulate	 ions	before	 sending	 them	 to	 the	orbitrap	 for	mass	 analysis.	 In	 the	Q	exactive	Plus,	










isolation	 and	 fragmentation.	 In	 the	DDA	method	 used	 on	 the	 LTQ-Orbitrap	 XL	 instrument	 full	MS	
spectra	(m/z	375-1,800)	were	acquired	with	30,000	resolution	at	m/z	400.	The	5	most	intense	ions	for	
each	full	MS	scan	survey	were	selected	for	CID	fragmentation	(35%	normalised	energy	collision)	and	














A	 dionex	 UltiMate	 3000	 RSLC	 nano	 is	 coupled	 to	 an	 Orbitrap	 Q	 Exactive	 Plus	mass	 spectrometer	
(Thermo	Fisher	Scientific).	For	the	LC	solvent	A	(0.1%	FA)	and	solvent	B	(100%	+	0.1%	ACN)	were	used	
as	mobile	phases.	A	total	of	4	μL	of	reconstituted	phosphopeptide	solution	were	loaded	in	an	Acclaim	
PepMap	μ-Precolumn	 for	 2	min	 at	 a	 back	 pressure	 of	 15	 bar	 and	 a	 nanoflow	of	 10	µL/min.	 Then	
phosphopeptides	were	separated	in	an	Acclaim	PepMap	100	column	using	a	gradient	that	went	from	
3%	to	23%	B	for	120	min	with	a	background	pressure	of	155	bar	and	a	nanoflow	of	0.3	µL/min.	Finally,	






Phosphopeptides	 were	 transferred	 to	 the	 online	 connected	 to	 a	 Q	 Exactive	 Plus	 system.	 For	
phosphoproteomics	and	proteomics	analysis,	 chromatographic	peaks	were	about	30	 s	 at	 the	base	
which	allowed	the	construction	of	extracted	ion	chromatograms	(XICs)	with	at	least	10	data	points.	




























































Figure	 2.4	 Schematic	 representation	 of	 the	 KSEA	principle.	 The	 log2	mean	 intensities	 of	 exclusive	 peptides	
phosphorylated	 at	 sites	 phosphorylated	 by	 each	 kinase	 is	 normalised	 to	 the	 SD	 of	 the	 intensities	 of	
phosphopeptides	in	the	whole	dataset	and	by	the	number	of	known	substrates	of	the	given	kinase.	
				Unsupervised	 k-means	 clustering	 algorithm	 was	 used	 to	 distribute	 the	 quantified	 peptides	 (for	
proteomics	experiments)	or	phosphopeptides	(for	phosphoproteomics	experiments)	across	a	number	



































200	 µg	 of	 DNA	 from	MCF7	 sensitive	 and	G	 resistant	 cells	was	 extracted	 using	 a	 commercial	 DNA	
purification	kit	(Quiagen).	DNA	amount	was	quantified	using	the	Qubit	fluorometric	system	(Thermo	
Fisher).	 Raw	 FASTQ	 reads	 were	 aligned	 using	 the	 Burrows-Wheeler	 Aligner	 (BWA)	 [287]	 to	 the	
reference	human	genome	version	hg19.	Output	alignments	in	SAM	format	were	sorted	and	converted	
to	 BAM.	 PCR	 duplicates	 were	 marked	 and	 removed	 using	 Picard	 algorithm	
(http://picard.sourceforge.net.).	 Local	 alignment	 around	 indels	 and	 base	 quality	were	 recalibrated	
using	the	GATK	algorithm	[288].	Somatic	single	nucleotide	variants	(SNVs)	and	indels	were	identified	
with	the	Strelka	algorithm	[289].	To	calculate	the	VAFs,	the	number	of	variant	reads	was	divided	by	
































Figure	 3.1	 Experimental	 approach	 followed	 to	 characterise	 cells	 that	 had	 acquired	 resistance	 to	 a	 PI3K	
inhibitor	at	the	phenotype	level.	Three	models	of	resistance	to	1	μM	GDC-0941	had	been	previously	derived	in	






















































3.1).	 Each	experiment	was	performed	 in	 triplicate.	 The	number	of	 viable	 cells	was	 then	measured	
using	the	Beckman	Vi-CELL	counter	according	to	manufacturer’s	instructions.	For	these	experiments,	







































				Analysis	of	 these	data	showed	that	parental	 cells	were	sensitive	 to	 the	panel	of	 targeted	kinase	












































































































































































PI3Ki GDC-0941 1 ɼM
AKTi1 A-VII 1 ɼM
AKTi2 MK-2206 1 ɼM
mTORC1/2i KU-0063794 1 ɼM
mTORC1i Everolimus 20 nM
SGKi GSK 650394 0.5 ɼM























replacements.	 These	 experiments	 clearly	 demonstrated	 that	 drug	 holidays	 influenced	 the	
















































































































































































































































Figure	 3.5	 Resistant	 cells	 increase	 their	 size	 and	 protein	 content	 during	 drug	 holidays.	 (A)	 Representative	
images	 and	diameter	 size	 of	 parental	 and	 resistant	 cells	maintained	 in	 culture	 for	 5	 days	 in	 the	absence	or	
presence	of	1	µM	GDC-0941	(PI3Ki).	(B)	Protein	content	of	parental	and	resistant	cells	growing	in	the	absence	
















































































































these	 cells	 to	 the	 PI3Ki.	 Protein	 quantification	 assays	 revealed	 that	 resistant	 cells	 increased	 the	
amount	of	protein	during	drug	holidays	(Fig	3.5B);	instead	of	using	this	increased	in	cell	biomass	to	






cells	 that	had	acquired	 resistance	 to	a	PI3K	 inhibitor,	 the	 changes	on	 the	proteome	and	 signalling	










The	 results	 presented	 in	 Chapter	 3	 characterised	 the	 phenotypic	 responses	 of	 models	 of	 PI3Ki-
resistant	 cells	 to	 the	 presence	 of	 PI3Ki	 or	 its	 absence.	 Phenotypic	 changes	 occurring	 in	 several	
diseases,	 such	 as	 the	 development	 of	 a	 particular	 metabolic	 features	 in	 metabolic	 diseases	 [11],	
modification	 of	 migration	 programs	 during	 metastasis	 [297]	 involve	 the	 alteration	 of	 numerous	
proteins	 comprised	 in	 molecular	 pathways	 that	 regulate	 a	 particular	 phenotype	 (e.g.	
anabolic/migratory	phenotype).		
				The	aim	of	the	work	presented	in	this	Chapter	sought	to	understand	how	cells	can	survive	in	the	
absence	of	PI3K	 signalling.	 It	was	hypothesised	 that	 the	observed	phenotypic	differences	of	PI3Ki-
resistant	cells	exposed	to	the	presence	of	PI3Ki	or	to	drug	holidays	from	PI3Ki	could	be	recapitulated	
















parental	 and	 PI3Ki-resistant	 cells.	 (A)	 Parental	 and	 resistant	 cells	 were	 seeded	 in	 175	 cm2	 flasks	 at	 70%	
confluence	 and	 kept	 in	 culture	 for	 5	 days	 either	with	 1	 µM	GDC-0941	or	 0.1%	DMSO.	 The	 experiment	was	
performed	 in	 quadruplicate.	 Cells	 were	 then	 collected	 and	 lysed,	 proteins	 were	 digested	 with	 trypsin	 and	
peptides	 desalted	 by	 solid-phase	 extraction.	 (B)	 Same	 experimental	 conditions	 as	 in	 (A)	 modified	 for	
phosphoproteome	analysis	(cells	were	grown	in	duplicate).		
	











Harvesting, cell lysis, trypsin digestion 
LC-MS/MS 
Identification : Mascot (MS+MS/MS Data)
Quantification : Pescal (MS Data)
200 μg protein
Top 5 (CID)







Harvesting, cell lysis, trypsin digestion 
TiO2 phosphoenrichment
LC-MS/MS (Q Exactive Plus)
Identification : Mascot (MS+MS/MS Data)
Quantification : Pescal (MS Data)
Kinase activity: KSEA (Phosphopeptides)






under	 the	 total	 ions	 chromatogram;	 (ii)	 determination	of	 the	MS	 fragmentation	performance;	 (iii)	
assessment	of	 the	 identity	 assignation	 to	 each	peptide	or	phosphopeptide;	 (iv)	 assessment	of	 the	
chromatography	linearity	by	calculating	the	linear	relation	in	retention	times	across	all	samples;	(v)	
evaluation	 of	 the	 normality	 distribution	 of	 peptides	 or	 phosphopeptides	 intensities	 and;	 (vi)	
determination	of	intensity	normalisation	efficiency	to	remove	technical	noise.	
				First,	the	mass	spectrometer	performance	was	estimated	by	determining	the	sum	of	the	total	area	






each	of	 the	 total	 28	 LC-MS/MS	 runs	 that	 generate	 the	database	was	 calculated.	A	 total	of	13,843	








image).	 Fifth,	 and	 after	 label-free	 quantification	 by	 the	 PESCAL	 algorithm,	 the	 data	 were	 log2	
transformed.	 Normal	 distribution	 of	 the	 data	 was	 deduced	 by	 visual	 inspection	 of	 the	 peptide	
intensities,	which	enabled	following	parametric	statistical	analyses	(Fig	4.2E).	Six,	the	log2-transformed	










cells	 grown	 in	 the	 presence	 or	 in	 the	 absence	 of	 PI3Ki.	 (A)	 Quantification	 of	 total	 area	 under	 the	
chromatographic	peaks	contained	in	28	proteomics	MS	runs.	(B)	Number	of	MS	and	MS2	scans	quantified	by	
RawMeat.	(C)	Quantification	of	the	number	of	identified	peptide	ions	(FDR<0.05)	that	generate	the	database	























in	 Fig	 4.3	 was	 performed.	 This	 analysis	 revealed	 that,	 as	 expected,	 proteomic	 sample	 replicates	
grouped	closer	in	the	PCA	space	(Fig	4.4).	This	analysis	also	showed	that	PI3Ki-resistant	cells	separated	
well	from	parental	cells	on	the	first	principal	component	(PC1),	indicating	that	acquisition	of	resistance	
was	 the	 principal	 factor	 determining	 diversity	 in	 the	 proteomes	 of	 parental	 and	 resistant	 cells.	

















































				To	 determine	 the	 cellular	 functions	 potentially	 modulated	 in	 PI3Ki-resistant	 cells,	 a	 pathway	




including	 glucose	 metabolism,	 monosaccharide	 metabolism	 and	 oxidation-reduction	 processes	
(Appendix	1).	Analysis	of	the	pathways	containing	proteins	modulated	because	of	drug	holidays	(i.e.	
G1 G2 G3
GO:0009267~cellular response to starvation GO:0043038~amino acid activation GO:0019748~secondary metabolic process
GO:0042594~response to starvation GO:0006418~tRNA aminoacylation for protein translation
GO:0031669~cellular response to nutrient levels GO:0043039~tRNA aminoacylation





GO:0009070~serine family amino acid biosynthetic process
GO:0008219~cell death
GO:0016265~death










that	 proteins	 involved	 in	 cellular	 response	 to	 starvation,	 amino	 acid	 activation	 and	 secondary	
metabolic	 processes	were	overrepresented	 in	 PI3Ki-resistant	 cells	 in	 response	 to	 the	drug	holiday	
treatment	(Table	4.1).	
			To	 provide	 additional	 evidence	 of	modulated	metabolic	 features	 in	 PI3Ki-resistant	 cells,	 various	
proteins	involved	in	diverse	metabolic	processes	were	extracted	from	the	proteomic	dataset	and	their	




fatty	 acid-binding	 protein,	 and	 ACLY	—	 ATP-citrate	 synthase),	 TCA	 cycle	 (e.g.	 IDH3A	—	 isocitrate	
dehydrogenase	3A)	and	electron	transport	chain	(e.g.	TXNL—	thioredoxin-like	protein).	The	data	also	
showed	that	upon	drug	removal,	PI3Ki-resistant	cells	increased	the	levels	of	proteins	involved	in	the	


















To	systematise	 the	classification	of	 the	proteomics	dataset	and	 further	explore	 the	 relationship	of	
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+PI3Ki-PI3Ki
































Fold over control (log2, n=4)
-5 -4 -3 -2 -1 0 1 2 3 4 5
























































































































































































































had	higher	 levels	of	 c-MYC	protein	 compared	 to	 the	parental	 cells.	Moreover,	 PI3Ki-resistant	 cells	
showed	 an	 increase	 c-MYC	protein	when	 treated	with	 the	 PI3Ki	 (Fig	 4.7).	 This	 suggested	 that	 the	




















































































































To	 investigate	 if	 PI3K	 remained	 inhibited	 in	 PI3Ki-resistant	 cells	 treated	 with	 PI3Ki,	 several	
phosphorylation	 sites	known	 to	be	 substrates	of	 kinases	of	 this	 signalling	 cascade,	were	extracted	





















































suggesting	 that	 the	 pathway	 activity	 is	 restored	 after	 drug	 withdrawal.	 The	 immunoblotting	 data	
reflected	 the	 pattern	 observed	 in	 the	 phosphoproteomics	 data	 that	 PI3K	 signalling	 was	 inhibited	
during	PI3Ki	treatment	and	reactivated	upon	PI3Ki	removal	from	the	culture	media	(Fig	4.9B).	
	
Figure	 4.9	 PI3K/mTOR	 signalling	 decreased	 in	 PI3Ki-resistant	 cells	 treated	with	 PI3Ki	 and	 recovered	 after	
removal	of	the	compound.	 (A)	Heatmap	of	selected	phosphorylation	sites	associated	with	the	PI3K	pathway	
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AKT1S1 seq: 244 - 251  + Phospho (ST) ; (z=2) *** ** *** *** *** *** *** **
EIF4EBP1 seq: 64 - 99  + 2 Phospho (ST) ; (z=4) * * *** * *** ** *
EIF4EBP1 seq: 20 - 51  + 2 Phospho (ST) ; (z=3) *** *** *** ** *
EIF4EBP1 seq: 20 - 56  + 2 Phospho (ST) ; (z=4) * ***
GSK3A seq: 17 - 50  + Phospho (ST) ; (z=3) * *** *** * ***
GSK3A seq: 19 - 50  + Phospho (ST) ; (z=3) ** *** *** ** *** **
GSK3B seq: 7 - 27  + Phospho (ST) ; (z=3) ** *** ** * *** **
RPS6KB1 pT444 pS447 ; (z=2) *** ** *** *
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AKT1S1 seq: 244 - 251  + Phospho (ST) ; (z=2) *** ** *** *** *** *** *** **
EIF4EBP1 seq: 64 - 99  + 2 Phospho (ST) ; (z=4) * * *** * *** ** *
EIF4EBP1 seq: 20 - 51  + ho (ST) ; (z=3) *** *** *** * *
EIF4EBP1 seq: 20 - 56  +  ho (ST) ; (z=4) * ***
GSK3A seq: 17 - 50  + Phospho (ST) ; (z=3) * *** *** * ***
GSK3A seq: 19 - 50  + Phospho (ST) ; (z=3) ** *** *** ** *** **
GSK3B seq: 7 - 27  + Phospho (ST) ; (z=3) ** *** ** * *** **
RPS6KB1 pT444 pS447 ; (z=2) *** ** *** *















To	 understand	 the	 relationships	 between	 the	 phosphoproteomes	 of	 PI3Ki-resistant	 cells,	 the	
consensus	 phosphorylation	 motifs	 present	 in	 the	 phosphoproteomics	 dataset	 were	 analysed.	
Hierarchical	 clustering	 of	 the	mean	 log2	 fold-change	 across	 common	 173	 specific	 phosphorylation	
motifs	 revealed	 similar	 patterns	 of	 association	 between	 PI3Ki-resistant	 cells	 to	 those	 observed	
previously	 (Figs	 3.2	 and	4.4).	 For	 example,	 the	 consensus	phosphorylation	motifs	 of	G1+	 and	G2+	
resistant	cells	grouped	close	together,	whereas	the	same	cells	grown	in	the	absence	of	PI3Ki	(i.e.	G1-	







































revealed	an	enrichment	of	 substrates	 specific	of	MEK	and	CAMKII,	 suggesting	a	greater	activity	of	
these	kinases	 in	PI3Ki-resistant	compared	 to	parental	 cells	 (Fig	4.12B).	The	 functional	 relevance	of	
these	kinases	in	PI3Ki-resistant	cells	was	further	evaluated	and	results	will	be	discussed	in	Section	4.5.	





























































Figure	4.12	K-means	consensus	clustering	 for	 the	phosphoproteomes	of	MCF7	parental	and	 resistant	 cells	
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Markers of kinase activity
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demonstrated	 in	vitro	and	 in	vivo	 [304].	 It	was	therefore	hypothesised	that	the	MAPK	and	Calcium	
signalling	pathways	may	be	compensating	for	the	lack	of	PI3K	activity	in	PI3Ki-resistant	cells.	
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parental	 cells,	 but	 rather	 different	 signalling	 network	 landscapes.	 This	 was	 shown	 by	 the	
phosphorylation	motifs	present	in	PI3Ki-resistant	cells	compared	to	those	in	parental	cells	(Fig	4.11),	











during	 drug	 holidays	 increased	 the	 levels	 of	 proteins	 associated	with	 different	metabolic	 process,	
including	pentose	phosphate	pathway	and	gluconeogenesis	(Fig	4.5A	and	Table	4.1).	In	addition,	the	

















				In	 addition,	 during	 routine	 cell	 culture	 it	 was	 consistently	 appreciated	 that	 PI3Ki-resistant	 cells	
acidified	 the	culture	media	 to	a	greater	extent	 than	parental	cells,	which	was	considered	to	be	an	
indicator	of	an	altered	metabolism	in	these	models.	



















additional	panel	of	 seven	pairs	of	 sensitive/resistant	 cells	 resistant	 to	mTORC1/2	 inhibition	 [226]	 and	PI3Kα	













































7.64.	 The	 glycolytic	 phenotype	 of	 PI3Ki-resistant	 cells	 was	 proved	 to	 be	 reversible,	 since	 drug	
readministration	reverted	the	initial	phenotype	(Fig	5.2B).	
				The	oxidative	capacity	of	parental	and	PI3Ki-resistant	cells	exposed	to	the	absence	and	presence	of	
PI3Ki	 was	 then	 quantified	 by	 the	 ability	 of	 cells	 to	 oxidise	 the	 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium	(MTS)	reagent.		Equal	number	of	cells	(0.02	
x	106	per	well)	were	seeded	in	96-well	plates	and	the	cells	were	maintained	with	either	1	μM	GDC-
0941	or	0.1%	DMSO	for	1,	2,	3	or	5	days.	The	production	of	 formazan	 from	the	MTS	assay	by	 the	
cellular	oxidoreductase	enzymes	was	used	as	a	surrogate	measure	for	the	oxidative	activity	of	cells	at	



















































































































































































































				A	 series	 of	 optimisation	 steps	 were	 performed	 to	 maximise	 the	 outcome	 of	 the	 Seahorse	
experiments.	Initially,	given	that	the	performance	of	the	sensors	depends	on	the	physical	chamber	of	
media	created	by	the	cells	as	well	as	on	the	measuring	time,	the	optimal	cell	seeding	density	and	the	
instrument	 timing-framework	 measurements	 were	 determined.	 To	 achieve	 this,	 and	 based	 on	






a	 basal	 ECAR	within	 20-120	mpH/min,	 the	 number	 of	 cells	was	 increased	 to	 80,000	 cells/well	 for	
further	testing,	to	increase	the	degree	of	cell	confluence	and	the	amount	of	oxygen	consumed	as	well	
as	the	capacity	of	acidifying	the	extracellular	milieu.	The	result	of	this	initial	experiment	also	led	to	the	
decision	 to	 increase	 the	 operational	 cycles	 length	 to	 gain	 consistency	 across	 measurement	

























the	mitochondrial	 inhibitory	 compounds	 and	 three	measurements	were	 recorded	 after	 those	 (i.e.	
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(mpH/min)






































































of	PI3Ki	 (Fig	5.5B).	Maximal	 respiration	capacity,	 i.e.	 the	greatest	 rate	of	 respiration	achievable	by	
cells,	was	significantly	elevated	in	PI3Ki-resistant	cells	on	drug	holidays	conditions:	1.5-fold	greater	for	


















18 36 54 72 90 108 126 144


































































18 36 54 72 90 108 126 144
















































Time (min) Time (min)





























































The	 contribution	 of	 CO2,	 product	 of	 the	 TCA,	 to	 the	 cellular	 acidification	 is	 derived	 from	 the	
CO2	hydration	to	H2CO3	and	further	dissociation	to	HCO3-	and	H+.	Although	this	contribution	is	minimal	




growth	 media.	 Prior	 to	 measurement	 of	 lactic	 acid	 by	 comparison	 to	 a	 lactic	 acid	 standard,	
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extracellular	 lactic	 acid	 measured	 in	 the	 culture	 media	 of	 PI3Ki-resistant	 cells.	 It	 was	 therefore	
hypothesised	that	the	levels	of	ROS,	which	could	derived	from	the	mitochondrial	respiratory	activity,	
may	increase	in	PI3Ki-resistant	cells	after	a	period	of	drug	holidays.		
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of	 these	 cells	 (Fig	 5.5A).	Moreover,	 G1-	 cells	 showed	 1.6-fold	 times	 higher	 ROS	 levels	 (P=	 0.005)	
compared	to	the	ROS	levels	of	parental	cells	and	G2-	cells	showed	1.4	-fold	times	higher	ROS	levels	
(P=	0.004)	 compared	 to	 the	ROS	 levels	 of	 parental	 cells,	 indicative	of	 higher	 accumulation	of	 free	
radicals	in	G1-	and	G2-	resistant	cells	(Fig	5.7A).	
				To	understand	the	impact	of	intracellular	ROS	accumulation	on	the	proliferation	of	PI3Ki-resistant	
cells,	ROS	were	down-regulated	by	 the	 free	 radical	quencher	N-acetyl	 cysteine	 (NAC).	 Initially,	 the	









NAC	 (14	 days)	 was	 then	 explored.	 In	 agreement	 with	 the	 previous	 observations,	 this	 experiment	
showed	that	antioxidant	treatment	enhanced	the	proliferation	of	cells	that	accumulate	high	levels	of	
ROS,	but	reduced	the	proliferation	of	cells	with	 lower	ROS	 levels.	For	example,	after	two	weeks	of	
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increasing	 concentrations	 of	 α-tocopherol	 (grey	 line)	 and	 resistant	 cells	 were	 exposed	 to	 increasing	
concentrations	of	α-tocopherol	in	the	presence	(dash	line)	or	absence	(continuous	line)	of	GDC-0941.	Before	α-






To	 profile	 the	 changes	 in	 expression	 of	 genes	 usually	 associated	 to	 metabolic	 activity	 in	 PI3Ki-
resistance	 cells,	 the	 transcription	 levels	 of	 76	 genes	 involved	 in	 15	 metabolic	 pathways	 were	
quantified.	For	this	purpose,	1	x	106	parental	and	PI3Ki-resistant	cells	grown	with	and	without	PI3Ki	
were	pelleted	into	RNA	free	tubes.	After	RNA	extraction,	transcripts	were	pre-amplified	by	qRT-PCR.		




























































of	 PI3Ki	 treatment	 was	 then	 analysed.	 Fig	 5.10	 showed	 that	 removal	 of	 PI3Ki	 led	 to	 increased	

















































Figure	 5.10	 Levels	 of	 transcripts	 for	 known	 metabolic	 genes	 increase	 in	 PI3Ki-resistant	 cells	 upon	 drug	













that	HIF’s	 transcriptional	 activities	 in	 normoxic	 conditions	 increased	 between	 3.3	 to	 13.6	 times	 in	
PI3Ki-resistant	cells	grown	without	the	PI3Ki	compared	to	the	same	cells	grown	with	the	compound.	














counter	 and	 a	 pH	meter,	 respectively.	 	 The	 results	 presented	 in	 Fig	 5.11D	 showed	 that	 chetomin	
reduced	the	proliferation	of	parental	cells.	The	proliferation	of	G1-	and	G2-	cells	was	not	significantly	
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significantly	 decreased	 upon	 HIF	 inhibition	 (Fig	 5.11F).	 These	 data	 were	 consistent	 with	 the	
transcriptional	activities	of	HIF	controlling	the	expression	of	genes	involved	in	the	production	of	lactic	







































				To	 test	 this	 hypothesis,	 HIF-1α	was	 analysed	 by	Western	 blot	 after	 treating	 parental	 and	 PI3Ki-
resistant	cells	with	the	ROS	quencher	NAC.	The	resulting	data	clearly	demonstrated	that	the	levels	of	
HIF-1α	protein	decreased	after	ROS	scavenging,	indicating	that	ROS	contribute	to	the	stability	of	HIF-
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In	 addition	 to	 HIF,	 c-MYC	 also	 regulates	 the	 glycolytic	 activity	 in	 some	 systems	 [152].	 Given	 the	
observed	 increased	of	 c-MYC	protein	 levels	 (Fig	4.7),	 and	 the	 increased	 c-MYC	phosphorylation	at	
Thr58/Ser62	 in	 PI3Ki-resistant	 cells	 (Fig	 4.10),	 the	 role	 of	 c-MYC	 contributing	 to	 the	 resistance	 and	
metabolic	 phenotype	 of	 PI3Ki-resistant	 cells	 was	 then	 investigated.	 To	 do	 so,	 the	 transcriptional	
activity	of	c-MYC	was	prevented	with	compounds	that	compete	for	the	formation	of	the	c-MYC-MAX	
heterodimer	(i.e.	10058-F4	and	10074-G5)	[155,	156].	Here,	it	was	important	to	stress	that	given	that	
these	 compounds	 prevent	 the	 assembly	 of	 the	 transcriptional	 machinery	 rather	 than	 directly	
inhibiting	 c-MYC,	 two	 highly	 selective	 and	 structurally	 diverse	 disruptors	 of	 the	 c-MYC-MAX	
































plates	 containing	 2	 mL	 of	 growth	 media	 and	 treated	 with	 several	 kinases	 inhibitors.	 For	 the	
luminescence	experiment,	 cells	 were	 grown	 on	 coverslip	 as	 described	 in	 Section	 2.7.4.	 Media	
acidification	was	measured	by	means	of	a	pH	meter	and	ROS	were	visualised	by	means	of	a	fluorescent	
microscope.	 Analysis	 of	 these	 results	 showed	 that	 inhibition	 of	 PI3K	 and	 mTOR	 impeded	 the	
acidification	of	the	media	used	to	grow	PI3Ki-resistant	cells	(Fig	5.15A),	suggesting	that	these	kinases	
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µM	GDC-0941	 (PI3Ki),	 1	 µM	 AV-II	 (AKTi1),	 1	 µM	MK-2206	 (AKTi2),	 1	 µM	 KU-0063794	 (mTORC1/2i),	 20	 nM	





































































































































*** ****** pH 
media











































































































































































To	determine	 the	extent	of	PI3K-mTOR,	but	AKT-independent,	 signalling	 in	PI3Ki-resistant	cells,	an	
experiment	was	designed	to	treat	in	duplicate	G2	resistant	cells	with	1	μM	GDC-0941	(PI3Ki),	1	μM	
MK-2206	(AKTi),	1	μM	KU-0063794	(mTORC1/2i)	or	0.1%	DMSO	(control)	for	1	h.	After	cell	lysis	and	






mTORC1	 (Fig	 5.16B).	 In	 contrast,	 the	 inhibitors	 of	 PI3K,	 AKT,	 and	 mTORC1/2	 reduced	 the	
phosphorylation	of	the	AKT	substrate	PRAS40	at	Thr246.	
				Hierarchical	 clustering	 of	 the	 significantly	 modulated	 phosphopeptides	 demonstrated	 a	 clear	
separation	between	the	phosphopeptides	modulated	as	a	function	of	treatment	of	G2	resistant	cells	
with	AKTi,	PI3Ki	or	mTORC1/2i	(Fig	5.16C).	
				The	 inhibitory	effect	of	AKT	and	mTORC1	 inhibitors	was	 confirmed	by	Western	blot	 (Fig	5.16D).	
Thus,	the	allosteric	AKT	inhibitor	prevented	the	phosphorylation	of	PRAS40	at	Thr246	(an	AKT	target)	
but	not	of	4E-BP1	at	Thr37/Thr45	(a	mTOR	target).	The	mTORC1	inhibitor	reduced	the	phosphorylation	
of	 4E-BP1	 at	 Thr37/Thr45.	 These	 data	 confirmed	 that	 inhibition	 of	 AKT	 does	 not	 prevent	 the	









Heatmap	 showing	 phosphopeptides	 significantly	 modulated	 in	 G2	 resistant	 cells	 treated	 for	 1h	 with	 the	
indicated	 kinase	 inhibitors.	 (B)	 Relative	 intensity	 of	 selected	 targets	 downstream	 of	 AKT	 and	 mTORC1.	 (C)	
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a	 Vi-CELL	 counter.	 These	 data	 showed	 that	 withdrawal	 of	 PI3Ki	 made	 PI3Ki-resistant	 cells	 more	
sensitive	to	glucose	starvation	compared	to	the	same	cells	cultured	in	the	presence	of	PI3Ki	(Fig	5.17A,	
upper	panel).	PI3Ki-resistant	cells	 in	drug	holidays	were	also	more	sensitive	to	glucose	deprivation	
than	 parental	 cells.	Of	 note,	 the	 extent	 of	 the	 sensitivity	was	 proportional	 to	 the	 intensity	 of	 the	






such	 as	 H2O2,	 was	 also	 explored.	 The	 result	 of	 this	 experiment	 demonstrated	 that	 cells	 that	
accumulated	 intracellular	 ROS	 responded	 to	 an	 oxidative	 challenge.	 For	 example,	 G1-	 and	 G2-	
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(considered	 as	 a	 pro-proliferative	 metabolic	 parameter,	 when	 in	 homeostasis)	 against	 ROS	
(considered	as	an	anti-proliferative	metabolic	parameter,	when	homoeostasis	is	lost)	was	performed.	
Plotting	the	ratio	of	cell	proliferation	upon	drug	removal	and	the	ratio	of	glycolytic	activity	 to	ROS	


































of	excessive	amount	of	ROS	was	 toxic	 for	 some	cells	 (e.g.	G2-	 resistant	cells),	and	 the	detrimental	
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HIF	 transcriptional	 activity	 were	 increased	 in	 PI3Ki-resistant	 cells	 (Fig	 4.6D),	 the	 activity	 of	 HIF	 in	
resistant	cells	was	further	explored.		
				In	 normoxic	 conditions,	 HIF’s	 activities	 of	 PI3Ki-resistant	 cells	 grown	 in	 the	 absence	 of	 the	 lipid	










was	 explored.	 Immunoblotting	 data	 revealed	 that	 ROS	 scavenging	 reduced	 the	 amount	 of	 HIF-1α	
protein	 of	 PI3Ki-resistant	 cells	 (Fig	 5.13A)	 and	 the	 amount	 of	 lactic	 acid	 in	 the	 culture	media	 (Fig	
5.13B),	suggesting	that	ROS	maintained	the	glycolytic	activity	by	stabilising	HIF-1α.	
				c-MYC	 oncogene	 has	 been	 identified	 in	 several	 preclinical	 models	 as	 a	 mechanism	 to	 acquire	
resistance	to	PI3K	inhibition	[301,	313,	314],	and	it	is	known	to	coordinate	the	expression	of	metabolic	
genes	 in	 some	 biological	 systems	 [100].	 Because	 proteins	 transcriptionally	 controlled	 by	 c-MYC	













signalling,	 PI3Ki-resistant	 cells	 presented	 a	 signalling	 cascade	 mediated	 by	 PI3K/mTOR	 that	 was	







inhibition	 showed	 that	 drug	 holidays	 enhanced	 the	 bioenergetic	 profile	 of	 most	 of	 PI3Ki-	 and	
mTORC1/2i-resistant	 cells	 (Fig	 5.18	 B-D).	More	 remarkably,	 there	was	 a	 high	 correlation	 between	
impaired	proliferation	of	 resistant	cells	during	drug	holidays	and	defective	metabolic	homeostasis,	
characterised	by	the	accumulation	of	ROS	relative	to	the	glycolytic	activity	of	these	cells	(Fig	5.19B).		










genomic	 aberrations	 during	 long	 term	 drug	 treatment	 conjointly	 with	 non-mutational	 changes	















Whole exome sequencing (WES)











To	 explore	 the	 genomic	 background	 of	 PI3Ki-resistant	 cells,	 DNA	 of	 these	 cells	 was	 extracted	 as	
described	 in	 Section	 2.11.	 The	 initial	 quality	 control	 of	 the	 generated	 libraries	 for	 paired-end	
sequencing	is	shown	in	Appendix	13.	Short	sequence-reads	of	parental	and	PI3Ki-resistant	cells	were	
matched	 to	 the	 reference	 human	 genome,	 with	 a	 89-98%	 span	 coverage	 at	 more	 than	 20	 reads	
sequencing	depth	(i.e.	number	of	times	a	nucleotide	base	is	sequenced)	(Table	6.1).	The	mean	number	
of	reads	for	parental	and	PI3Ki-resistant	cells	was	between	67-152	million	reads	(Table	6.1).	The	sizes	












lung	 cancer	 tumours	 [318].	 Moreover,	 most	 of	 the	 point	 mutations	 of	 PI3Ki-resistant	 cells	 were	
missense	mutations,	 indicating	 a	 potential	 selective	 advantage	 for	 those	missense	mutations	 (Fig	
6.2C).	The	variant	allele	frequencies	(VAFs)	of	PI3Ki-resistant	cells	showed	average	VAFs	between	0.21-
0.27	(Fig	6.2D).	
Parental G1 G2 G3
Mean	number	of	reads	per	sample		(M) 95.7 115.3 151.8 67.1
Mean		sequenced nucleotides	(Gb)	 4.8 5.8 7.7 3.4





















protein	 deletes	 the	 Tyr1248	 from	 its	 sequence.	 The	 phosphorylation	 status	 of	 this	 site	 has	 been	






























































































































effect	 of	 amino	 acid	 alterations	 based	 on	 each	 protein’s	 3D	 structure,	 returning	 the	 impact	 of	 a	
substitution	as	being	'probably	damaging',	'possibly	damaging',	'benign'	or	'unknown'	for	the	protein	















I II III IV TKD SD
22 196 321 489 720 987 1255
NH2 COOH


































in	 breast	 cancer	 cell	models	 of	 acquired	 resistance	 to	 PI3Ki	 [313].	 HEY1,	 another	member	 of	 the	
NOTCH1	pathway,	was	amplified	 in	 the	 three	PI3Ki-resistant	cell	 lines	 (Fig	6.5A).	RAD21	and	EXT1,	
located	the	chromosome	8	long	arm,	were	also	amplified	in	G1,	G2,	and	G3	resistant	cells.	
Chr Position Reference	 Alteration Gene	name Amino	acid	position	
Amino	acid	
change Mutation	type	 Sift_Prediction Poly_Prediction
10 25273776 A	 T	 ENKUR	 218 I>K	 nonsyn TOLERATED PROBABLY	DAMAGING
12 20787953 C	 T	 PDE3A	 655 A>V	 nonsyn TOLERATED BENIGN
14 105517794 T	 G	 GPR132	 227 K>T	 nonsyn TOLERATED POSSIBLY	DAMAGING
14 59961938 C	 A	 JKAMP	 166 P>T	 nonsyn DAMAGING PROBABLY	DAMAGING
14 74388787 G	 A	 ZNF410	 400 S>N	 nonsyn DAMAGING BENIGN
16 68156591 T	 C	 NFATC3	 269 S>P	 nonsyn DAMAGING PROBABLY	DAMAGING
17 37884010 C	 T	 ERBB2	 1161 R>*	 nonsyn:stop-gain	 Na na
19 7975396 TG	 T	 MAP2K7	 211 V>V	 frameshift:stop-gain	 Na na
22 21991190 C	 A	 CCDC116	 558 P>H	 nonsyn TOLERATED POSSIBLY	DAMAGING
3 180327887 T	 A	 TTC14 624 S>T	 nonsyn DAMAGING PROBABLY	DAMAGING
4 103682008 C	 A	 MANBA	 15 G>V	 nonsyn TOLERATED UNKNOWN
4 20736354 A	 T	 KCNIP4 145 F>Y	 nonsyn DAMAGING PROBABLY	DAMAGING
4 56865526 A	 G	 CEP135	 690 K>E	 nonsyn TOLERATED PROBABLY	DAMAGING
4 6052337 G	 A	 JAKMIP1	 626 L>F	 nonsyn DAMAGING PROBABLY	DAMAGING
5 78602211 C	 T	 JMY	 632 A>V	 nonsyn TOLERATED PROBABLY	DAMAGING
8 110497292 T	 A	 PKHD1L1	 3199 I>K	 nonsyn DAMAGING PROBABLY	DAMAGING
8 94767182 TG	 T	 TMEM67	 14 W>C	 frameshift:stop-gain	 Na na
8 94767184 G	 T	 TMEM67	 14 W>C	 nonsyn TOLERATED POSSIBLY	DAMAGING
9 139735084 C	 G	 RABL6	 409 C>W	 nonsyn DAMAGING UNKNOWN











































of	 regions	 that	 showed	 copy	 number	 alteration	 in	 resistant	 cells	 compared	 to	 parental.	 (A)	 Type	 of	 copy	
number	variant	and	chromosomal	location	identified	in	the	resistant	cells.	Genes	catalogued	in	the	database	of	




				Copy-number	 neutral	 LOH	 events	 originate	 either	 through	 homologous	 chromosomal-






















































































































































































































































































































































































































































































































































































































































G2 828282 82 82 82828272 4 62808080808070608283828282828282628282 2 80808080808080828282 3 4 2 2 2 60808070 2 2 2 0 8060
G1 826282 82 82 8282827274 2 828182828272 2 60608080808080806080807080808080808080 2 2 2 3 4 2 2 2 2 3 2 7270706060 0 0
G3 808080 80 80 8080807070608080808080706080808080808080808080807082828282828282 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 62
B
1Non-silent	mutation	 # Copy	Neutral	LOH+Non-silent mutation
# Copy	Neutral	LOH # Gain+Non-silent mutation










	A	 comprehensive	 characterisation	 of	 the	 exome	 landscapes	 of	 three	 cell	 lines	 that	 had	 acquired	
resistance	to	GDC-0941	(G1:G3)	and	the	parental	MCF7	cells	(P)	was	performed	using	whole-exome	
sequencing.	 This	 analysis	 recapitulated	 the	 higher	 similarity	 between	G1	 and	G2	 resistant	 cells in	





and	 Table	 6.2).	 The	 orphan	 receptor	 ERBB2	 serves	 as	 a	 partner	 to	 form	 heterodimers	with	 other	
receptors	 of	 the	 ERBB	 family	 (e.g.	 ERBB3	 or	 EGFR),	 or	 constitute	 ERBB2	 homodimers,	 and	 its	
expression	 is	 low	 in	MCF7	cells	 compared	 to	other	breast	 cancer	 cell	 lines	 [324].	 The	precipitated	
termination	 of	 ERBB2	 protein	 at	 amino	 acid	 1161	 located	within	 the	 protein	 intracellular	 domain	
























prognosis	 and	 chemotherapy	 resistance	 in	 various	 breast	 carcinoma	 types	 [327].	 In	 addition,	 the	























				MCF7	 cells	 were	 selected	 as	 a	 model	 because	 the	 lactic	 acid	 production	 of	 this	 cell	 line	 was	
previously	quantified	and	changes	 in	 the	 lactic	acid	production	 in	drug-resistant	cells	derived	from	
MCF7	 cells	were	detected	 (these	 results	were	presented	 in	 Chapter	 5).	 Several	 experiments	were	
performed	to	understand	the	lactic	acid-mediated	changes	in	the	proteome	and	phosphoproteome	
of	these	cells	as	well	as	functional	impact	of	exposing	these	cells	to	lactic	acid.	Initially,	the	protein	
expression	of	MCT1,	MCT2,	 and	MCT4	 transporters	was	assessed.	 The	effect	of	pharmacologically	
















Figure	7.1	Schematic	representation	of	experiments	performed	to	assess	the	 impact	of	 lactic	acid	 in	MCF7	
cells.	(A)	Lactate	transport	is	modulated	via	MCTs.	The	MCT	family	includes	14	members	and	MCT1-4	mediate	





acid	 to	 promote	 resistance	 to	 glucose-starvation	 in	 these	 cells	 was	 examined.	 (E)	 The	 signalling	 cascades	
modulated	 upon	 treatment	 of	MCF7	 cells	 with	 lactic	 acid	 or	 hydrochloric	acid	 (this	 treatment	 was	 used	 to	
account	for	acidosis)	were	analysed.	(F)	The	modulation	of	the	proteome	of	cells	upon	exposure	to	lactic	acid	or	















































Figure	 7.2	MCF7	 parental	 and	 PI3Ki-resistant	 cells	 express	 lactate	membrane	 transporters.	Western	 blots	


































































































































The	 acidic	 milieu	 can	 affect	 the	 cellular	 behaviour	 [113].	 To	 resemble	 the	 acidity	 resulting	 from	
exposure	of	cells	to	lactic	acid	(which	dissociated	in	lactate	and	protons	[H+])	an	acidic	environment	
was	mimicked	using	HCl	(which	dissociates	in	protons	[H+]	and	the	chloride	ion	[Cl-]).	To	obtain	the	
equivalence	 point	 for	 lactic	 acid	 and	 HCl,	 pH	 values	 were	 measured	 as	 a	 function	 of	 increasing	
concentrations	of	these	acids	in	media.	More	specifically,	range	of	0-50	mM	lactic	acid	was	added	to	
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ability	of	 lactic	acid	to	trigger	signalling	events	 [168,	331],	 it	was	hypothesised	that	 lactic	acid	may	
compensate	the	proliferative	action	of	FBS-contained	factors.	An	experiment	was	designed	to	explore	
this	 hypothesis,	 whereby	 MCF7	 cells	 were	 grown	 in	 DMEM	 media	 depleted	 from	 FBS	 and	
supplemented	 with	 increasing	 concentrations	 of	 lactic	 acid	 —	 1	 mM,	 5	 mM,	 and	 10	 mM	 —,	
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The	 normalised	 phosphoproteomics	 data	 was	 compared	 against	 the	 non-treated	 control.	 The	
resulting	analysis	of	the	abundance	of	statistically	significant	modulated	phosphopeptides	for	each	
time-point	and	condition	is	shown	in	Fig	7.8.	These	data	serve	as	an	overview	of	the	effect	of	lactic	







































































































































































































































































involved	 in	MAPK	and	PI3K	 signalling	pathways	were	extracted	 from	 the	data,	 and	 their	 temporal	
modulation	 profiles	 upon	 lactic	 acid	 and	 HCl	 treatment	 analysed.	 These	 data	 showed	 that	 upon	








PI3K	 signalling,	 a	 site	 on	 AKT1S1	 (most	 probably	 at	 Thr246),	 also	 known	 as	 PRAS40,	 increased	 its	
phosphorylation,	 and	 the	 magnitude	 of	 this	 activation	 was	 greater	 after	 treatment	 with	 higher	
concentrations	 of	 lactic	 acid	 or	 hydrochloric	 acid	 (Fig	 7.9A).	 In-line	 with	 AKT’s	 activation,	 the	
phosphorylation	 of	 peptide	 derived	 from	 GSK3β	 seq	 7-27	 (most	 probably	 Ser9,	 a	 direct	 AKT’s	
substrate)	increased	upon	treatment	with	high	concentrations	of	lactic	acid	or	HCl.	This	site	had	a	later	
kinetics	 than	 the	phosphorylation	of	AKT1S1.	Phosphorylation	of	ACLY	at	Ser455,	another	 substrate	
target	 of	 AKT	 that	 engages	 the	 activity	 of	 ACLY	 [334],	 also	 increased	 under	 lactic	 acid	 or	 HCl	
treatments.					
				Additional	 downstream	 markers	 related	 to	 the	 PI3K	 pathway,	 such	 as	 phosphorylation	 sites	
substrates	of	mTOR,	including	EIF4,	RICTOR,	RPS6KB1,	EEF2K,	and	ULK1	were	modified	in	abundance	
under	 treatment	with	 different	 concentrations	 of	 acids.	 For	 example,	 low	 concentrations	 of	 acids	
induced	an	increase	in	the	phosphorylation	of	the	RICTOR	on	a	phosphopeptide	seq	1217-1235	(most	
likely	 at	 Ser1235),	 but	 the	 abundance	 of	 this	 phosphorylation	 inhibitory	 site	 was	 reduced	 upon	
treatment	with	high	 levels	of	acids	 (Fig	7.9A).	The	RICTOR	site	Ser1235	 is	a	 substrate	of	GSK3β	 that	
prevents	the	interaction	between	AKT	and	mTORC2	[335];	blockade	of	activity	of	GSK3β	associated	
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-5 -4 -3 -2 -1 0 1 2 3 4 5
-5 -4 -3 -2 -1 0 1 2 3 4 5





AKT1S1	seq:	244	- 251		+	Phospho (ST) * * *** *** *** * ** ** ** **
GSK3B	seq:	7	- 27		+	Phospho (ST) *** * *** ***
ACLY	pS455 * * * * * ** *
EIF4EBP1	seq:	64	- 73		+	2	Phospho (ST) *** ***
EIF4EBP1	seq:	64	- 99		+	2	Phospho (ST) * * * ** *
EIF4EBP1	seq:	70	- 99		+	2	Phospho (ST) ** * * *** *
EIF4EBP1	seq:	70	- 99		+	Oxidation	(M);	Phospho (ST) * * *
EIF4EBP1	seq:	74	- 99		+	Phospho (ST) * * ** ** *
EIF4EBP2	seq:	21	- 51		+	Phospho (ST) *
EIF4EBP2	seq:	21	- 51		+	Phospho (ST);	Phospho (Y) **
EIF4EBP2	seq:	63	- 92		+	2	Phospho (ST) * **
EIF4EBP2	seq:	63	- 92		+	Phospho (ST) **
EIF4EBP2	seq:	64	- 92		+	Oxidation	(M);	Phospho (ST) * * **
EIF4EBP2	seq:	64	- 92		+	Phospho (ST) * ** * * * *
EIF4EBP2	seq:	93	- 106		no	mod * * * *** *
RICTOR	seq:	1217	- 1238		+	Phospho (ST) * * * **
RICTOR	seq:	1282	- 1298		+	Phospho (ST) * *** *** ** * *** *** *** *
RPTOR	pS863 ** * * * *** ** **
RPTOR	pS877 ** * ** ***
RPTOR	pS859	pS863 ** * * ** * *
EEF2K	pS72	pS74 * * ** *** **
EEF2K	seq:	69	- 82		+	Phospho (ST);	Phospho (Y) *** * *
EEF2K	seq:	69	- 82		+	Phospho (ST) * * ** * *
EEF2K	seq:	69	- 82		+	Phospho (ST) *
EEF2K	seq:	69	- 82		+	2	Phospho (ST) *** * *
ULK1	pS556 * * ** * **
ULK1	pS758 * *
SAFB	seq:	601	- 612		+	Phospho (ST) ** ** * * *
SAFB	pS601	pS604 ** ** *
SAFB	pS601 * ** ** * * ** ** *
SAFB	pS601	pS604 *** *** *** *** *** *** *** * * *** ** * ** *
SAFB	pS604 ** ** ** * ** ** *** *** *** * ** *** ***
MAPK1	pY187 *** *** * ** * ***
MAPK1	seq:	173	- 191		+	Phospho (ST) *** *** ** * **
MAPK3	pT202	pY204 *** * * *
MAPK3	pY204 *** ** * ** *
RAF1	pS621 *
RAF1	seq:	257	- 275		+	Oxidation	(M);	Phospho (ST) * *
RPS6KA1	seq:	729	- 735		+	Phospho (ST) *** *** *** ** *** ***
RPS6KB1	pS447 ** * ** * * * ** *

























IGF-1	 stimulation).	 To	 define	 this	 signalling	 network,	 cells	 were	 treated	 with	 a	 panel	 of	 kinase	
inhibitors	and	sites	that	change	their	phosphorylation	status	were	considered	readouts	of	the	kinase	
affected	 by	 the	 inhibitor,	 the	 so	 called	 CTAM	 network	 analysis,	 from	 Compound	 targets	 activity	
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				Further	 analysis	 of	 these	 data	 revealed	 that	 those	 pathways	 that	 are	 both	 up-regulated	 upon	
EGF/IGF-1	stimulation	and	down-regulated	when	MEK	and	PI3K	are	 inhibited	were	activated	upon	






min	 treatment	 with	 20	 mM	 lactic	 acid	 or	 with	 9.7	 mM	 HCl,	 respectively	 (Fig	 7.10,	 blue	 square).	
Alongside,	the	extent	of	modifications	of	EGF/IGF-1-ROCK	and	EGF/IGF-1-CAMKII	branches	was	lower	





























Fig	7.12,	 the	phosphoproteomics	dataset	was	 filtered	and	clustered	using	k-means	 to	 include	only	
those	peptides	that	were	significantly	modulated	in	at	least	one	condition	compared	to	t=0.	Of	the	
6,319	peptides	quantified	in	this	experiment,	5,155	were	phosphorylated.	Peptides	were	grouped	into	
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5 min 0.97 mM HCl





5 min 9.7 mM HCl
15 min 9.7 mM HCl
30 min 9.7 mM HCl
60 min 9.7 mM HCl


































5 min 5 mM LA
15 min 5 mM LA
30 min 5 mM LA
60 min 5 mM LA
5 min 0.97 mM HCl
15 min 0.97 mM HCl
30 min 0.97 mM HCl
60 min 0.97 mM HCl



































5 min 20 mM LA
15 min 20 mM  LA
30 min 20 mM LA
60 min 20 mM LA
5 min 9.7 mM HCl
15 min 9.7 mM HCl
30 min 9.7mM HCl















			Phosphopeptides	 that	 increased	 when	 cells	 were	 exposed	 to	 high	 concentration	 of	 acids	 and	
decreased	 upon	 treatment	with	 low	 acidic	 concentrations	 located	 in	 cluster	 2	 (160	 peptides)	 and	
cluster	5	(752	peptides),	whereas	phosphopeptides	that	increased	when	cells	were	exposed	to	with	
low	 concentration	 of	 acids	 and	 decreased	when	 cells	were	 exposed	 to	 high	 acidic	 concentrations	
located	in	cluster	6	(1,273	peptides)	and	cluster	7	(364	peptides)	(Fig	7.13A).	Analysis	of	the	biological	
processes	 associated	 to	 cluster	 2	 and	 cluster	 5	 revealed	 an	 enrichment	 of	 the	 activity	 of	 proteins	
related	 to	 the	 signalling	mediated	 by	 p38α/β	 (Fig	 7.13B).	Moreover,	 there	was	 an	 enrichment	 of	
processes	associated	to	glucose	metabolism	and	structural	function	in	phosphopeptides	contained	in	
cluster	 5	 and	 an	 enrichment	 of	 processes	 associated	 to	 rRNA	 processing	 for	 phosphopeptides	
contained	in	cluster	2	(Fig	7.13B).		
				Cytoskeleton-involving	processes	were	enriched	upon	treatment	of	cells	with	low	concentration	of	
acids,	 as	 suggested	 by	 the	 enrichment	 of	 Arf6	 trafficking	 (in	 cluster	 6),	 regulation	 of	 Rho	 GTPase	
activity	(in	cluster	6),	regulation	of	RAC1	(in	cluster	7),	and	Rho	GTPase	regulation	activity	(in	cluster	







low	 and	 high	 concentration	 of	 lactic	 acid	 and	 HCl.	 (A)	 k-means	 algorithm	 grouped	 phosphopeptides	 that	
increased	or	decreased	upon	treatment	with	low	or	high	concentrations	of	lactic	acid	and	HCl	for	5,	15,	30,	and	
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after	short	time	(4	h)	treatments	 in	cluster	2	–	which	contains	368	proteins	–	 	 	and	proteins	which	
levels	decreased	at	short	times	and	increase	at	 	 long	time	(24	h)	treatments	 	 in	cluster	6	 	–	 	which	
contains	 327	 proteins	 (Fig	 7.19A).	 The	 complete	 data	 is	 shown	 in	 Appendix	 18.	 Analysis	 of	 the	
biological	 processes	 associated	 to	 proteins	 contained	 in	 these	 two	 clusters	 revealed	 that	 proteins	
involved	in	“cellular	components	organization	or	biogenesis”	were	enriched	as	a	result	of	the	exposure	
of	MCF7	cells	to	lactic	acid	or	HCl	(Fig	7.19B).	Extraction	of	some	proteins	contained	in	this	ontology	
is	 shown	 in	 Fig	 7.19C.	 These	 data	 revealed	 that	 the	 levels	 of	 several	 proteins	 involved	 in	 the	
cytoskeletal	 organization,	 such	 as	 α-actinin	 1	 and	 Cadherin	 1,	 significantly	 decreased	 upon	 8	 h	
treatment	with	9.7	mM	HCl	(Fig	7.19C).		
	







































































































































































































































































































































































































































































































































































































































































































































































































































































































ACTN4 * * Alpha-actinin-4	 2
ACTN1 * * Alpha-actinin-1	 2
CADH1 * Cadherin-1	 2
AGFG1 * Arf-GAP	domain	and	FG	repeat-containing	protein	1	 2
ARPC4 * Actin-related	protein	2/3	complex	subunit	4	 6
ACTN2 * Alpha-actinin-2	 6
ARC1B ** Actin-related	protein	2/3	complex	subunit	1B	 6
K2C6B * * Keratin,	type	II	cytoskeletal	6B	 6
ACTN3 *** Alpha-actinin-3	 6
K1C15 ** *** * Keratin,	type	I	cytoskeletal	15	 6
K1C17 * Keratin,	type	I	cytoskeletal	17	 6
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A	 characteristic	 of	 the	 tumour	microenvironment	 is	 local	metabolic	 acidosis,	mainly	 caused	by	 an	
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				Low	glucose	 is	 another	 characteristic	of	 the	microenvironment	of	many	 solid	 tumours	 [338].	 To	
determine	the	nutrient	capacity	of	lactic	acid	during	glucose	starvation,	glucose	was	withdrawal	from	
cell	 culture	 media	 and	 supplemented	 with	 lactic	 acid.	 This	 experiment	 revealed	 that	 lactic	 acid	
reduced	by	more	than	two-fold	the	death	of	MCF7	cells	(Fig	7.5).		
				A	 minimal	 concentration	 of	 FBS	 is	 needed	 to	 provide	 the	 signalling	 molecules	 that	 MCF7	 cells	
require	to	proliferate	[340].	Given	the	expression	of	the	lactate-specific	receptor	GPR81	in	these	cells	














lactic	 acid	 and	 HCl	 (Fig	 7.9A).	 It	 was	 interesting	 to	 observe	 that	 the	 phosphorylation	 of	 known	
substrates	of	AMPK	—	including	ULK1	at	Ser556	and	SAFB	Ser601/604	—	was	induced	upon	treatments	
with	lactic	acid	and	HCl	(Fig	7.9A).		





differences	 between	 acids	 at	 equivalent	 concentrations	 (Fig	 7.12B).	 Altogether,	 these	 analyses	
demonstrated	that	the	amount	of	acidic	perturbation	impact	very	differently	the	phosphoproteome	













lactic	 acid	 or	 HCl	 (Figs	 7.17	 and	 7.18).	 Analysis	 of	 the	 biological	 processes	 associated	 to	 proteins	







levels,	 and	 functional	 processes	 in	 a	 model	 breast	 cancer	 cell	 line	 treated	 with	 two	 different	
concentration	of	lactic	acid	and	HCl.	
	





The	 PI3K/AKT/mTOR	 pathway	 responds	 to	 external	 and	 internal	 stimuli	 and	 has	 an	 essential	 role	
modulating	key	cellular	functions	[85].	Targeting	kinases	of	this	signalling	pathway	is	relevant	in	cancer	
biology,	 as	 their	 activities	 are	 frequently	 altered	during	 carcinogenesis	 [6].	Nevertheless,	 acquired	





genomic,	 transcriptomic,	 proteomic	 and	 signalling	 characterization	 of	 cellular	 models	 of	 acquired	
resistance	to	PI3K	blockade,	and	the	functional	implications	of	those	modifications;	(ii)	the	metabolic	
status	 of	 cancer	 cells	 that	 had	 acquired	 resistance	 to	 PI3K	 and	mTORC1/2	 inhibition;	 and	 (iii)	 the	
response	to	lactic	acid,	a	metabolic	product,	of	a	predefined	signalling	network	of	the	MCF7	breast	
cancer	cell	line.	
				Understanding	 the	 mechanisms	 used	 by	 cancer	 cells	 that	 have	 evolved	 to	 survive	 the	 chronic	
inhibition	of	kinase-driven	signalling	pathways	is	fundamental	to	optimise	therapeutic	strategies	to	
eliminate	cancer	cells.	Nevertheless,	the	biochemical	changes	of	drug-resistant	cancer	cells	exposed	
to	 differential	 selection	 pressures	 have	 not	 been	 comprehensively	 investigated.	 Therefore,	 the	
phenotypes	as	well	as	the	proteomes	and	phosphoproteomes	of	PI3Ki-resistant	cells	exposed	to	the	




metabolism-derived	 products	 quantified	 (Chapter	 5).	 To	 then	 provide	 insights	 into	 the	 genomic	


















of	 additional	 mutations	 and	 epigenetic	 adaptations	 of	 cancer	 cells,	 whereby	 the	 proliferation	 of	
resistant	 cells	 is	 strengthened	 upon	 transformations	 aside	 from	 inbuilt	 programs	 of	 cancer	 cells	
behaviour.	
				Given	the	central	role	of	PI3K	in	cell	biology	and	cancer	[2,	345],	characterising		phenotypic	changes	































In	 addition,	 immunoblotting	 of	 substrates	 of	 the	 targeted	 kinases	 would	 have	 determined	 the	
inhibitory	effects	of	the	small	molecule	inhibitors	panel	used	in	this	study.		
				PI3Ki-resistant	 cells	 proliferated	 at	 lower	 rate	 compared	 to	 the	 parental	 cells	 from	 which	 they	
originated,	and	this	proliferative	deficiency	was	not	reverted	after	removal	of	PI3Ki	treatment.	It	was	









proliferate	 during	 drug	 holidays,	 even	 though	 they	 increase	 their	 biomass	 and	 cell	 size	 in	 those	
conditions.	















				The	discovery	 that	 cessation	of	PI3K	 inhibitor	 treatment	changes	various	phenotypic	 features	of	
PI3Ki-resistant	cells	could	have	major	implications	for	cancer	treatment	given	that	several	agents	that	









[363].	 Even	 though	 a	 previous	 study	 demonstrated	 that	 the	 signalling	 plasticity	 of	 cells	 that	 had	
acquired	 PI3Ki	 resistance	 is	 high	 [226],	 the	 global	 pathways	 rewiring	 of	 those	 PI3Ki-resistant	 cells	
prompted	by	PI3Ki	withdrawal	remained	unexplored.	From	a	therapeutic	standpoint,	understanding	
the	molecular	remodelling	occurring	in	drug-resistant	cells	during	drug	holidays	may	help	to	identify	
druggable	molecular	 targets	 and	 guide	 the	 selection	 of	 effective	 treatment	 schemes	 during	 dose	
intermittent	regimes,	often	implemented	to	overcome	therapy	toxicities	[178].	
				The	proteomes	and	phosphoproteomes	of	PI3Ki-resistant	cells	under	treatment	with	the	PI3Ki	or	

















increased	 in	PI3Ki-resistant	 cells	and	 that	proteins	 transcriptionally	 controlled	by	 c-MYC	as	well	 as	
members	of	the	HIF-1α	transcription	factor	network	increased	in	PI3Ki-resistant	cells.	It	is	interesting	













reactivation	 of	 the	 signalling	 activity	 downstream	 of	 PI3K	 upon	 drug	 withdrawal	 confirmed	 the	
conservation	 of	 this	 signalling	 cascade’s	 activity	 in	 this	 context.	 This	was	 similar	 to	 the	 functional	
reactivation	of	 kinases	downstream	of	PI3K	upon	drug	 removal	observed	 in	other	models	of	PI3Ki	
resistance	[305].	
				PI3Ki	 removal	 led	 to	 signalling	 rewiring	of	 PI3Ki-resistant	 cells,	 and	 the	network	of	G1-	 and	G2-	
resistant	cells	was	markedly	distinct	to	that	one	of	G3-	resistant	cells.	The	antioxidant	activity	of	PI3Ki-
resistant	 cells	 was	 engaged	 as	 a	 consequence	 of	 drug	 holidays,	 as	 deduced	 from	 the	
phosphoproteomics	data.	Previous	in	vivo	and	in	vitro	studies	have	reported	that	antioxidant	agents	


























































cancer	 cells	 that	 could	 be	 exploited	 therapeutically,	 as	 shown	 for	 other	 models	 of	 resistance	 to	
targeted	therapies	[344,	374].	
				Finally,	 it	 was	 reasoned	 that	 delineation	 of	 cellular	 metabolic	 profiles	 could	 assist	 designing	
experiments	to	 investigate,	by	means	of	LC-MS,	the	signalling	changes	that	occur	 in	cancer	cells	 in	







changes,	 as	 indicated	 by	 the	 reversible	 capacity	 of	 resistant	 cells	 to	 acidify	 the	 culture	 media.	
Metabolic	plasticity	 in	response	to	specific	stress	was	recently	found	in	metformin-resistant	cancer	








cells.	 This	 is	 the	 first	 characterisation	 of	 the	metabolic	 profiles	 of	 cancer	 cells	 that	 had	 acquired	
resistance	to	a	class	I	PI3K	inhibitor,	and	implies	that	altered	cellular	metabolism	is	not	only	a	hallmark	
of	 oncogenesis,	 but	 also	 happens	 during	 the	 process	 of	 acquiring	 resistance	 to	 targeted	 therapy.	
During	 drug	 holidays,	 however,	 PI3Ki-resistant	 cells	 enhanced	 their	 metabolic	 activity.	 Given	 the	
central	 role	of	 the	PI3K	 signalling	pathway	 coordinating	 the	metabolism	 [376],	 restoration	of	PI3K	
signalling	activity	possibly	aggregated	to	the	metabolic	activity	gained	by	PI3Ki-resistant	cells	over	the	
course	of	acquisition	of	resistance.		
				The	amount	of	metabolic	products	 (i.e.	 lactic	acid	as	a	product	of	 the	glycolytic	activity	and	 the	
intracellular	ROS	as	product	of	the	mitochondrial	respiration)	increased	in	PI3Ki-resistant	cells	during	
drug	 holidays,	 mirroring	 their	 enhanced	 metabolic	 activity.	 ROS	 overproduction	 limited	 the	
proliferation	of	resistant	cells,	and	such	deficient	proliferative	capacity	was	reverted	upon	treatment	
with	antioxidants.	This	observation	suggests	that	despite	the	increased	antioxidant	activity	of	PI3Ki-
resistant	 cells	 during	 drug	 holidays	 (as	 presented	 in	 Section	 4.4.6),	 those	 adaptations	 were	 not	
sufficient	 to	 counteract	 the	 toxic	 effects	 of	 ROS	 accumulation	 derived	 from	 an	 augmented	
metabolism.	











which	 in	 conjunction	 with	 HIF-1α	 accounts	 for	 the	main	 effect	mediated	 by	 HIF,	 remained	 to	 be	
elucidated	for	these	cells.	In	this	study	it	was	showed	that	the	stability	of	HIF-1α	was	promoted	by	






glycolytic	and	glutaminolytic	pathways	 [100,	378].	 It	was	previously	appreciated,	and	presented	 in	




c-MYC	transcription	machinery	has	proven	 in	other	studies	 [379].	The	data	presented	 in	Chapter	5	




























				Overall,	 these	 data	 are	 in	 agreement	 with	 several	 studies	 that	 implicated	 various	 kinases	 —		
including	RAC,	mTORC2	and	PDK1	—	in	the	AKT-independent	PI3K	signalling	activity	of	cancer	cells	





















could	 predict	 their	 proliferative	 outcome	 and	 could	 be	 an	 indicator	 of	 the	 potential	 efficacy	 of	






lipid	synthesis	prevents	metastatic	dissemination	of	 those	models	 [385].	Alternatively,	 the	balance	















study	 reveals	 that	 PI3Ki-resistant	 cells	 exposed	 to	 drug	 holidays	 are	 sensitive	 to	 metabolic	
manipulation.	 The	 therapeutic	window	of	 agents	 that	 target	 the	metabolism	during	drug	holidays	
might	be	of	easier	application	in	the	clinic	than	combinatorial	approaches.	As	for	any	other	therapies,	
the	 pharmacokinetics,	 pharmacodynamics,	 safety,	 and	 efficiency	 of	 these	 treatments	 entail	 close	
monitoring	during	therapy	[140].		
				This	research	introduces	the	concept	that	targeting	metabolic	dependencies	of	cancer	cells	may	be	





				Lastly,	 the	 hypothesis	 that	MCF7	 parental	 cells	 have	 a	 transduction	 cascade	 that	 by-passes	 the	
activity	of	AKT	to	connect	PI3K	and	mTOR	is	yet	to	be	determined.	To	test	this,	the	phosphoproteomes	
of	 these	cells	 treated	with	 inhibitors	against	PI3K,	AKT	and	mTOR	would	need	to	be	analysed.	The	
hypothesis	 would	 be	 confirmed	 if	 inhibition	 of	 PI3K	 and	 mTOR,	 but	 not	 AKT,	 prevents	 the	









genomes.	 Large	 scale	genomic	 sequencing	 initiatives,	 such	as	COSMIC	have	unveiled	 thousands	of	



















The	 functional	effects	of	each	of	 these	mutations	—	for	example,	 the	ability	of	mutated	ERBB2	to	
dimerise	with	other	members	of	the	ErbB	family	—	were	not	evaluated	in	this	study.	
					The	lack	of	secondary	mutations	in	PI3K	supports	the	hypothesis	that	the	targeted	inhibitor	GDC-
0941	effectively	binds	 to	 the	 kinase,	 suggesting	 that	 the	mechanism	by	which	PI3Ki-resistant	 cells	
overcome	the	 inhibition	of	the	PI3K	pathway	 is	not	mediated	by	secondary	mutations	 in	PI3K.	 It	 is	
interesting	to	note	that	neither	loss-of-function	mutation	nor	loss	of	PTEN	was	not	found	in	any	of	the	
three	 PI3Ki-resistant	 cell	 lines.	 This	 observation	 contrast	 the	 convergent	 PTEN	 loss	 found	 in	 other	
tumour	models	 [168].	Further	validation	of	 the	 identified	genomic	alterations	by	methods	such	as	
Sanger	 sequencing	 or	 tagged	 amplicon	 sequencing	would	 be	 necessary	 to	 confirm	 their	 value.	 In	
addition,	the	contribution	of	other	non-synonymous	mutations	to	the	resistant	phenotypes	could	be	











in	 various	 tumour	 types,	 including	 breast	 cancer	 cells	 [301,	 313,	 314]	 and	 acute	 lymphoblastic	
leukaemia	 (ALL)	 [172].	 In	 addition	 to	 this	 documented	mechanism	 of	 acquired	 resistance	 to	 PI3K	
inhibitors,	copy	number	analysis	showed	that	the	three	PI3Ki-resistant	cell	lines	carry	amplifications	






resistant	 cells	 that	 may	 have	 potential	 implications	 in	 cancer	 therapeutics	 (Fig	 8.1).	 First,	 drug-
sensitive	cancer	cells	exposed	to	identical	drug	selecting	pressure	evolve	into	heterogeneous	drug-
resistant	cells.	This	observation	mirrors	the	notion	that	the	sequence	of	antecedent	states	determines	
the	outcome	proposed	by	Stephen	Jay	Gould	to	explain	 the	diversity	of	 life	 forms	 in	 the	Cambrian	






















of	 PI3K	 signalling.	 (A)	 Parental	 cells	 in	 basal	 conditions:	 the	 glycolytic	 and	 respiratory	 activities	 are	 in	
homeostasis,	sustained	by	the	activity	of	signalling	pathways	to	maintain	a	positive	cell	proliferation	of	drug-
sensitive	cancer	cells.	(B)	Parental	cells	treated	with	a	PI3K	inhibitor	(represented	in	purple):	inhibition	of	PI3K	
signalling	 induces	 cell	 death	 and	 loss	 of	metabolic	 activity.	 (C)	 Resistant	 cells	 treated	with	 a	 PI3K	 inhibitor:	
resistant	cells	develop	genomic	mutations	(represented	in	red),	modulate	the	activity	of	several	proteins	and	
recover	the	metabolic	balance	by	activating	compensatory	signalling	pathways	that	enable	cell	proliferation.	(D)	
Resistant	 cells	 during	 drug	 holidays:	 reactivation	 of	 the	 suppressed	 signalling	 pathway	 causes	 a	 defective	
metabolic	activity	that	hinders	the	proliferation	of	drug-resistant	cells.	(E)	Oxidative	challenge	in	resistant	cells	





A	 common	 characteristic	 of	 tumours	 is	 the	 accumulation	 of	 lactic	 acid	 in	 the	microenvironment,	
ascribed	to	an	enhanced	glycolic	activity	of	cancer	cells	[392].	Published	studies	have	demonstrated	
that	metabolism-derived	lactate	can	directly	stimulate	the	activity	of	some	signalling	networks	in	an	
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supporting	 the	 anti-cancer	 therapeutic	 usage	 of	 chemical	 inhibitors	 that	 target	 MCT1	 [141].	 The	
observed	effect	of	MCT1i	in	these	cells	was	agreement	with	other	studies	that	revealed	that	targeting	
MCT1’s	activity	impaired	the	proliferation	of	breast	cancer	cells	in	vitro	and	in	vivo	[142,	394].	Analysis	




reported	 for	 other	PIK3CA-mutant	 cell	 lines,	which	 could	 not	 compensate	 the	 glucose	withdrawal	



































				Autophagy	 contributes	 to	 recycling	 intracellular	 components	 to	 promote	 cell	 survival,	 and	 is	
triggered	in	non-malignant	and	cancer	cells	in	response	to	stress	conditions,	including	acidosis	[55].	
The	 hypothesis	 that	 lactic	 acid	 and	 acidosis	 induce	 autophagy	 in	 these	 cells	 could	 be	 tested	 by	
measuring	 well-known	 autophagic	 markers	 such	 as	 the	 conjugate	 LC3-phosphatidylethanolamine	




signalling	 branches	 (e.g.	 EGF-ERK	 axis,	 IGF-1-ERK	 axis,	 EGF-AKT	 axis,	 and	 IGF-1-AKT	 axis).	 This	was	
previously	 uncharacterised.	 Indeed,	 this	 study	 provides	 the	 first	 large	 scale	 analysis	 of	 how	 the	
signalling	 networks	 of	 MCF7	 respond	 to	 lactic	 acid	 and	 HCl,	 and	 was	 in	 agreement	 with	 other	





of	 HCl	 may	 have	 been	 overlooked;	 actually,	 experiments	 conducted	 to	 understand	 the	 signalling	
activity	of	lactate	through	GPR81	did	not	control	for		acidosis	[108].		




with	 low	 concentration	 of	 acids.	 Data	 from	 previous	 studies	 associated	 glycolytic	 rates	 with	
cytoskeletal	 remodelling	 [401];	 however,	 a	 direct	 role	 of	 lactic	 acid	 in	 the	 regulation	 of	 Rho/Rac	



























were	not	optimised	 to	enrich	 for	membrane	proteins	 and	alternative	 fractionation	methods	 [405]	
could	help	in	this	regard.	
					A	substantial	improvement	in	this	study	would	have	been	to	use	a	method	to	selectively	inhibit	the	
GPR81	 cognate	 receptor	 for	 lactate.	 However,	 several	 attempts	 using	 siRNA	 targeting	 GPR81	
transcripts	were	disappointing,	and	did	not	consistently	reduce	the	expression	levels	of	GPR81	(Fig	7.3	
as	 a	 representative	example).	Optimisation	of	 siRNA	 transfection	 conditions	or	usage	of	 inhibitors	
against	GPR81	(such	as	pertussis	toxin)	or	analogues	of	lactic	acid	(such	as	3-hydroxybutyrate)	would	
contribute	to	characterise	the	signalling	pathways	mediated	by	lactate.	In	addition,	and	as	previously	
mentioned,	 given	 that	 limited	 glucose	 is	 common	 in	 the	 tumour	microenvironment,	 the	 signalling	
response	 to	 lactic	 acid	 of	 cells	 exposed	 to	 glucose	 limiting	 conditions	 could	 be	 explored	 in	 future	
experiments.							









8	 h	 and	 an	 increased	 after	 24	 h	 treatments.	 Ontology	 analyses	 revealed	 that	 several	 biological	
processes	changed	in	response	to	treatment	with	lactic	acid	or	HCl.	For	instance,	essential	cytoskeletal	
proteins,	 such	 as	 α-actinins	 1-4,	 known	 to	 be	 actin-crosslinking	 proteins	 [406],	 were	 significantly	
reduced	after	8	h	treatment	with	9.7	mM	HCl.		
				Albeit	 the	 intracellular	 pH	 or	 the	 lactate	 uptake	were	 not	measured	 in	 these	 experiments,	 the	
cellular	location	and	pH-sensing	domains	of	proteins	could	impact	their	response	to	intracellular	pH	
and	might	explain	some	of	the	observed	changes;	indeed,	changes	in	protein	protonation	has	shown	












the	higher	number	of	 apoptotic	 cells.	Although	enhanced	 cellular	 apoptosis	 and	 reduced	 cytokine	
production	of	T-cells	exposed	to	high	concentration	of	lactic	acid	has	been	documented	before	[116],	












and	 the	activity	of	AMPK	—	may	be	modulated	upon	 treatment	of	 these	cells	with	 lactic	acid	and	
acidosis,	as	indicated	by	time-resolved	phosphoproteomics	experiments.		




regarding	 the	 therapeutic	 relevance	of	 interfering	with	 the	 transport	of	 lactic	acid	 to	 limit	 tumour	
growth	[408].		
				Ultimately,	functional	metabolic	assays	could	be	instrumental	to	determine	the	effect	of	lactic	acid	
and	 acidosis	 treatments	 on	metabolism	 (e.g.	 glycolytic	 activity	 and	 oxidative	 phosphorylation).	 In	










signalling	 pathways	 facilitates	 a	 comprehensive	 understanding	 of	 the	molecular	mechanisms	 that	
control	 cellular	 systems.	 Signalling	 networks	 evolve	 during	 treatment,	 and	 adapt	 in	 response	 to	
stimuli.	Mass	 spectrometry-based	 (phospho)-proteomics	 allows	 the	 quantification	 of	 proteins	 and	
phosphate-mediated	post-translational	modification	of	proteins	in	an	extensive	manner.		
				The	aim	of	 this	 thesis	was	 to	understand	 the	biochemical	adaptations	 that	allow	cancer	 cells	 to	
compensate	 for	 the	 chronic	 PI3K	 signalling	 inhibition,	 with	 the	 ultimate	 objective	 to	 identify	
vulnerabilities	in	those	cells	when	exposed	to	differential	selection	pressures.		
				The	results	presented	in	this	thesis	revealed	exciting	associations	between	metabolic	modulations	
and	 kinase-mediated	 signalling	 pathways,	 and	 characterise	 how	 these	 modulations	 impact	 the	
functionalities	 of	 cancer	 cells	 resistant	 to	 targeted	 therapies.	 In	 particular,	 exploiting	 the	 loss	 of	
metabolic	homeostasis	of	drug-resistant	cells	is	proposed	as	an	effective	adjuvant	therapy	to	the	drug	
holidays	 approach	 to	 delay	 drug-resistance	 of	 cancer	 cells	 treated	 with	 targeted	 drugs.	 Future	
research	in	this	topic	should	focus	on	pre-clinical	studies	in	in	vivo	systems.	
    Furthermore,	the	impact	of	lactic	acid	on	the	signalling	activity	of	a	luminal	epithelial	breast	cancer	
cell	 line	was	 characterised	 in	 this	 thesis.	 These	experiments	demonstrated	a	dose-response	 in	 the	













































































































































FABP5 *** *** *** *** GSTM3 *** *** ** ** *** MURC ** *
HID1 * * HS905 * * * ** ** IPO5 * * ** ** *
PGTA * * * RM10 * * TXTP * *** *
MGT5A * ** EIF3L ** FKB1A *** ** ** ***
ADSV *** *** *** *** *** *** *** ** ** RNH2B ** * EIF3I ** * *
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RIR2B *** ** * ** *** * LYAG ** ** PUR6 * * * ** ** ** **
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PDE12 ** ** * ENSA ** ** FAHD1 **
IMA5 ** *** * LYPA2 * ** TCPH * ** *** *** * **
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GFPT1 * ** HS74L * * * TBR1 *
IDH3A * ** ** * ** THOP1 * GYS1 * *
NAA50 ** TPC * ** * HSB11 * *
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TIM9 ** ** * * * PYGB * RENT1 * *
ACON * *** * RL7L * * GDIB * *** * *** *** *
PGAM1 ** * * * PSAL * XRCC1 *
ERGI1 * RBBP4 * * MSH4 * *
PNMA5 * ** EDC3 * ** PANK4 * ** *
PDCD4 * *** * EIF3B *** ** ** ** ** ** IF5 ** ** ** * * **
DHTK1 * ** AMPL ** ** * TRPM8 * * *
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PFD6 ** * 1433T * ** AT1B3 ** *
SYVC * PAP1M * ** * H90B2 ** ** * ** ** **
CALX ** RB3GP * NIT2 * * *
MYO9A * RB33B * PABP3 * *** * ** *
RANG * * RB27B * CYBP ** * ** ** *
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SAFB1 * IPO4 ** * * ** TCPD ** ** * *
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DDX20 *** ** ** * ** ***
BAP31 ** * *
P4HA2 * *** ** *
LR37B * * **
SRS11 * * ** ** *
HTSF1 *** * ** * *
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STOM **
OAS1 *** *** *** *** *** **
FAAH2 ** *** ** **
GTR1 ** * * *
STMN2 **
PESC *** *** *** *** *** *** *
ACOC * * * * *




DLRB1 * *** ** *
DYLT1 *** *
CD81 *
PLDN ** ** **
TEX26 * * ** *
S10AA * ** *
AN32B * * * *
AHNK *** *** *** *** * * ***
TOX4 ** *
FERM2 *
CORO7 * * * *
KAD1 ** ** * *
PSMG1 * * **
CPNE9 ** ** * **
AP4S1 ** *
THIO * *
PP1R7 * * *
ING4 **
GTD2B ** * *
GSHR *** ** * **
CHSP1 ** * * *
FAH2B *
DPP3 *** ** *** *** ** * *
NH2L1 *** **
RD23B ** * * **
TBB8 * ** *
DCTN2 * *
PSMD5 * **
UGGG1 * * *
EF1D *** * ***
















































































































AMOTL1	pS793 * ** 1 ERRFI1	pS251 *** * *** 2
FAM195B	seq:	16	-	38		+	2	Phospho	(ST) *** 1 NUP35	seq:	295	-	310		+	Phospho	(ST) * * ** ** 2
PDS5B	seq:	1152	-	1169		+	Phospho	(ST) *** *** 1 PPFIA3	pS1164 *** *** 2
KRT8	seq:	226	-	252		no	mod *** *** *** *** *** 1 EIF2B4	pS130 ** * ** * *** ** *** 2
RPL22L1	seq:	108	-	122		+	Phospho	(ST) * *** *** 1 DLGAP4	seq:	971	-	991		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** * ** * ** 2
IRF2BP2	seq:	454	-	467		+	2	Phospho	(ST) ** * * *** 1 DLGAP4	seq:	971	-	991		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** ** 2
SRRM2	seq:	2114	-	2129		+	2	Phospho	(ST) * *** ** 1 SRRM2	pS2272 ** ** * ** *** ** 2
AHNAK	seq:	204	-	225		+	2	Phospho	(ST) * ** * * 1 PANK2	pS189 * ** ** ** 2
CTNNB1	pS191 * ** 1 TUBA3E	seq:	41	-	60		+	Phospho	(ST) ** * 2
ENSA	pS109 * ** * ** 1 NFX1	seq:	47	-	58		+	Phospho	(ST) *** *** 2
RBM39	pS127	pS129 * ** 1 CCDC88C	seq:	1599	-	1611		+	Phospho	(ST) *** *** ** ** 2
HINT1	seq:	31	-	37		no	mod * ** *** *** 1 PPP1R12A	seq:	299	-	315		no	mod *** * * *** ** 2
FOXK1	seq:	416	-	430		+	2	Phospho	(ST) *** ** *** *** *** *** ** 1 CHD8	pS2046 ** * * * 2
PRKAR2A	pS78	pS80 ** * ** *** 1 TPD52L1	pS149 *** ** * * *** *** 2
FOXJ3	pS223 *** *** ** ** * 1 S100A11	seq:	56	-	62		no	mod ** * 2
CALM1	seq:	92	-	107		no	mod * ** ** 1 ZYX	pS267 *** *** ** * ** *** 2
AHSG	pS138 ** ** *** * 1 PKM	pS37 *** ** * * *** ** * 2
MFAP1	pS52	pS53 ** 1 GBF1	seq:	1315	-	1331		+	Phospho	(ST) ** ** 2
SP110	seq:	373	-	388		+	Phospho	(ST) *** *** 1 MAP7D1	seq:	111	-	129		+	Phospho	(ST) *** *** ** * ** 2
ACTBL2	seq:	185	-	192		no	mod ** * *** *** * 1 MAVS	pS165 ** * 2
CCDC94	pS211	pS213 * ** 1 VPS13D	pS1042 *** ** ** *** * ** 2
ZYX	seq:	254	-	265		+	Phospho	(ST) *** * ** 1 TFPT	seq:	171	-	190		+	Phospho	(ST) * * * ** 2
MFAP1	pS116 * *** ** *** 1 RAD23B	seq:	145	-	173		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) ** ** ** 2
CBPA6_HUMAN	seq:	58	-	64		+	Phospho	(ST) * * * ** 1 ATXN2L	pS111 *** * * *** ** * 2
MCM3	seq:	696	-	724		+	2	Phospho	(ST) ** * 1 TPD52L1	pS149 *** *** * *** *** 2
NCL	seq:	298	-	318		no	mod * ** 1 CLCC1	seq:	432	-	443		+	Phospho	(ST) ** ** *** ** ** ** 2
FAM134C	pS258	pS260 ** * 1 PKLR	seq:	338	-	348		no	mod * * ** 2
CDK12	pS681	pS685 ** * ** 1 ATXN2L	pS111 *** ** * *** *** ** * 2
NACA	seq:	128	-	142		no	mod ** * ** *** ** 1 HID1	seq:	591	-	614		+	Phospho	(ST) ** ** * *** ** 2
F11R	seq:	278	-	286		+	Phospho	(ST) * ** * * 1 ZMYM2	seq:	298	-	312		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) ** *** 2
PAICS	seq:	202	-	215		no	mod * ** ** 1 VDAC1	seq:	97	-	109		+	Phospho	(ST) * ** * ** 2
PARN	seq:	568	-	605		+	2	Phospho	(ST) *** * 1 PPAN	pS359 *** * * ** ** 2
FAM53C	pS232	pS234 ** ** *** ** 1 PRKAR1A	pS83 ** *** * 2
SRRM1	pS605	pS607 * *** *** ** * * 1 COBLL1	pS294 *** * *** * ** 2
MAP2	seq:	1770	-	1785		+	Phospho	(ST) * * ** * *** * 1 CLASP1	pS1091 ** * ** ** 2
TXLNG	pS97 ** * ** * 1 DYNC1LI1	pS510 *** ** ** ** ** 2
MYC	seq:	52	-	66		+	2	Phospho	(ST) ** *** ** *** *** * 1 DDX21	pS89 * ** * ** * 2
DYNC1H1	seq:	229	-	251		no	mod ** * 1 LAD1	seq:	120	-	135		+	Phospho	(ST) ** ** 2
GTPBP1	pS44	pS47 * ** *** * *** 1 ERRFI1	seq:	249	-	263		+	Phospho	(ST) *** ** *** ** * 2
ATP5B	seq:	388	-	406		no	mod ** ** * *** 1 PELP1	seq:	732	-	759		+	Phospho	(ST) ** * ** *** 2
RANBP2	pS2270 ** ** * 1 CTPS1	seq:	571	-	591		+	Phospho	(ST) *** ** * *** * 2
TRA2B	pS264	pS266 ** * *** *** *** 1 CTPS1	seq:	571	-	591		+	Phospho	(ST) *** * * ** 2
EDC4	seq:	727	-	754		+	Phospho	(ST) ** * 1 TRIM28	seq:	32	-	69		+	Phospho	(ST) ** 2
EDC4	seq:	727	-	754		+	Phospho	(ST) * ** * 1 SRRM2	seq:	987	-	998		+	Phospho	(ST) ** * 2
PDCD4	seq:	87	-	96		+	Phospho	(ST) *** *** *** *** *** *** ** 1 DTNA	seq:	654	-	667		+	Phospho	(ST) *** * * 2
GATAD2B	seq:	117	-	137		+	3	Phospho	(ST) *** *** ** *** 1 CCDC86	pS18 ** ** ** *** * 2
PCBP2	seq:	246	-	276		+	Phospho	(ST) ** * ** * ** ** 1 PKP3	seq:	312	-	326		+	Phospho	(ST) ** *** * * ** *** 2
FOXK1	pT436	pS441	pS445 *** ** *** *** *** *** *** ** 1 SPTBN2	pS2171 *** ** 2
CD2BP2	seq:	189	-	201		+	Phospho	(ST) *** 1 TXLNA	seq:	504	-	517		+	Phospho	(ST) *** ** ** 2
SMN1	pS28	pS31 ** ** *** *** *** 1 NUFIP2	pS629 ** * * ** 2
G3BP1	seq:	79	-	106		no	mod ** ** 1 SNTB2	pS95 ** * * * 2
NFKB1	seq:	935	-	953		+	Phospho	(ST) ** * * 1 NUP35	pS73 * ** * 2
NAV1_HUMAN	seq:	1554	-	1564		no	mod ** ** * 1 EIF4EBP1	seq:	20	-	51		+	2	Phospho	(ST) *** *** *** ** * 2
HSPA8	seq:	57	-	71		+	Oxidation	(M) *** 1 MYBBP1A	pS1267 *** ** *** * * 2
RPLP1	pS101	pS104 *** ** ** ** 1 KIAA1522	pS545 *** 2
WWC3	pT909 ** *** ** ** *** *** * 1 PSMD2	pS16 *** * * ** * 2
SSFA2	pS737	pS739 ** * 1 TPD52L2	pS166 *** ** ** 2
COMMD8	seq:	35	-	60		no	mod ** *** 1 MAVS	seq:	135	-	167		+	Phospho	(ST) *** * 2
PRKCD	pS645	pS664 * ** 1 UNC45A	seq:	2	-	25		+	Phospho	(ST) * ** ** 2
MCM3	pT151 *** *** 1 DMAP1	pT445 ** * 2
RBL1	pS640 ** 1 SEPT9	pS30 ** *** ** * ** * 2
SRRM1	pT572	pT574 * * * * ** 1 RCC1	pS11 ** ** * * 2
PROSER2	pS179 * *** * 1 SRRM2	seq:	1041	-	1058		+	Phospho	(ST) * ** 2
SAP30BP	seq:	5	-	38		+	2	Phospho	(ST) * ** *** 1 ZC3HC1	pS321 ** * * *** ** 2
PRPF19	seq:	304	-	339		no	mod * ** 1 MYO9B	pS1405 *** *** ** *** ** 2
FXR1	seq:	89	-	111		no	mod * ** ** ** 1 ZC3H3_HUMAN	seq:	567	-	572		+	2	Phospho	(ST) *** * * 2
AHSG	seq:	219	-	225		no	mod * ** * * 1 POLH	pS379	pS380 *** * * 2
HSPB1	seq:	13	-	20		no	mod ** * * 1 RPS3	seq:	215	-	227		+	Phospho	(ST) ** * * * * 2
RBM15B	seq:	544	-	555		+	Phospho	(ST) ** * ** 1 PGRMC1	pS57 *** * 2
PPIA	seq:	20	-	31		no	mod * ** ** 1 TNKS1BP1	pS836 *** *** ** * ** *** 2
SRSF11	pS323	pT325 ** *** * 1 TPD52L2	pS166 ** * * * 2
SLC4A1AP	pS466 * ** * * ** 1 ZYX	pS344 *** *** * * ** *** *** * 2
CHAMP1	pS427	pS432	pS436 * ** ** ** *** ** * 1 AFF4	seq:	178	-	196		+	Phospho	(ST) ** ** * 2
MTRR	seq:	183	-	203		+	Phospho	(ST) ** * *** *** 1 SZRD1	seq:	37	-	61		+	Phospho	(ST) ** ** 2
KRT18	seq:	383	-	407		no	mod * *** ** *** *** 1 KRT18	seq:	176	-	186		+	Gln->pyro-Glu	(N-term	Q) ** 2
ARHGAP21	seq:	316	-	336		+	Phospho	(ST) *** ** * * 1 EFHD2	pS74 ** * * * 2
SRRM2	pS1444 *** ** *** * * 1 STOX2_HUMAN	seq:	695	-	700		+	Phospho	(ST) ** * * * ** ** 2
TBC1D4	pS591 *** ** *** *** *** ** 1 MARCKSL1	pS104 ** * * * ** ** 2
NFIC	seq:	312	-	327		+	Phospho	(ST) * * * *** 1 DDX42	seq:	721	-	761		+	Phospho	(ST) *** 2
C19orf43	seq:	28	-	71		+	Phospho	(ST) ** *** *** * ** 1 EIF3G	pS42 ** *** ** * * ** 2
CTPS1	seq:	571	-	591		+	2	Phospho	(ST) *** *** * *** *** 1 PRDX1	seq:	17	-	27		+	Oxidation	(M) *** * * *** * 2
HNRNPA1L2	seq:	123	-	140		+	Oxidation	(M) * ** *** 1 MARCKSL1	pS104 ** * * ** * 2
KARS	seq:	324	-	356		no	mod * ** * 1 TNKS1BP1	seq:	709	-	726		+	Phospho	(ST) * * *** 2
ATAD2	seq:	734	-	766		+	Phospho	(ST) ** 1 USP6	pS1214 ** 2
AKIRIN2	seq:	10	-	23		+	Phospho	(ST) *** *** *** 1 SGPP1	pS101 *** *** ** ** *** * 2
ATAD2	seq:	56	-	70		+	Phospho	(ST) *** * *** *** 1 GBF1	pS1784 ** * *** *** 2
PARD3	seq:	871	-	885		+	Phospho	(ST) *** *** 1 LARP4B	seq:	599	-	610		+	Phospho	(ST) *** ** 2
ALDOC	seq:	141	-	149		no	mod ** * * ** 1 SRRM2	seq:	852	-	870		+	Phospho	(ST) ** 2
SCIN	seq:	223	-	246		no	mod * ** *** ** 1 NDRG1	seq:	364	-	388		+	Phospho	(ST) ** ** * *** ** 2
HNRNPU	seq:	388	-	423		no	mod * ** 1 GOLGA4	seq:	39	-	53		+	Phospho	(ST) ** 2
SAP30BP	seq:	6	-	38		+	2	Phospho	(ST) ** 1 SRRM2	seq:	2289	-	2301		+	Phospho	(ST) *** ** * ** ** ** 2
MFAP1	pS52	pS53 * ** * * 1 LIMA1	pS362 ** ** 2
SCRIB	pS1475 *** * ** ** 1 ZBTB7A	seq:	503	-	530		+	2	Phospho	(ST) * ** 2
SRRM2	seq:	346	-	356		+	Phospho	(ST) ** *** 1 PDIA4	seq:	314	-	331		no	mod ** * 2
EIF5B	pS135	pS137 *** *** *** * 1 EPRS	seq:	871	-	889		+	Phospho	(ST) ** 2
CIAPIN1	seq:	197	-	233		+	Phospho	(ST) ** 1 MCM3AP	seq:	520	-	542		+	Phospho	(ST) *** * * *** 2
BCL2L12	seq:	238	-	248		+	Phospho	(ST) *** *** *** * ** ** 1 ACTG1	seq:	96	-	113		no	mod *** * *** 2
ACTR8	pS562 ** ** 1 ACTBL2	seq:	97	-	114		no	mod *** * *** 2
RPS6	seq:	234	-	243		+	Phospho	(ST) *** *** *** 1 GIGYF2	pS139 *** *** *** * *** ** ** 2
KIAA1671	pS1366 *** *** ** *** 1 SCFD1	pS303 ** * 2





















































































































TRAP1	seq:	389	-	402		no	mod *** ** ** * 2 ZC3H4	pS1275 *** 2
HN1	pT54 ** ** * *** ** 2 HELZ	pS1614	pS1620 *** ** * ** 2
SEPT9	seq:	19	-	29		+	Phospho	(ST) *** * ** *** * 2 KRT8	seq:	134	-	148		+	Oxidation	(M) ** *** 2
MTDH	pS568 *** ** ** ** 2 TP53BP1	pS500 ** * 2
SRRM2	seq:	303	-	329		+	Phospho	(ST) ** * * 2 NRD1	pS94 *** * 2
LSM12	seq:	73	-	86		+	Phospho	(ST) ** 2 DIDO1	seq:	1011	-	1023		+	Phospho	(ST) *** ** 2
TXLNA	seq:	18	-	53		+	Phospho	(ST) *** * * 2 HAPLN4	pS111 ** ** 2
DBNL	pT291 *** ** * ** * 2 EIF4B	seq:	280	-	287		+	Phospho	(ST) ** ** 2
SCFD1	pS303 ** *** * 2 FAM84B	seq:	288	-	310		+	Phospho	(ST) *** *** * ** 2
CCDC86	pS91 ** * * * 2 HSPA8	seq:	160	-	171		no	mod * *** * ** *** 2
SEC22B	pS137 ** * *** 2 PKM	seq:	368	-	376		no	mod ** * * 2
SRRM2	pS994 ** 2 LIMA1	pS132 ** ** *** *** * * 2
ERBB2IP	seq:	1077	-	1095		+	Phospho	(ST) ** * ** 2 KRT8	seq:	353	-	362		no	mod ** ** ** * 2
CRIP2	seq:	113	-	128		+	Phospho	(ST) * ** ** *** ** 2 PACSIN2	seq:	391	-	430		+	Phospho	(ST) ** 2
EIF4G3	pS232 ** 2 LAD1	seq:	392	-	403		+	Oxidation	(M);	Phospho	(ST) ** 2
L1RE1	seq:	25	-	49		+	Phospho	(ST) ** 2 SRRM2	pS2449 ** ** * * 2
SRRM2	seq:	987	-	998		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** * 2 HMGCR	pS872 *** *** 2
LEMD2	pS499 *** ** ** ** 2 NOLC1	pT607	pT610 * ** ** * * 2
PSMF1	seq:	149	-	164		+	Phospho	(ST) *** ** *** * 2 CBX3	seq:	93	-	103		+	Phospho	(ST) ** ** 2
TPI1	pS58 * ** ** 2 CDC42EP1	pS121 * *** 2
STAU2	pS440 *** *** * 2 NOC2L	pS49 * * ** 2
KDM5A	seq:	1324	-	1333		+	Phospho	(ST) ** 2 ADAM17	pS791 *** * 2
HSP90AA1	seq:	500	-	510		no	mod *** ** ** *** 2 SRSF11	seq:	198	-	211		+	Phospho	(ST) *** ** *** ** ** 2
SRRM2	pS2272 ** * ** ** ** 2 DES	seq:	194	-	201		no	mod *** *** * * ** 2
GORASP2	seq:	404	-	420		+	Phospho	(ST) ** * ** 2 KRT8	seq:	317	-	325		no	mod *** *** * * ** 2
PLCH1	seq:	1297	-	1312		+	Phospho	(ST) *** ** *** * ** * ** 2 SRRM1	pT220 *** ** 2
FXR2	pS601	pS603 ** ** ** ** ** 2 AFF4	pS1043 *** ** *** *** * ** * 2
EEF1A1P5	seq:	267	-	290		+	Oxidation	(M) ** ** 2 SRRM2	seq:	852	-	870		+	2	Phospho	(ST) *** ** 2
LIMA1	pS609 *** * 2 ACTBL2	seq:	185	-	192		+	Oxidation	(M) * ** ** *** * ** 2
TVP23C	seq:	221	-	227		+	Phospho	(ST) *** * 2 TXN	seq:	97	-	105		no	mod ** *** * ** 2
LMNB1	seq:	15	-	26		+	Phospho	(ST) *** ** ** * 2 CD3EAP	seq:	117	-	148		+	Phospho	(ST) ** * ** 2
ACLY	pS481 *** *** ** *** ** 2 YRDC	pS60 *** *** ** *** ** ** *** * 2
UBE2O	seq:	1165	-	1213		+	2	Phospho	(ST) *** ** * *** 2 LIMA1	seq:	486	-	500		+	Phospho	(ST) ** * *** *** 2
PGAM1	seq:	142	-	162		no	mod ** * * 2 HSPB1	seq:	128	-	136		+	Gln->pyro-Glu	(N-term	Q) ** * ** *** * 2
VGLL4	seq:	138	-	157		+	Phospho	(ST) ** * * ** * 2 KRT6C	seq:	447	-	455		+	Oxidation	(M) * *** ** * * ** 2
EPRS	seq:	871	-	889		+	Phospho	(ST) *** ** 2 NSUN2	seq:	591	-	602		no	mod * * *** 2
DDI2	seq:	109	-	139		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) ** * ** 2 KRT19	seq:	100	-	111		no	mod *** * 2
HSPA6	seq:	503	-	509		no	mod *** ** ** 2 LIMA1	pS490 * ** *** *** 2
SZRD1	seq:	39	-	61		+	Phospho	(ST) ** * * 2 KRT18	pS23	pS30 ** * ** 2
SPECC1	pS847 ** 2 MLLT10	pS689 ** * * 2
ATAD2	pS342 ** 2 RNF169	pS403 ** * ** * 2
SZRD1	pS107 *** * ** 2 ZCCHC8	seq:	643	-	655		+	Phospho	(ST) *** *** ** 2
NACA	seq:	201	-	215		+	Oxidation	(M) *** ** *** ** * ** 2 CXB1_HUMAN	seq:	231	-	238		+	Phospho	(ST) ** *** * 2
SRRM2	seq:	1101	-	1111		+	Phospho	(ST) ** * * * 2 CTPS1	seq:	558	-	564		+	Phospho	(ST) ** *** * 2
PKM	seq:	33	-	43		no	mod *** * ** *** 2 STAU2	seq:	484	-	498		+	Phospho	(ST) ** *** *** ** 2
PUM1	seq:	707	-	718		+	Phospho	(ST) ** 2 KRT18	seq:	318	-	325		no	mod *** ** ** 2
CDK7	pT170 ** ** 2 KIAA1614	seq:	582	-	588		no	mod * ** *** * 2
SRRT	pS67 ** * 2 ACTBL2	seq:	330	-	336		no	mod * ** *** * 2
TRUB1	seq:	16	-	38		+	Phospho	(ST) ** * ** 2 SRRM2	pS1179 ** 2
PROSER2	pS179 ** *** * *** *** * 2 CGN	seq:	288	-	294		+	Phospho	(ST) ** * 2
KRT8	seq:	402	-	414		+	2	Oxidation	(M) * ** 2 PHC3	pT609	pS616 ** ** 2
MARCKS	pS170 ** 2 SRRM1	pS713	pT718 ** *** * * 2
AJUBA	pS119 *** *** * 2 WARS	pS467 ** ** ** * * ** 2
YRDC	pS37 *** *** * ** *** *** ** * 2 SRRM1	pS402	pT406 ** * 2
RPL23A	seq:	140	-	152		no	mod ** ** * ** ** 2 SRRM2	seq:	2371	-	2384		+	Oxidation	(M);	Phospho	(ST) *** * *** ** * 2
EIF3B	seq:	68	-	113		+	Phospho	(ST) *** * ** * * * 2 KRT8	seq:	253	-	264		no	mod ** ** ** ** 2
RHBDF1	pS76 *** ** *** * *** 2 NOP58	pS502	pS514 *** ** 2
LIMA1	pS362 * * *** *** * 2 SRRM2	pS351	pS353	pS357 ** 2
SRP72	seq:	618	-	645		+	2	Phospho	(ST) *** ** * * * 2 HSP90AB1	seq:	292	-	306		no	mod *** ** *** *** ** * 2
ALDOA	seq:	29	-	42		no	mod *** *** *** 2 LIG3	pS210 *** * *** * 2
LUZP1	pS659 * ** 2 SLC4A8	pS237 *** ** ** 2
KANK1	pS325 ** * * * * 2 PFN1	seq:	39	-	54		no	mod ** * 2
HNRNPAB	pS242 ** *** * ** 2 ENO1	seq:	203	-	221		no	mod *** * *** * * 2
YRDC	pS37 *** *** * * *** *** ** * 2 PROSER2	pS179 *** ** *** * 2
ACLY	pS481 *** ** ** *** * 2 DFFA	pS315 *** *** * *** ** ** 2
LYSMD2	seq:	17	-	28		+	Phospho	(ST) *** * * * 2 SRRM2	seq:	1394	-	1412		+	Oxidation	(M);	Phospho	(ST) *** * ** * 2
PATL1	seq:	177	-	188		+	Phospho	(ST) ** ** * 2 HSPB1	pS82 *** ** ** ** ** ** 2
GDI1	seq:	310	-	328		no	mod * * ** 2 EIF3F	pS258 *** *** 2
SRRM1	seq:	247	-	266		+	Phospho	(ST) ** * 2 TUBA3E	seq:	327	-	336		no	mod *** *** * 2
SRSF1	pS199 ** 2 SRRM1	seq:	711	-	722		+	2	Phospho	(ST) ** *** ** * 2
MAPT	seq:	414	-	440		+	Phospho	(ST) *** * ** * * 2 MAP7	pS365 ** * ** 2
NOP56	seq:	511	-	533		+	Phospho	(ST) ** 2 EEF1A1P5	seq:	396	-	423		+	2	Oxidation	(M) ** * * 2
STMN1	pS38 ** * *** * * ** 2 HSPB1	seq:	172	-	188		no	mod ** * ** *** 2
FAM195B	seq:	21	-	38		+	Phospho	(ST) ** * ** 2 ARHGEF2	pS886 * ** * 2
SON	pS1697 *** 2 TACC3	seq:	313	-	332		+	Phospho	(ST) ** * 2
RSL1D1	seq:	462	-	471		+	2	Phospho	(ST) * *** * *** ** 2 TMEM87A	pS540 *** * ** 2
TCOF1	pS1228 ** 2 WARS	pS467 ** ** ** ** 2
MAPT	pS519 *** *** * *** 2 IQSEC1	pS512 *** *** ** 2
NLRP11	pS1019 *** * *** 2 SLC4A7	pS233 *** ** ** 2
SRRM2	pS1124 *** ** * *** 2 PLPL8_HUMAN	pS347 ** * * * * 2
HSP90AB2P	pS177 ** * * * 2 SNIP1	pS35 *** *** ** * * 2
IRF2BP1	pS436 ** * 2 ALB	seq:	287	-	298		no	mod ** * 2
GAPDH	seq:	220	-	227		no	mod ** * * 2 BCLAF1	seq:	284	-	299		+	Phospho	(ST);	Phospho	(Y) ** *** 2
PDLIM2	pS197 * ** * 2 BCLAF1	seq:	284	-	299		+	2	Phospho	(ST) ** *** 2
FAM117B	seq:	105	-	121		+	Phospho	(ST) ** * * * 2 TUBA8	seq:	353	-	370		no	mod ** ** 2
AAAS	pS495 ** ** * 2 SRRM1	pS696 *** *** * * * 2
FAM102B	pS276 * * *** *** 2 ACLY	pS481 ** ** 2
ACTA1	seq:	318	-	328		+	Oxidation	(M) ** ** * * 2 OTOA	seq:	106	-	111		no	mod *** ** * *** 2
EDC4	seq:	870	-	898		+	Phospho	(ST) ** *** ** 2 ABCC11	seq:	364	-	369		no	mod *** ** * *** 2
SSB	seq:	288	-	297		no	mod ** * * 2 SRRM1	pS260 ** * 2
PRKCD	pS645 ** * 2 ENO1	seq:	203	-	221		no	mod ** ** 2
HSP90AB3P	seq:	73	-	82		no	mod * *** ** *** *** 2 DKC1	seq:	448	-	467		+	2	Phospho	(ST) * ** * 2
PPP1R9A	seq:	334	-	354		+	Phospho	(ST) * * * *** 2 ILF3	seq:	6	-	12		no	mod ** 2
DDX3X	seq:	82	-	93		+	Phospho	(ST) *** ** * 2 AMPD2	pS168 ** ** *** 2
CTNNB1	seq:	550	-	565		+	Oxidation	(M);	Phospho	(ST) ** * 2 SOD1	seq:	11	-	24		no	mod *** *** 2
MAVS	pS222 *** ** * 2 HSPB1	pS82 *** *** *** *** *** ** *** *** 2
ABLIM1	seq:	429	-	443		+	Phospho	(ST) *** ** * *** * 2 RAPGEF6	pS1094 *** ** *** *** ** 2
RRM2	pS20 *** *** ** 2 SON	pS1697 ** * 2
CEP170B	pS969 *** ** ** 2 KRT18	seq:	254	-	261		no	mod *** ** * ** 2
TRIM25	seq:	96	-	112		+	Phospho	(ST) *** ** * * ** *** * 2 BCLAF1	seq:	284	-	299		+	2	Phospho	(ST) * *** 2





























































































SLC9A3R1	seq:	41	-	50		no	mod ** ** * * 2 PRRC2A	pS456 ** *** *** 2
SRRM2	pS2132 ** * * ** 2 PNN	pS100 *** ** ** ** ** * 2
NRD1	seq:	92	-	105		+	Phospho	(ST) *** ** 2 MCM2	pS108 * ** *** *** ** 2
KRT18	seq:	302	-	314		+	Oxidation	(M) ** 2 ATXN2L	seq:	333	-	345		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) ** 2
TPD52	pS176 *** *** ** *** *** * 2 SRRM1	pS653 ** ** * 2
SRRM1	pS738 ** ** * * 2 CHAMP1	pS427 * ** 2
SRRM2	seq:	1539	-	1556		+	Phospho	(ST) *** *** * ** 2 SRRM1	pS605	pS607 ** 2
STK10	seq:	447	-	464		+	2	Phospho	(ST) *** ** 2 EEF1A1P5	seq:	167	-	172		no	mod ** *** 2
TPI1	seq:	180	-	186		no	mod ** * 2 HSP90AA1	seq:	339	-	345		no	mod ** 2
KRT8	seq:	473	-	483		no	mod *** ** *** ** *** 2 XPNPEP3	seq:	149	-	155		no	mod ** 2
MAPT	seq:	713	-	723		+	Phospho	(ST) *** *** * 2 KRT18	seq:	7	-	14		no	mod *** ** 2
ENO1	seq:	72	-	80		no	mod * ** *** * * 2 BCLAF1	pS385 *** * * 2
TUBGCP4	seq:	48	-	54		no	mod ** ** * * ** 2 SRRM1	pS402	pT406 *** * ** 2
KRT18	seq:	91	-	97		no	mod ** ** * * ** 2 RPS25	seq:	86	-	94		no	mod *** ** ** 2
FAM195B	seq:	21	-	38		+	Phospho	(ST) ** * * * 2 PSMD2	pS361 ** *** 2
MTFR1L	pS103 ** ** 2 HSPD1	seq:	134	-	141		no	mod *** *** * 2
ABLIM1	pS655 * ** *** 2 RPS28	seq:	52	-	63		no	mod ** * 2
HMGCR	pS872 ** *** 2 SRSF5	seq:	110	-	118		no	mod *** * * 2
SHROOM3	pS439	pS443 ** * 2 PRKCD	seq:	505	-	524		+	Phospho	(ST) *** *** 2
PRDX2	seq:	140	-	150		no	mod * *** ** ** 2 GNL1	seq:	45	-	61		+	Phospho	(ST) ** ** * 2
HSPA2	seq:	104	-	109		no	mod * ** 2 WRNIP1	pS153 * ** 2
NOS1AP	seq:	255	-	268		+	Phospho	(ST) *** 2 JUN	seq:	57	-	70		+	Phospho	(ST) *** ** ** *** ** ** ** 2
HSPB1	seq:	172	-	188		no	mod * ** * ** 2 ACTA1	seq:	318	-	328		no	mod * * ** ** 2
PRPF4B	seq:	427	-	440		+	2	Phospho	(ST) ** * 2 SIPA1L1	seq:	254	-	269		+	Phospho	(ST) ** *** 2
SNIP1	pS35 *** *** ** *** 2 ENO1	seq:	270	-	281		no	mod * ** ** ** *** 2
ASPSCR1	pS502 *** * *** ** ** * ** 2 HOMEZ	pT451 ** * ** * * 2
SRRM2	pS2272 *** *** ** *** *** ** * ** 2 RANBP2	pS955 *** * ** * ** 2
HSPB1	seq:	80	-	89		no	mod * *** ** *** *** 2 PSMF1	seq:	51	-	62		no	mod *** *** ** * * 2
MYCBP2	seq:	2831	-	2844		+	Phospho	(ST) *** * *** * ** 2 PRKCH	pS675 *** 2
RCC1	pS11 *** * 2 PREX1	seq:	800	-	832		+	Phospho	(ST) * ** *** *** * 2
SNW1	pS224 ** ** 2 SRRM1	pT614	pS616 ** ** 2
SRRM2	pS1124 ** * * * 2 PROSER2	seq:	283	-	315		+	Phospho	(ST) ** ** 2
KNOP1	pS42 ** *** * 2 HSP90AA2	seq:	283	-	291		no	mod * * ** * 2
NPM1	seq:	33	-	45		no	mod ** ** * 2 HDGF	pS165 ** * * *** ** ** 2
SHROOM2	seq:	919	-	937		+	2	Phospho	(ST) *** ** *** 2 SRRM2	pS2132 ** * * ** ** * 2
ENO1	seq:	344	-	358		no	mod * ** * * * 2 FIP1L1	seq:	490	-	504		+	Phospho	(ST) *** *** ** ** * 2
ENO3	seq:	344	-	358		no	mod * ** * * * 2 MAPT	seq:	701	-	723		+	3	Phospho	(ST) * * ** * * * 2
CUL4A	pS10 * ** * ** ** 2 TACC1	seq:	262	-	283		+	Phospho	(ST) *** *** *** 2
TBC1D9B	seq:	409	-	440		+	Phospho	(ST) ** ** * 2 SRRM1	pS769 *** ** *** *** 2
SRRM2	seq:	871	-	882		+	Phospho	(ST) * * *** * * * * 2 HSPA8	seq:	129	-	137		no	mod ** ** *** *** ** * 2
RBBP8	seq:	325	-	337		+	Phospho	(ST) * *** * * ** * 2 NCL	seq:	64	-	70		+	Phospho	(ST) * *** ** *** ** 2
STK10	pS438 ** * 2 FRPD1_HUMAN	seq:	1095	-	1101		+	Phospho	(ST) * ** *** ** *** ** * 2
IRF2BP1	pS66 *** ** 2 ILF3	pT592 ** * * 2
HSPA2	seq:	173	-	189		no	mod * ** * 2 PSMA5	pS56 *** *** *** * * *** *** *** 2
HSP90AB3P	seq:	56	-	69		no	mod * ** *** 2 TERF2IP	seq:	154	-	165		+	Phospho	(ST) * * *** ** 2
FNBP4	pS116 *** ** *** 2 HNRNPK	seq:	208	-	219		no	mod *** 2
SRRM2	pS1132 ** ** 2 ACIN1	pS825 * * * * *** ** 2
SRSF10	pS131	pS133 ** *** ** ** * 2 HSPB1	seq:	115	-	123		no	mod ** *** *** *** * ** 2
PRCC	seq:	259	-	282		+	Phospho	(ST) * *** * *** 2 RCOR1	pS257 *** *** 2
SRRM1	pS769	pS773	pS781 *** *** * *** 2 PDE5A	pS86 *** * *** * 2
RPLP1	pS101 *** *** * 2 CLMN	pS419 * * *** 2
LAD1	seq:	392	-	403		+	Phospho	(ST) * ** ** ** ** ** 2 HSPD1	seq:	397	-	405		no	mod * *** *** * * ** 2
TRAM1	pS365 *** *** *** *** * 2 RIPK2	seq:	529	-	538		+	Phospho	(ST) *** * ** * ** *** 2
TBC1D4	seq:	747	-	768		+	2	Phospho	(ST) ** *** ** *** 2 SRRM2	pS1179 ** ** 2
ABI2	seq:	220	-	230		+	Phospho	(ST) ** * * 2 CHD4	seq:	1529	-	1539		+	Phospho	(ST) ** 2
BTF3	seq:	95	-	122		no	mod *** 2 PRDX6	seq:	42	-	53		no	mod *** ** ** ** *** ** 2
PRDX2	seq:	17	-	26		no	mod ** *** * * 2 SRRM2	pS1329 *** * * ** 2
EEF1A1P5	seq:	173	-	179		no	mod * *** *** ** 2 FKBP4	seq:	359	-	373		no	mod *** * 2
MTA1	seq:	516	-	527		+	Phospho	(ST) *** ** *** ** * 2 YWHAE	seq:	143	-	153		no	mod *** *** *** ** * 2
HNRNPA2B1	seq:	204	-	213		no	mod ** ** ** ** ** * 2 ALB	seq:	438	-	452		no	mod * * * ** 2
RAN	seq:	13	-	23		no	mod ** *** * * * 2 DSG2	seq:	262	-	275		no	mod *** ** 2
SRSF10	pS133 *** * *** *** * 2 EPB41L3	pS409 ** *** ** * 2
TAF2_HUMAN	pS790 *** * *** *** * 2 SRRM1	pS560	pS562 * ** * * 2
HSPA1A	seq:	160	-	171		no	mod ** ** 2 EEF1A2	seq:	248	-	255		no	mod *** *** * *** * ** 2
SRRM2	pS1179 ** * * * * 2 AHSG	seq:	312	-	317		no	mod * * ** * 2
NPM1	seq:	240	-	248		no	mod * *** 2 RPL27A	seq:	95	-	105		no	mod * *** ** ** *** ** 2
KRT9	seq:	164	-	170		no	mod *** *** ** 2 NCL	seq:	334	-	342		no	mod *** *** ** *** *** * 2
LATS1	pS464 ** ** * ** *** 2 DKC1	pS451	pS453 * *** ** 2
SRRM1	pT614	pS616 ** *** ** 2 SRRM1	pT581	pS583 * ** * ** * 2
NOP58	pS502	pS514 *** ** *** 2 PRCC	pS157	pS159 ** 2
HSP90AB2P	pS177 * ** ** * ** 2 CTPS1	pS571	pS573 * *** 2
SORBS3	seq:	520	-	532		+	Phospho	(ST) *** *** ** ** ** * 2 PRDX4	seq:	201	-	208		no	mod * *** * *** * ** * 2
SRRM1	pS769	pS775 * ** ** *** * 2 ANKS1A	pS663 ** ** *** ** * 2
KRT2	seq:	189	-	195		no	mod ** *** ** ** * 2 CTPS1	seq:	565	-	591		+	Phospho	(ST);	Phospho	(Y) * *** 2
MKI67	seq:	1806	-	1818		+	Phospho	(ST) *** 2 NPM1	seq:	268	-	273		no	mod * * ** ** * 2
NHS_HUMAN	seq:	504	-	509		+	Phospho	(ST) * ** * ** * 2 CCNL2	pS369 *** 2
SRRM2	seq:	1589	-	1594		+	Phospho	(ST) * ** * ** * 2 RXRA	seq:	5	-	25		+	Phospho	(ST) ** *** 2
PRPF38B	pS268 * ** * ** * 2 TPR	seq:	367	-	387		+	Phospho	(ST) *** *** *** 2
TRAF3IP3	seq:	108	-	113		+	Phospho	(ST) * ** * ** * 2 ALB	seq:	500	-	508		no	mod * *** * * 2
DHX9	pS321 *** 2 RPS6	seq:	120	-	131		no	mod *** 2
HSPB1	seq:	189	-	198		no	mod * * *** * 2 EBAG9	pS36 *** *** ** *** * *** * 2
SRSF11	seq:	198	-	211		+	Phospho	(ST) *** *** *** * 2 ZNF687	pS1057 *** * 2
SRRM2	pS2272 *** *** *** *** ** ** * 2 ESF1	pS663 * ** ** 2
SNIP1	pS35 *** ** * * 2 SRRM1	pS549	pS551 * ** * * * 2
SRSF11	seq:	443	-	451		+	Phospho	(ST) * ** * 2 DOCK7	pS1432 *** ** *** *** ** 2
SNIP1	pS35 *** *** *** ** * * * 2 EBAG9	pS36 *** ** ** ** * *** *** 2
SRRM1	pS769	pS775 *** * *** *** 2 CIT	seq:	1937	-	1951		+	Phospho	(ST) * ** * * * 2
KRT8	seq:	226	-	233		no	mod *** ** *** * 2 AHNAK	pT5824 *** *** ** *** 2
HSPB1	seq:	80	-	89		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** *** *** ** * * *** *** ** 2 KRT12	seq:	343	-	349		no	mod * ** 2
USP24	pS2047 *** * *** * * ** 2 EFHD2	seq:	63	-	78		+	Phospho	(ST) *** 2
KRT8	seq:	134	-	148		+	Oxidation	(M) * ** *** 2 BCLAF1	seq:	256	-	271		+	2	Phospho	(ST) * ** * 2
FIP1L1	pS492 *** *** * 2 SMTN	seq:	271	-	287		+	Phospho	(ST) * * ** 2
NOLC1	pT607	pT610 * ** ** * * * *** 2 NCL	seq:	325	-	333		no	mod ** ** *** * ** * 2
ATXN2L	seq:	400	-	411		+	Oxidation	(M);	Phospho	(ST) ** ** 2 ATF2	pS112 * *** *** ** *** 2
KRT19	seq:	266	-	274		no	mod *** *** 2 ESF1	pS657	pS663 ** * ** * ** 2
CGN	pS149 * ** * 2 KIAA1671	seq:	1224	-	1234		+	Phospho	(ST) *** *** *** *** *** * 2
CUX1	pS1270 ** 2 NCK1	seq:	82	-	103		+	Phospho	(ST) * ** 2
MED1	seq:	1475	-	1496		+	2	Phospho	(ST) * * *** * 2 CLDN3	pS209 ** * ** *** 2
PPIG	pS356	pT358 *** *** ** ** * 2 OSBP	seq:	186	-	212		+	Phospho	(ST) *** *** 2
MARCKSL1	seq:	26	-	43		+	Phospho	(ST) *** 2 TPD52	pS176 *** *** ** ** *** ** * 2



























































































HSPA4	seq:	737	-	748		+	Oxidation	(M) ** * ** ** 2 TBX2	pS401 ** ** 3
SRRM1	pS560	pS562 ** *** * *** * 2 WDHD1	pS868 *** ** * 3
FASN	seq:	317	-	326		no	mod *** *** *** * ** *** 2 NUMA1	pS1862 *** * * 3
PDE5A	pS86 *** * *** ** * 2 SENP3	pS188 ** ** 3
FLNB	seq:	2476	-	2495		+	Phospho	(ST) *** *** ** *** * *** 2 NUCKS1	pS181 *** ** * ** ** * 3
ALB	seq:	258	-	264		no	mod ** *** * * 2 SRRM1	pT872	pS874 ** * * 3
SOX13	seq:	301	-	314		+	Phospho	(ST) *** 2 GTF2I	seq:	674	-	702		+	Phospho	(ST) ** * * * ** 3
CAPZA1	seq:	20	-	37		no	mod ** 2 TMPO	pS66	pS67 ** *** 3
RPL27	seq:	85	-	93		no	mod ** * * ** 2 AHNAK	seq:	5724	-	5744		+	Phospho	(ST) * *** ** * ** 3
FARP1	seq:	417	-	438		+	2	Phospho	(ST) *** * ** 2 CTNND1	pS268 ** ** ** * 3
NCL	seq:	363	-	370		no	mod * *** * *** ** ** * 2 AHNAK	seq:	5724	-	5744		+	2	Phospho	(ST) *** *** ** ** *** ** *** 3
ATP5A1	seq:	134	-	149		no	mod * ** * * * 2 GTF2I	seq:	674	-	702		+	Phospho	(ST) ** * * ** * * 3
PRDX1	seq:	159	-	168		no	mod *** * *** *** ** ** 2 NUMA1	pS2077 * * ** ** 3
CLK1	pS140 ** *** * ** 2 TPM4	seq:	56	-	69		no	mod ** * 3
CD2AP	pS224 ** ** 2 ANP32A	seq:	21	-	28		no	mod ** 3
NME1	seq:	7	-	18		no	mod ** ** 2 OCIAD1	pS108 ** * * * *** 3
CIAO1	seq:	128	-	154		no	mod * ** 2 SMC4	seq:	13	-	38		+	Phospho	(ST) ** * ** ** 3
KRT18	seq:	371	-	381		no	mod *** * ** 2 FAM21B	seq:	448	-	467		+	Phospho	(ST) ** 3
SRP72	seq:	618	-	645		+	3	Phospho	(ST) ** * * * * * 2 PRC1	pT481 ** * * *** 3
FOXK1	seq:	416	-	430		+	Oxidation	(M);	2	Phospho	(ST) *** ** *** ** *** *** 2 SIPA1L1	seq:	1248	-	1259		+	Phospho	(ST) *** * * * 3
PRDX2	seq:	128	-	135		no	mod ** * *** * *** 2 NUCKS1	pT179	pS181 * ** * 3
SMAP2	seq:	210	-	226		+	Phospho	(ST) *** ** ** * * * 2 SMC4	pS28 *** * * 3
MAP4K5	seq:	431	-	454		+	Phospho	(ST) * * ** 2 SNX1	pS188 *** * * ** *** 3
CTU2	pS419 * * ** * ** 2 CAP2	seq:	294	-	314		+	Phospho	(ST) ** ** * * 3
MDH2	seq:	92	-	104		no	mod * ** ** ** * * 2 AHNAK	pS5731 * *** *** * 3
ARFGAP2	pS432 ** * * ** 2 BCL11B	seq:	369	-	390		+	2	Phospho	(ST) *** 3
SRRM2	seq:	1856	-	1862		+	Phospho	(ST) ** ** * * 2 POTEI	seq:	729	-	739		no	mod ** * 3
PRKD2	seq:	195	-	208		+	Phospho	(ST) * ** ** * 2 SNRPD3	seq:	9	-	29		no	mod * * ** 3
SVIL	seq:	850	-	867		+	Phospho	(ST) ** *** *** * ** 2 LMO7	seq:	1591	-	1604		+	Phospho	(ST) ** * * ** 3
MAP4	pS507 ** 2 AHNAK	pS216 *** * ** 3
EEF1D	pT147	pS162 *** 2 TRPV3	pS374 ** 3
PDCD4	pS457 *** *** ** *** *** *** 2 NSFL1C	seq:	137	-	156		+	Phospho	(ST) ** * * 3
MAP3K2	seq:	329	-	348		+	Phospho	(ST) ** * ** 2 LRRFIP1	seq:	118	-	134		+	Phospho	(ST) * * ** ** 3
ZNRF2	pS135 * *** * 2 HERC2	pS2928 ** 3
ENO1	seq:	222	-	228		no	mod * ** * ** ** * *** 2 TRIP11	pS1891 ** * * 3
TAGAP_HUMAN	seq:	56	-	65		+	Oxidation	(M) *** * ** 2 SRRM1	seq:	870	-	888		+	Phospho	(ST) *** * * 3
SVIL	pS221 ** ** * ** * 2 PHLDB1	pS419 ** ** *** ** 3
AMPD2	pS100 *** *** * ** *** *** ** 2 NSRP1	seq:	15	-	47		+	Phospho	(ST) *** 3
EIF3E	pS399 ** *** ** ** *** * 2 RPS3	seq:	202	-	227		+	Phospho	(ST) *** ** 3
PA2G4	seq:	34	-	62		no	mod *** *** 2 CDC42EP4	seq:	269	-	297		+	Phospho	(ST) ** 3
PCBP1	seq:	178	-	200		+	Phospho	(ST) ** * ** * ** 2 STMN1	pS25 ** ** * * * * 3
RPS6	seq:	233	-	243		+	2	Phospho	(ST) *** *** *** ** * ** 2 TMPO	seq:	345	-	356		+	Phospho	(ST) *** * * ** * * 3
PRDX2	seq:	111	-	119		no	mod *** ** * 2 EIF4EBP1	seq:	20	-	56		+	2	Phospho	(ST) * *** 3
FOXK1	pS416	pS420 ** ** *** *** *** 2 AHNAK	pS511 ** *** *** * * 3
MMACHC	pS275	pS279 * * *** ** 2 PPP1R12A	pS445 *** ** *** ** ** * 3
ETV5	pS425 *** ** *** *** ** ** 2 NUCKS1	pS181 *** ** ** * 3
SPDEF	pS308 *** ** *** *** ** ** 2 BUD13	pS271 ** ** 3
SFRP2	seq:	286	-	291		+	Phospho	(ST) *** ** *** *** ** ** 2 UBXN7	pS288 ** * 3
POLH	pS380 *** *** *** *** ** ** * 2 MTMR4	seq:	627	-	641		+	Phospho	(ST) *** * * *** * 3
NCL	seq:	411	-	420		no	mod * ** *** *** ** 2 CHAMP1	seq:	457	-	470		+	Phospho	(ST) * ** * 3
AHCTF1	seq:	1209	-	1225		+	Phospho	(ST) * ** 2 ZFP36L2	pS490 *** * * 3
MDH2	seq:	177	-	185		no	mod * ** ** ** * ** 2 HDAC2	pS394 ** 3
CHERP	seq:	817	-	838		+	2	Phospho	(ST) ** ** ** 2 AHNAK	seq:	5726	-	5744		+	Phospho	(ST) * *** ** ** 3
FOXK1	pS416	pS420 ** * *** ** ** *** * * *** 2 NUF2	pS247 *** *** * * *** *** * 3
FAM103A1	pS36 * * *** * * 2 NFATC2IP	pS204 *** 3
HSPB1	pS15 *** *** *** *** * *** ** ** * 2 RBM23	pS149 *** *** *** * ** * 3
PRDX1	seq:	111	-	120		no	mod ** *** *** *** *** *** 2 SHROOM2	pS413 * ** 3
CTPS1	seq:	571	-	591		+	2	Phospho	(ST) *** *** *** 2 IRS1	pS1078 * *** * ** * 3
AHNAK	pS570 ** ** * 2 BCLAF1	pS512 *** ** ** 3
ARPP19	seq:	102	-	109		+	Phospho	(ST) *** 2 PPP1R12A	seq:	442	-	456		+	Phospho	(ST) *** ** *** ** * ** * 3
SRRM2	pS1320 ** * 2 ZBTB17	seq:	113	-	136		+	Phospho	(ST) ** 3
AHNAK	pS511 *** * *** ** 2 SIPA1L1	seq:	174	-	197		+	Phospho	(ST) ** * 3
CHD4	seq:	306	-	338		+	2	Phospho	(ST) *** ** 2 ATAD2B	seq:	73	-	91		+	Phospho	(ST) *** * ** 3
USP14	pS143 ** 2 RALBP1	seq:	27	-	43		+	Phospho	(ST) ** * 3
TKT	seq:	556	-	594		no	mod *** * * * 2 MCM2	pS139 ** * 3
TBC1D22A	pS132 *** *** 2 WDR46	pS41 * * *** 3
SRRM2	pS2702	pS2706 * ** * 3 AHNAK	seq:	5780	-	5812		+	2	Phospho	(ST) ** * ** 3
CN159_HUMAN	pS9	pS13 * ** 3 ZC3H13	pS242 ** * 3
DPYSL2	pS522 * *** ** ** * *** * 3 SRSF9	pS211 *** * * 3
CCSER1	seq:	8	-	14		+	Phospho	(ST) ** 3 EEF1D	pS162 ** 3
ZC3H13	pT263	pS265 * ** * * * 3 HDAC2	pS394 ** 3
HSPA9	seq:	469	-	485		no	mod * * ** ** 3 NFATC2IP	seq:	231	-	263		+	Phospho	(ST) * ** * * * * 3
NDRG2	pS338 *** ** ** * *** *** * 3 KRT18	pS18 *** ** ** * ** ** 3
NUCKS1	pS181 * ** * ** * * 3 NUMA1	pS1991	pT2000 ** ** 3
CHMP3	pS200 ** 3 HSP90AA1	seq:	300	-	314		no	mod ** 3
TLE1	seq:	282	-	300		+	Phospho	(ST) *** *** *** *** * ** * 3 MSH6	seq:	4	-	22		+	Phospho	(ST) *** * * 3
GPATCH8	seq:	721	-	745		+	Phospho	(ST) ** * * 3 ZNF652	seq:	54	-	66		+	Phospho	(Y) *** *** 3
FAM83H	pS936 * ** ** 3 STMN1	pS63 ** * 3
MSL2	seq:	343	-	362		+	Phospho	(ST) *** ** *** 3 BCLAF1	pS512 *** * 3
CDK13	pS437	pS439 * ** *** 3 SRSF9	pS211 *** ** ** 3
RPS6	seq:	234	-	243		+	2	Phospho	(ST) ** 3 FAM91A1	seq:	826	-	838		+	Phospho	(ST) * ** 3
RBBP6	pS1179 *** * 3 BCLAF1	pS658 ** 3
PCBP1	seq:	244	-	268		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST)** * * 3 STMN2	seq:	120	-	129		no	mod *** ** * * *** ** * 3
RAB11FIP1	seq:	498	-	520		+	Phospho	(ST) *** * *** 3 STMN1	seq:	86	-	95		no	mod *** ** * * *** ** * 3
ADD3	seq:	664	-	684		+	Phospho	(ST) * ** * * 3 NAP1L4	seq:	108	-	138		+	Phospho	(ST) *** 3
AHNAK	pS5841 ** * * * * 3 IQGAP3	seq:	1424	-	1436		+	Phospho	(ST) * ** ** 3
FLNA	pS1459 * ** ** ** ** 3 SRSF3	seq:	12	-	28		no	mod ** 3
LZTS2	pS570 *** ** *** ** * * 3 USP1	pS327 *** * ** *** * * * 3
HSPA5	seq:	47	-	60		no	mod *** * 3 MYH14	pS1969 ** * 3
NOP56	seq:	511	-	534		+	Phospho	(ST) * * ** 3 NCL	pT76 * * ** 3
MAP4K5	seq:	333	-	350		+	Phospho	(ST) ** * * * ** 3 MAGI3	seq:	835	-	859		+	Phospho	(ST) ** ** 3
SEC16A	seq:	1872	-	1879		+	Phospho	(ST) * *** * 3 MCM4	seq:	114	-	149		+	Phospho	(ST) * ** 3
NUCKS1	pS181 *** * * 3 MCM2	pS139 *** * *** 3
SNRNP70	pS226 * ** ** 3 SRRM2	pS2702	pS2706 ** 3
AHNAK	seq:	5726	-	5744		+	2	Phospho	(ST) *** ** *** *** *** * 3 C9orf142	pS152 * ** * ** * 3
SHANK2	seq:	41	-	64		+	Phospho	(ST) *** ** ** ** * 3 AHNAK	seq:	5748	-	5765		+	Phospho	(ST) ** ** 3
ARHGEF16	pS107 *** * * *** * ** 3 FIP1L1	seq:	488	-	506		+	Phospho	(ST) * * ** 3
H1FX	pS31 *** ** * * 3 MYOF	pS174 * * * ** 3
MATR3	pS188 ** * * 3 DENND4C	seq:	1040	-	1059		+	Phospho	(ST) ** * 3
ZNF185	seq:	463	-	482		+	Phospho	(ST) *** * * * *** ** * 3 PRRC2C	pT2673 ** ** 3





























































































BRIP1	seq:	988	-	995		+	Phospho	(ST) ** *** *** *** 3 PUM2	pS587 ** ** *** ** 3
RGPD3	pS1535 ** 3 ATAD2	seq:	335	-	346		+	Phospho	(ST) ** *** * *** * 3
AHNAK	seq:	172	-	181		+	Phospho	(ST) ** * * 3 MCM3	seq:	701	-	724		+	Oxidation	(M);	Phospho	(ST);	Phospho	(Y) ** * ** 3
TMPO	seq:	151	-	173		+	2	Phospho	(ST) ** ** 3 RBM15	pT32 * ** * * * * * 3
NUCKS1	pS19 ** * * * 3 CHAMP1	seq:	441	-	456		+	2	Phospho	(ST) * * ** 3
NUCKS1	pS19 ** * * * 3 RNF20	seq:	126	-	142		+	Phospho	(ST) * ** ** * 3
C9orf142	pS148 ** *** ** ** 3 UNG	seq:	51	-	73		+	2	Phospho	(ST) ** 3
AGFG1	pS181 * *** * *** *** 3 CGN	pS332 ** * 3
THRAP3	seq:	678	-	688		+	Phospho	(ST) ** 3 IRS1	seq:	328	-	353		+	Phospho	(ST) ** ** ** *** 3
MSH6	seq:	129	-	140		+	Phospho	(ST) ** 3 MYL6	seq:	80	-	94		no	mod * ** ** 3
STMN1	pS16 * *** ** 3 POGZ	seq:	1322	-	1341		+	Phospho	(ST) ** 3
LMNB1	seq:	398	-	407		+	Phospho	(ST) ** 3 CDK11A	pS271 * * * ** 3
PPP1R12A	seq:	443	-	456		+	Phospho	(Y) * ** ** * * *** * 3 SRRM2	seq:	2114	-	2129		+	Phospho	(ST) ** 3
REPS1	seq:	270	-	286		+	Phospho	(ST) ** * 3 PLEC	pS1732 *** ** * 3
SLC9A3R1	seq:	288	-	331		+	Oxidation	(M);	Phospho	(ST) ** ** 3 PRPF4B	seq:	427	-	440		+	3	Phospho	(ST) *** *** *** 3
PPP1R12A	seq:	443	-	456		+	Phospho	(ST) * ** *** * * *** * 3 SLC9A3R1	seq:	288	-	331		+	Oxidation	(M);	2	Phospho	(ST) ** 3
SIPA1L1	pS1433 * ** * ** * ** ** 3 NOLC1	pS698 ** ** * 3
FIP1L1	pS492	pS500 ** * * 3 RANBP2	pS1456 * ** * ** 3
LARP1	seq:	620	-	642		+	Phospho	(ST) *** 3 TNS3	seq:	774	-	792		+	Phospho	(ST) ** *** ** *** * ** 3
XRCC1	pS241 ** * * 3 LASP1	seq:	131	-	153		+	Phospho	(ST) ** * 3
NCAPH2	pS284 ** ** * ** 3 PDHA2	seq:	287	-	300		+	2	Phospho	(ST) *** 3
KIAA1598	seq:	485	-	505		+	Phospho	(ST) *** 3 RBM15	seq:	666	-	681		+	2	Phospho	(ST) ** * ** * 3
TNKS1BP1	seq:	492	-	520		+	2	Phospho	(ST) ** * 3 HEATR6	seq:	630	-	645		+	Phospho	(ST) ** *** * ** *** ** ** 3
CDK13	seq:	861	-	873		+	Phospho	(ST) ** *** * ** * 3 DOCK7	seq:	896	-	916		+	Phospho	(ST) ** *** *** ** 3
STMN1	pS16 *** *** 3 SVIL	pT852 * ** ** *** 3
CPNE3	seq:	126	-	139		no	mod *** ** ** 3 OSBPL11	pS189 ** ** * 3
NPM1	pS70 *** * ** 3 MCM3	seq:	701	-	724		+	Oxidation	(M);	2	Phospho	(ST) * ** 3
SHROOM2	seq:	644	-	662		+	Phospho	(ST) *** *** ** ** *** *** ** *** 3 MYL9	seq:	18	-	35		+	Phospho	(ST) *** ** 3
AHNAK	pS4986 *** * * *** 3 CHAMP1	pS476 * * *** ** 3
ZNF652	seq:	54	-	66		+	Phospho	(ST) ** *** 3 KIAA1598	pS506 * ** * * 3
EML3	pS176 ** ** ** ** 3 SF3B1	seq:	214	-	231		+	2	Phospho	(ST) ** * * ** ** 3
MYOM2	seq:	1157	-	1162		+	Phospho	(ST) * * ** *** 3 PPP1R12A	pS862	pS871 ** ** * 3
H2AFZ	seq:	86	-	92		no	mod *** * * * * 3 NCL	seq:	611	-	624		no	mod ** 3
EEF1B2	pS106 *** 3 LMNB1	pS391	pS393 * ** 3
CCDC88C	pS1887 ** ** *** * ** 3 SRRM2	seq:	286	-	303		+	2	Phospho	(ST) ** 3
PHLDB1	pS563 * * * ** ** 3 STRN	pS245 ** ** 3
WDHD1	pS383 *** * * 3 PKP3	pS180 ** * 3
PRPF31	seq:	445	-	471		+	2	Phospho	(ST) ** * ** 3 C9orf40	pS69 * ** * 3
SIPA1L1	seq:	205	-	227		+	Phospho	(ST) * * * ** 3 HIRIP3	seq:	94	-	117		+	2	Phospho	(ST) *** ** * * ** *** *** * 3
TRAM1	seq:	349	-	367		+	Phospho	(ST) ** 3 CGN	seq:	129	-	146		+	2	Phospho	(ST) ** ** ** 3
NUCKS1	seq:	176	-	186		+	2	Phospho	(ST) ** ** ** *** ** 3 NELFE	pS131 * ** 3
NFYA	pS326 * ** 3 NCOR2	seq:	2048	-	2080		+	2	Phospho	(ST) ** 3
SRRM2	seq:	2114	-	2129		+	Oxidation	(M);	2	Phospho	(ST) * ** 3 ZC3H4	seq:	157	-	179		+	Phospho	(Y) ** 3
SF3B2	pT780 * ** * *** 3 PTPN21	pS637 ** 3
CHAMP1	pS308	pS319 *** * ** 3 XRCC1	pS241 * *** *** ** 3
RPS6KB1	seq:	444	-	459		+	Phospho	(ST) ** ** * 3 ZBTB7A	seq:	505	-	530		+	Phospho	(ST) ** 3
CHAMP1	pS308	pS319 *** * * * 3 FTSJ3	seq:	568	-	579		+	Phospho	(ST) ** 3
C11orf84	seq:	239	-	263		+	Phospho	(ST) *** ** *** * 3 SRSF9	pS211	pS216 * ** ** 3
EEF1B2	pS106 ** 3 MYH10	seq:	1945	-	1976		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** ** * 3
CHD3	pS1601	pS1605 ** * ** ** 3 LDB1	seq:	300	-	320		+	Phospho	(ST) ** * * * 3
TPI1	seq:	213	-	225		no	mod *** * 3 NUCKS1	pS19 ** ** ** *** 3
SMARCC1	pS328	pS330 ** ** 3 NCOA3	seq:	562	-	590		+	Phospho	(Y) ** ** 3
NUCKS1	pS19 ** * ** ** 3 NOTCH2	seq:	1801	-	1824		+	Phospho	(ST) * ** *** 3
NUCKS1	pS19 *** ** * *** ** 3 AHNAK	pS5400 ** *** 3
ZCRB1	pS155 * ** 3 CGN	seq:	129	-	146		+	2	Phospho	(ST) * ** * *** * 3
ANKRD34A	pS247 ** 3 EIF3H	seq:	341	-	352		no	mod * ** * 3
PPP2R5D	pS573 * * *** 3 NUCKS1	pS19 * ** ** * *** * 3
CLNS1A	pS102 ** 3 SIPA1L1	seq:	1430	-	1471		+	3	Phospho	(ST) *** * *** ** ** ** 3
HIST3H2BB	seq:	59	-	73		+	2	Oxidation	(M) ** * 3 TBC1D5	seq:	41	-	57		+	Phospho	(ST) * * ** ** 3
ARGLU1	pS77 *** * * * 3 TIMELESS	seq:	1082	-	1092		+	Phospho	(ST) *** * ** *** *** ** 3
CDK1	pT14	pY15 * *** 3 UBE2O	seq:	423	-	466		+	2	Phospho	(ST) * ** ** *** 3
CTR9	pT925 ** ** 3 PXN	seq:	111	-	123		+	Phospho	(Y) ** *** ** ** ** * 3
ZC3HC1	pS359	pS370 ** * * * ** 3 MAP3K2	pS153 * * ** * ** 3
ANKRD34A	pS461 *** * ** ** * 3 TBC1D10B	seq:	649	-	666		+	2	Phospho	(ST) * ** 3
SRRM2	pS508	pS510 ** 3 AMPD2	pS168 * *** *** *** 3
MCM2	pS139 ** ** ** *** *** 3 HNRNPA2B1	seq:	4	-	12		no	mod ** 3
NCOA3	pS214 ** * 3 OSBP	pS190	pS193 * ** ** 3
CDK18	pS12 ** ** * 3 PGM3	pS64 *** ** 3
KRT19	seq:	254	-	265		no	mod ** * 3 GATAD2B	seq:	117	-	137		+	2	Phospho	(ST) *** ** *** ** 3
TNKS1BP1	pS1029 ** 3 LDB1	seq:	300	-	320		+	Oxidation	(M);	Phospho	(ST) *** * ** 3
PPP6R3	pS617 * * ** ** 3 SRRM2	seq:	777	-	787		+	Phospho	(ST) ** * ** * 3
UNG	pS23 ** * ** 3 EEF2K	pS74 ** ** * ** *** * 3
SCRIB	seq:	1575	-	1615		+	Phospho	(ST) * ** 3 BCL9L	pS1017 ** 3
PLEC	seq:	4361	-	4383		+	Phospho	(ST) ** 3 SRRM2	pT2738	pS2740 * * ** 3
HNRNPK	pS216 *** * * 3 NPM1	pS70 *** ** 3
ZC3H4	seq:	1265	-	1292		+	2	Phospho	(ST) ** ** * 3 KRT19	seq:	371	-	381		no	mod ** * ** ** 3
UBL4A	pS90 ** * * * 3 FLNB	pS2465 * *** *** ** 3
CEP170B	pS1179 ** * ** ** ** 3 KRT38	seq:	395	-	405		no	mod ** * ** ** 3
SRRM2	seq:	1078	-	1089		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** * 3 KRT18	pS7 ** * * ** *** *** * *** 3
ZC3H4	seq:	1265	-	1292		+	2	Phospho	(ST) *** *** *** 3 UBL7	pS230 * ** * * 3
CENPT	pS397 ** * 3 MAGED2	seq:	241	-	249		+	Phospho	(ST) ** 3
C9orf142	pS148 * ** * ** ** 3 ANKRD34A	pS392 *** ** ** *** 3
SVIL	pS221 ** 3 RB1	seq:	788	-	798		+	2	Phospho	(ST) * *** 3
TPI1	pS58 * * * * *** ** 3 SRRM2	pT2738	pS2740 * * ** * 3
KRT8	seq:	317	-	328		no	mod *** ** 3 RABL6	pS596	pT599 * ** * 3
TBC1D30	seq:	111	-	131		+	Phospho	(ST) ** * ** * 3 KRT19	seq:	126	-	138		no	mod ** 3
CDK18	pT152 *** * *** 3 HAT1	seq:	358	-	364		+	Phospho	(ST) ** *** * *** 3
CDK3	pT14 *** * *** 3 TJP3	pS164	pS169 * * ** * *** * 3
KRT8	seq:	317	-	328		no	mod ** *** 3 PPIAL4G	seq:	119	-	125		no	mod * ** 3
STMN1	pS16	pS25 ** * * * ** 3 DCDC2	seq:	261	-	276		+	Phospho	(ST) * * *** ** ** *** ** 3
HNRNPK	pS216 *** * ** 3 BCKDHA	pS347 ** * ** 3
CHAMP1	seq:	280	-	301		+	Phospho	(ST) ** ** * ** 3 CALM1	seq:	92	-	107		no	mod ** *** * * 3
RB1CC1	seq:	641	-	655		+	Phospho	(ST) * ** *** * 3 CNKSR3	seq:	380	-	393		+	Phospho	(ST) * ** ** ** ** * 3
LAMTOR1	seq:	48	-	60		+	Phospho	(ST) * *** 3 SORBS3	seq:	542	-	550		+	Phospho	(ST) ** ** 3
CPNE3	seq:	126	-	139		no	mod ** * ** 3 KRT18	seq:	166	-	175		no	mod *** ** 3
ZFYVE20	seq:	208	-	227		+	2	Phospho	(ST) ** * 3 KIF1B	pS1057 ** 3
SRRM2	seq:	1878	-	1885		+	2	Phospho	(ST) * *** 3 DDX55	pS544 ** 3
STC2	seq:	274	-	301		+	Phospho	(ST) * ** * *** ** 3 CCDC88C	seq:	1815	-	1838		+	Phospho	(ST) ** 3
CABL1_HUMAN	seq:	284	-	289		+	Phospho	(ST) * ** ** * * * * 3 SIPA1L1	seq:	205	-	227		+	2	Phospho	(ST) * ** 3
ZC3H13	seq:	316	-	330		+	2	Phospho	(ST) *** 3 MTDH	seq:	492	-	504		+	Phospho	(ST) *** 3
STMN1	pS16	pS25 ** * *** ** 3 TMEM54	seq:	84	-	91		+	Phospho	(ST) *** * ** ** * 3
ERBB2IP	seq:	1077	-	1095		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) ** 3 ANK3	pS1459 * ** *** ** ** * 3





































































































KRT18	seq:	371	-	381		no	mod ** 3 SNTB2	pS110 ** ** * *** 4
SRRM1	seq:	387	-	396		+	2	Phospho	(ST) * *** ** *** * 3 LDHAL6B	pT358 * * *** * 4
MCM2	pS108 * *** 3 PLEC	pS4386	pS4389 *** * *** *** * *** * 4
SH3KBP1	pS230 * ** * ** 3 SLC9A1	seq:	680	-	698		+	Phospho	(ST) ** *** * ** * 4
AHNAK	seq:	208	-	225		+	2	Phospho	(ST) *** ** * 3 BAD	seq:	73	-	94		+	Phospho	(ST) * *** ** ** ** * * 4
PDHA2	seq:	287	-	300		+	2	Phospho	(ST) *** 3 BAD	seq:	97	-	109		+	Phospho	(ST) ** * *** *** * *** 4
LARP1	seq:	620	-	642		+	2	Phospho	(ST) *** *** ** 3 WDR77	seq:	122	-	145		no	mod * ** * 4
SIPA1L1	seq:	153	-	164		+	Phospho	(ST) * * ** ** 3 MAP4	seq:	600	-	634		+	Phospho	(ST) * ** 4
NDE1	seq:	304	-	315		+	Phospho	(ST) ** * * 3 CLASP2	seq:	323	-	338		+	Phospho	(ST) * ** * ** *** 4
MLPH	seq:	550	-	556		+	Phospho	(ST) ** *** 3 ARID1A	pS696 *** ** ** *** 4
EIF5B	pS135	pS137 *** 3 BAD	pS99 *** *** *** *** *** ** 4
KIF13B	pS1410 * ** *** ** * 3 RBM14	pS618 ** * *** *** *** ** *** * 4
PLEKHF2	pS16 *** ** 3 TPI1	seq:	187	-	193		no	mod ** 4
CDK3	pT14	pY15 * *** *** ** 3 FRMD6	seq:	520	-	532		+	Phospho	(ST) *** ** ** *** 4
CDK18	seq:	148	-	158		+	Phospho	(ST);	Phospho	(Y) * *** *** ** 3 ACLY	seq:	453	-	469		+	Phospho	(ST) * *** ** ** * ** 4
PPP1R12A	seq:	908	-	917		+	Phospho	(ST) * * * ** *** * 3 TMPO	pS306 ** *** 4
NASP	seq:	610	-	617		no	mod * *** * ** 3 DPYSL2	seq:	512	-	532		+	3	Phospho	(ST) *** 4
ZC3H4	seq:	1094	-	1124		+	3	Phospho	(ST) * * ** * * 3 RTN4	seq:	178	-	201		+	2	Phospho	(ST) ** ** *** *** 4
HMGN2	pS25	pS29 *** *** * 3 DPYSL2	seq:	512	-	525		+	Phospho	(ST) ** ** * 4
NGDN	seq:	130	-	162		+	2	Phospho	(ST) ** *** 3 LIMD2	pS29 *** ** * ** 4
PCBP1	pS173 ** ** 3 ZCCHC8	pT479 ** * 4
MRE11A	pS649 ** ** 3 HMGCS1	pS495 * *** * *** ** * 4
HCFC1	seq:	2016	-	2024		+	Phospho	(ST) *** 3 NOP2	seq:	773	-	789		+	Phospho	(ST) *** *** * 4
CHD3	pS1601	pS1605 * ** * ** *** 3 DGCR8	seq:	365	-	384		+	Phospho	(ST) ** * ** * 4
SRRM2	seq:	852	-	870		+	Gln->pyro-Glu	(N-term	Q);	Phospho	(ST) *** 3 TP53I11	pS14 * *** * ** 4
SEZ6_HUMAN	seq:	782	-	788		+	Phospho	(ST) ** 3 BAZ1B	seq:	345	-	354		+	Phospho	(ST) * ** ** * 4
PARK7	seq:	149	-	156		no	mod *** 3 NPY1R	pS368 *** *** ** *** 4
SRRM1	seq:	603	-	611		+	2	Phospho	(ST) ** *** *** *** ** 3 FARP1	seq:	14	-	27		+	Phospho	(ST) ** *** *** ** *** ** * 4
TPM3	seq:	79	-	91		no	mod *** * *** 3 PLEC	pS1435 * *** *** *** *** 4
AHNAK	seq:	5745	-	5765		+	2	Phospho	(ST) *** *** * * 3 SLC9A1	seq:	766	-	790		+	Phospho	(ST) * ** ** * ** ** 4
PREX1	seq:	1188	-	1209		+	Oxidation	(M);	Phospho	(ST) ** *** *** ** *** * 3 PRRC2B	seq:	216	-	233		+	Phospho	(ST) ** * ** ** *** 4
VCL	seq:	340	-	352		+	Phospho	(ST) * * ** * ** ** 3 TRIM16	seq:	54	-	85		+	Phospho	(ST) * * ** 4
HASP_HUMAN	pT624 *** 3 SNRPD3	seq:	32	-	51		no	mod * ** *** 4
VCL	pS290 ** * * ** ** ** *** * 3 PLEC	seq:	4384	-	4401		+	Phospho	(ST) *** *** *** *** *** ** 4
PARD3	seq:	692	-	712		+	Phospho	(ST) *** 3 SYNRG	pS1075 ** ** *** * *** ** 4
GIGYF2	pS236 ** * 3 KRT8	pS475 ** * *** ** ** *** *** 4
MISP	seq:	154	-	171		+	Phospho	(ST) * *** * * * 3 DMXL2	pS1857 ** * ** 4
TBC1D15	pS70 *** *** * * *** 3 NOP2	pS67 ** * * ** 4
ZNF687	pS1057 *** 3 PACR_HUMAN	seq:	415	-	419		no	mod * * ** ** 4
EIF4B	seq:	445	-	472		+	Phospho	(ST) * ** 3 YWHAZ	seq:	140	-	158		no	mod * ** 4
HIST2H2BD	seq:	36	-	44		no	mod * ** ** *** *** ** 3 BAG3	seq:	366	-	388		+	Phospho	(ST) *** * *** *** ** 4
MAP7D1	seq:	273	-	283		+	Phospho	(ST) *** 3 DNMT1	seq:	952	-	960		+	Phospho	(ST) ** ** ** ** * 4
PKP4	pS221 ** ** ** *** 3 EIF3A	pS584 ** * * ** *** ** ** 4
FAM83B	pS664 ** *** *** * *** *** 3 YA023_HUMAN	pT54 ** * * ** *** ** *** 4
NELFB	pS557 ** * 3 LMNB2	pS296 *** 4
VCL	seq:	340	-	352		+	Phospho	(ST) * * ** * ** ** 3 EAF1	seq:	157	-	175		+	Phospho	(ST) *** 4
TNS3	seq:	774	-	792		+	Phospho	(ST) * ** *** 3 TUBA4A	seq:	340	-	352		no	mod ** *** * 4
WDR70	pS638 ** * ** *** * ** 3 XBP1	pS47 ** ** *** ** *** ** ** * 4
MISP	seq:	154	-	171		+	Phospho	(ST) * *** *** 3 FAM129B	pS665 ** *** *** ** *** 4
MLPH	seq:	300	-	320		+	Phospho	(ST) ** * 3 ZC3H13	seq:	204	-	214		+	2	Phospho	(ST) ** * 4
PKD1L1	seq:	2276	-	2281		+	Phospho	(ST) ** *** 3 ELMSAN1	pS461 * ** ** * * ** 4
FNBP4	seq:	448	-	453		+	Oxidation	(M);	Phospho	(ST) *** 3 PLEC	seq:	4610	-	4627		+	Phospho	(ST) *** ** *** *** ** 4
MKI67	pS2002 * * *** * *** 3 PGRMC1	seq:	45	-	67		+	Phospho	(ST) ** 4
TRIM33	seq:	1085	-	1113		+	Phospho	(ST) * * ** 3 TNKS1BP1	pS178 *** ** *** * * 4
FAM53C	pS232	pS234 * ** * * 3 ELMSAN1	seq:	698	-	722		+	Phospho	(ST) *** *** 4
FLNB	seq:	2198	-	2205		no	mod * *** 3 RANBP3	seq:	124	-	138		+	Phospho	(ST) * ** * * ** 4
FAM110B	pS301 ** * ** * 3 GNB2L1	seq:	140	-	155		no	mod ** 4
MINK1	seq:	699	-	709		+	Phospho	(ST) * * *** ** * * 3 AEBP1	seq:	402	-	407		+	Phospho	(ST) ** ** * 4
ANXA2P2	seq:	120	-	135		no	mod *** 3 BRSK2	pS489 ** * 4
SMN1	pS28	pS31 * ** *** ** *** 3 GSK3B	seq:	7	-	27		+	Phospho	(ST) ** *** ** * *** ** 4
FBXO4	pS12 * * *** *** ** *** ** * 3 GSK3A	seq:	17	-	50		+	Phospho	(ST) * *** *** * *** 4
ZNF74	seq:	635	-	643		+	Phospho	(ST) *** 3 YBX1	seq:	205	-	234		+	Phospho	(ST) * *** *** *** *** 4
PREX1	pS1200 *** *** *** ** * ** ** 3 ABI1	pS183 ** ** *** ** * 4
PKP4	seq:	325	-	339		+	Phospho	(ST) ** *** 3 BAG3	pS386 *** * *** *** *** *** ** * 4
UBR4	seq:	2712	-	2721		+	Phospho	(ST) *** 3 FAM129B	seq:	686	-	705		+	Phospho	(ST) *** *** * *** ** 4
PREX1	pS1200 ** *** *** *** *** *** * 3 CREBBP	pS2063 ** *** *** * 4
DECR1	seq:	189	-	214		no	mod ** 3 ACLY	seq:	453	-	469		+	Phospho	(ST) * *** *** *** ** *** 4
PREX1	pS1200 ** ** ** *** ** ** 3 LMNA	pT19 *** *** *** ** *** ** 4
RBMXL3	seq:	50	-	63		+	Phospho	(ST) *** 3 TRIP10	pS296 * ** * 4
WDR77	seq:	93	-	118		no	mod ** 3 TJP3	pS591 *** * *** *** *** *** ** * 4
SRSF2	pS189	pS191 *** *** 3 RELA	seq:	134	-	149		no	mod ** ** 4
PREX1	pS319 ** 3 SMTNL2	pS344 * ** *** *** ** ** 4
SRRM1	pS260 *** 3 SEC31A	pS799 * * ** 4
CDK1	seq:	7	-	20		+	Phospho	(Y) *** 3 TJP3	seq:	164	-	182		+	Phospho	(ST) * * ** *** ** *** 4
STC2	seq:	276	-	301		+	Phospho	(ST) *** * ** *** *** *** * ** * 3 KIF21A	pS1212 * ** * * 4
RPLP1	pS101	pS104 * ** 3 EPPK1	seq:	2713	-	2732		+	Phospho	(ST) *** ** *** 4
PROSER2	seq:	283	-	315		+	Phospho	(ST) *** 3 TBC1D4	seq:	584	-	594		+	Phospho	(ST) ** * * * 4
TBC1D15	seq:	68	-	81		+	Phospho	(ST) * * *** *** * ** ** 3 NOP2	pS786 * ** * * 4
CDV3	pS30 *** 3 CASZ1	seq:	735	-	771		+	Phospho	(ST) ** *** * ** 4
KRT2	pS191 *** ** *** ** *** 3 ELMSAN1	pS461 * *** *** * ** ** 4
ROCK1	seq:	1094	-	1120		+	2	Phospho	(ST) ** ** ** * 3 CTAGE5	pS536 *** ** 4
PRPF31	seq:	445	-	470		+	2	Phospho	(ST) ** ** 3 FARP1	seq:	417	-	431		+	Phospho	(ST) ** ** ** ** ** *** 4
PRPF4B	seq:	385	-	391		+	Phospho	(ST) *** ** 3 DLG5	seq:	1248	-	1260		+	Phospho	(ST) * * ** ** 4
PDHA2	seq:	287	-	300		+	Phospho	(ST) ** * *** *** * ** 3 STX17	seq:	286	-	300		+	Phospho	(ST) *** *** ** ** ** ** 4
FOSL2	pS200 *** *** ** 4 SPICE1	seq:	228	-	250		+	Phospho	(ST) * * * *** ** *** * * 4
MACF1	pS4521 * * *** *** 4 BAG3	seq:	194	-	203		+	Phospho	(ST) *** ** * *** ** *** * 4
MTA2	seq:	50	-	64		+	Phospho	(ST) ** *** *** ** 4 ZBTB7A	seq:	505	-	531		+	Phospho	(ST) * *** ** 4
VGLL4	seq:	46	-	56		+	Phospho	(ST) ** 4 RAD51C	pS20 * ** * 4
GPRIN1	seq:	606	-	621		+	Phospho	(ST) ** *** * *** *** ** * ** 4 EEF1D	seq:	112	-	123		+	Phospho	(ST) ** * * ** * 4
PDYN_HUMAN	seq:	98	-	104		+	Phospho	(ST) * ** 4 BAG3	seq:	194	-	203		+	Phospho	(ST) *** ** ** *** ** *** 4
WIPI2	seq:	407	-	416		+	Phospho	(ST) * * ** * 4 BET1L	pS9 * ** 4
EPB41L5	seq:	413	-	445		+	Phospho	(ST) *** *** *** ** *** ** 4 NCOR2	seq:	1975	-	2004		+	Phospho	(ST) *** ** ** *** 4
UBA1	pS816 ** * ** *** 4 FAM129B	pS665	pS681 *** *** *** *** ** *** 4
EHMT2	pS232 ** * *** *** *** *** 4 ARID3A	seq:	67	-	95		+	Phospho	(ST) *** *** *** 4
ACIN1	seq:	384	-	396		+	2	Phospho	(ST) * ** * * ** 4 ULK1	pS450 * ** ** *** ** 4
TRIM33	pS1119 *** * *** *** *** *** 4 ZNF560	seq:	585	-	592		+	Phospho	(ST);	Phospho	(Y) ** 4
KRT8	seq:	234	-	252		+	Oxidation	(M) ** *** * 4 CHD7	pS2559 ** *** 4
TUBA3E	seq:	41	-	60		no	mod * * ** * 4 EPPK1	pS2716 *** *** *** ** 4
CDCA5	seq:	19	-	28		+	Phospho	(ST) * * ** 4 TJP2	seq:	702	-	715		+	Phospho	(ST) * ** ** 4
CALR	seq:	56	-	73		no	mod * * ** * 4 NCOR2	seq:	2398	-	2410		+	Phospho	(ST) ** ** ** * 4
IER3	seq:	29	-	56		+	Phospho	(ST) ** ** *** 4 DSP	seq:	163	-	185		+	2	Phospho	(ST) * * *** * *** * 4
ETV6	seq:	15	-	39		+	2	Phospho	(ST) *** *** ** ** ** ** 4 PAK4	pS181 *** *** * *** *** 4
KRT8	pS478 *** * * ** 4 TMPO	pS306 ** ** 4



























































































FARP1	pS427 * ** ** ** ** ** 4 GALNT6	seq:	503	-	517		no	mod *** ** ** * 4
TPI1	seq:	138	-	150		no	mod *** ** *** * ** * ** 4 SLTM	seq:	989	-	1006		+	Phospho	(ST) * ** ** * ** * 4
	pS91 *** * *** ** ** ** * 4 FAM129B	seq:	686	-	705		+	2	Phospho	(ST) *** *** *** *** ** ** 4
STK10	pS438 * ** 4 UBAP2L	seq:	601	-	618		+	Phospho	(ST) *** ** *** ** * 4
PCBP1	seq:	244	-	268		+	Gln->pyro-Glu	(N-term	Q);	Oxidation	(M);	Phospho	(ST)** *** ** *** *** 4 MAP4	seq:	277	-	290		+	Oxidation	(M);	Phospho	(ST) * ** * 4
ACD	seq:	422	-	437		+	Phospho	(ST) * ** * 4 TRPS1	seq:	84	-	108		+	Phospho	(ST) * *** 4
KIF21A	pS1212 *** ** *** * ** * ** 4 TBC1D10B	pS687 *** * * *** *** 4
GTF3C3	seq:	40	-	63		+	Phospho	(ST) *** ** ** *** ** 4 UBR5	pS1549 ** ** 4
ZDHHC5	seq:	375	-	392		+	Phospho	(ST) *** *** * 4 ZC3H11A	seq:	100	-	124		+	Phospho	(ST) * ** ** *** 4
PKM	seq:	189	-	206		no	mod ** *** * * 4 PLEKHG3	pS76 ** *** * *** *** * * ** 4
BAD	pS118 *** ** *** * 4 TRPS1	pS178 * * *** *** 4
ANLN	seq:	293	-	307		+	Phospho	(ST) *** *** ** * 4 LARP4	seq:	643	-	671		+	Phospho	(ST) ** * *** ** 4
RPS6KB1	pT444	pS447 *** *** ** 4 MEF2D	pS251 *** ** ** *** 4
ZYX	seq:	273	-	295		+	Phospho	(ST) * ** * 4 KRT18	seq:	56	-	90		+	3	Oxidation	(M) ** ** ** 4
FAM129B	pS665 *** *** * *** * 4 TJP2	pS1159 ** ** ** 4
GAB2	seq:	403	-	414		+	Phospho	(ST) *** 4 DBN1	seq:	328	-	354		+	Phospho	(ST) *** ** ** * ** 4
KRT8	seq:	134	-	148		+	2	Oxidation	(M) ** *** * 4 HDAC1	seq:	405	-	413		+	Phospho	(ST) ** * * *** *** ** 4
KIAA1522	pS404 ** *** *** * ** ** 4 CAMSAP3	seq:	812	-	823		+	Phospho	(ST) *** ** ** *** ** 4
EPPK1	pS2716 * * *** *** *** * 4 PI4KB	seq:	253	-	270		+	Phospho	(ST) ** *** *** ** ** * 4
CRTC3	seq:	366	-	384		+	Phospho	(ST) * * *** *** *** * 4 GTF2I	seq:	681	-	702		no	mod ** ** 4
SLC35C2	seq:	332	-	344		+	Phospho	(ST) * * ** 4 TNKS1BP1	pS893 ** * ** 4
ARHGAP39	seq:	278	-	293		+	Phospho	(ST) * * ** ** ** 4 PAN3	seq:	349	-	358		+	Phospho	(ST) * * ** * ** 4
LARP4B	pS718 * ** 4 PXN	seq:	76	-	93		+	Phospho	(ST) ** *** *** *** *** ** * 4
PRKAR1B	seq:	69	-	92		+	Phospho	(ST) ** *** ** *** ** * *** *** 4 TP53BP1	pS1430 *** *** * ** 4
MAP4	seq:	634	-	651		+	Phospho	(ST) ** ** *** *** * * 4 ZFC3H1	pS655 * ** ** ** 4
UBR5	pS1549 * *** ** 4 BAG3	seq:	366	-	388		+	2	Phospho	(ST) * * ** ** *** * ** 4
RAB12	pS21 ** ** * * *** * * 4 EEF1D	pS133 ** * * * *** *** 4
SQSTM1	seq:	22	-	46		+	Phospho	(ST) ** ** *** *** * *** 4 KIAA1522	seq:	856	-	876		+	Phospho	(ST) * ** *** ** 4
NCOR2	pS956 *** *** *** *** *** *** ** ** 4 FAM208B	pS1025 * *** 4
PATL1	seq:	176	-	188		+	2	Phospho	(ST) * ** *** ** *** * * ** 4 CCDC88C	seq:	1578	-	1598		+	Phospho	(ST) ** ** * *** ** 4
BAG3	pS289 * *** ** *** *** ** * 4 AAK1	seq:	9	-	37		+	Phospho	(ST) ** ** * ** 4
MACF1	seq:	7328	-	7360		+	Phospho	(ST) ** *** * *** ** 4 RAF1	seq:	283	-	309		+	Phospho	(ST) *** *** *** ** *** * 4
TNKS1BP1	pS1138 *** *** *** *** ** 4 KIF21A	pS1239 ** ** * 4
PLEKHA5	seq:	853	-	870		+	Phospho	(ST) *** *** *** ** ** 4 CEP170B	pS829 * *** ** *** *** ** 4
GSK3A	seq:	19	-	50		+	Phospho	(ST) ** *** *** ** *** ** 4 TOP2B	pT1575 *** * ** * 4
CHMP3	seq:	184	-	216		+	Oxidation	(M);	Phospho	(ST) ** ** 4 CASKIN2	seq:	390	-	414		+	Phospho	(ST) *** * *** *** ** * 4
HDGFRP2	pS454 ** ** ** 4 PARD3	seq:	713	-	731		+	Phospho	(ST) * * ** ** ** 4
NCOR2	pS956 *** ** ** *** *** ** * 4 MAP4	pS1073 ** * ** * 4
TMCC1	pS382 * *** * * 4 EIF4G3	pS495 * * ** ** 4
BAZ2A	seq:	132	-	143		+	Phospho	(ST) *** * ** 4 CCT3	seq:	249	-	266		no	mod * ** 4
NCOR2	seq:	981	-	1020		+	Phospho	(ST) * * *** ** 4 CIAPIN1	seq:	181	-	196		+	Phospho	(ST) * * ** ** ** ** 4
ZBTB7A	seq:	503	-	530		+	Phospho	(ST) * ** ** * 4 FKBP15	seq:	1096	-	1124		+	Phospho	(ST) *** ** * * 4
PGRMC1	seq:	45	-	67		+	Phospho	(ST) ** * * * 4 LARP1	pS766	pS774 * * ** *** 4
ZMYND8	pS547 * * * ** *** * ** 4 CAST	seq:	213	-	249		+	Phospho	(ST) *** 4
BAG3	seq:	171	-	193		+	Phospho	(ST) ** ** ** *** * ** ** 4 PYGL	seq:	12	-	17		+	Phospho	(ST) ** 4
PPFIBP1	seq:	538	-	565		+	Phospho	(ST) * *** * * 4 MAP4	seq:	937	-	946		+	Phospho	(ST) ** * 4
SRRM2	seq:	979	-	998		+	2	Phospho	(ST) *** 4 NCOR2	pT1391 *** * * *** ** ** 4
TJP2	pS130 ** ** ** *** *** *** ** *** 4 FAM102B	seq:	282	-	294		+	Phospho	(ST) *** ** *** ** ** ** 4
PPP1R3D	seq:	40	-	63		+	Phospho	(ST) ** * ** * 4 ZMYND8	pS406 ** 4
ANKLE2	pS662 *** ** ** * *** * 4 TNK1	seq:	502	-	524		+	2	Phospho	(ST) * *** *** ** * 4
TOMM34	pS186 * * ** ** *** *** ** 4 TBC1D10B	pS22 ** ** 4
ZNF217	seq:	792	-	819		+	Phospho	(ST) * *** *** * 4 METTL3	pS43 ** 4
SCRIB	seq:	1536	-	1574		+	Phospho	(ST) ** 4 KLC2	pS445 ** *** * * * 4
ATXN2L	seq:	400	-	411		+	Phospho	(ST) ** *** 4 PAGR1	pS237 ** * * ** * 4
EEF1D	seq:	112	-	123		+	Phospho	(ST) ** * ** * 4 MAST4	pS206 *** ** ** ** 4
TNKS1BP1	seq:	859	-	879		+	Phospho	(ST) *** *** *** *** ** 4 EEF1D	pS133 ** ** *** ** 4
BAG3	pT285 *** ** *** *** ** 4 SMARCA5	seq:	98	-	119		+	Gln->pyro-Glu	(N-term	Q);	2	Phospho	(ST) *** * 4
DBN1	seq:	328	-	354		+	Oxidation	(M);	Phospho	(ST) *** * ** * *** 4 LRRC47	seq:	508	-	542		+	Phospho	(ST) *** * 4
NOP2	seq:	773	-	789		+	Phospho	(ST) *** ** * 4 C7orf43	seq:	515	-	525		+	Phospho	(ST) * * ** 4
TNKS1BP1	pS691 *** * *** 4 MYH9	seq:	1731	-	1751		no	mod ** ** ** 4
MBD3	seq:	81	-	90		+	Phospho	(ST) ** * *** 4 CTTN	seq:	397	-	428		+	2	Phospho	(ST) * *** ** ** ** * 4
KIF23	seq:	910	-	932		+	Phospho	(ST) * *** * * 4 WIZ	pS1151 ** ** ** * 4
TJP2	pS702 * *** *** 4 MKL2	seq:	535	-	561		+	Phospho	(ST) ** *** ** * 4
EPPK1	pS2716 * * ** * 4 SYTL2	pS535 ** *** ** ** 4
ANKLE2	pS662 *** *** *** *** 4 MAP4	seq:	353	-	368		+	Phospho	(ST) * *** ** *** 4
FNBP1L	seq:	293	-	308		+	Phospho	(ST) * * *** *** ** *** * 4 FAM102B	seq:	191	-	205		+	Phospho	(ST) * ** *** * ** * ** 4
COMT	seq:	129	-	135		+	Phospho	(ST) ** * ** *** *** *** 4 LMNA	seq:	281	-	296		no	mod * ** ** 4
DDX42	pS185 *** 4 TJP2	seq:	1155	-	1176		+	Phospho	(Y) ** * * ** 4
GSE1	pS909 *** * *** ** ** * 4 TJP2	seq:	1155	-	1176		+	Phospho	(ST) ** * * ** 4
RPS6KB1	pT444	pS447 *** ** *** * 4 MEF2D	pS180 *** *** *** *** * 4
BAZ2A	seq:	1388	-	1405		+	Phospho	(ST) *** * * ** * * * 4 FAM83H	pS881 ** * *** ** ** ** 4
ACLY	pS455 ** * * ** * *** *** 4 ABCF1	pS109 ** * ** * 4
VDAC2	pS115 ** *** ** * 4 NUMA1	pT2000 * *** * ** ** 4
EPPK1	seq:	2714	-	2732		+	Phospho	(ST) ** ** *** ** * 4 MAP4	pS1073 ** ** * *** * 4
MPRIP	seq:	346	-	368		+	Phospho	(ST) *** 4 DIP2B	seq:	98	-	113		+	Phospho	(ST) * *** ** *** 4
BTF3	pS30 * * *** ** *** * 4 ELF1	seq:	160	-	174		+	Phospho	(ST) * * ** 4
KRT18	seq:	56	-	90		+	3	Oxidation	(M) * *** ** *** 4 STIM1	pS512 ** 4
BAG3	seq:	171	-	193		+	Phospho	(ST) *** ** ** *** * *** * 4 NOP2	seq:	722	-	743		+	Phospho	(ST) ** ** *** ** 4
PTK2	pS840 ** 4 EIF4EBP1	seq:	64	-	99		+	2	Phospho	(ST) * * *** * *** ** * 4
NOP56	seq:	511	-	534		+	Oxidation	(M);	Phospho	(ST) ** ** 4 HABP4	seq:	96	-	119		+	Phospho	(ST) * *** ** *** ** 4
MORC2	seq:	722	-	736		+	Phospho	(ST) * ** *** *** *** 4 NUP210	pS1874 *** *** 4
CARHSP1	seq:	28	-	35		+	Phospho	(ST) ** *** *** ** * 4 AHNAK	seq:	5834	-	5858		+	Phospho	(ST) * ** ** * 4
TRIP12	seq:	310	-	321		+	Phospho	(ST) * * * ** * ** ** ** 4 ZC3H11A	pS132 ** * ** ** ** *** 4
MBD1	pS297 *** * 4 CAMSAP3	pS814 *** ** ** *** ** 4
CARHSP1	seq:	36	-	47		+	Phospho	(ST) *** * *** *** *** ** * ** 4 LAMTOR1	pS27 ** ** ** * 4
DBN1	pS142 ** *** ** *** * 4 CBX8	seq:	253	-	274		+	Phospho	(ST) ** * ** 4
RREB1	pS1653 ** 4 NUP35	seq:	270	-	282		+	Phospho	(ST) * * ** * 4
MKI67	pS1131 *** * * 4 BAZ2A	seq:	132	-	143		+	Phospho	(ST) * ** 4
NCOR2	seq:	1254	-	1265		+	Phospho	(ST) ** * ** *** ** ** 4 HMGA1	pT53 ** ** ** ** * 4
TOP2B	seq:	1574	-	1599		+	Phospho	(ST) *** * 4 BAZ1A	pS1413 * ** * ** 4
PDIA6	seq:	38	-	60		no	mod *** * * *** *** 4 FAM83H	seq:	923	-	933		+	Phospho	(ST) ** * *** *** ** *** * 4
PEBP1	pS52 ** * * *** *** *** *** *** ** 4 RPTOR	pS877 * * * ** * ** *** ** 4
MAP7	pS209 ** ** ** *** ** 4 MAP7D1	seq:	111	-	133		+	Phospho	(ST) *** * * * ** 4
ZNF687	seq:	422	-	435		+	Phospho	(ST) * * *** *** * * * 4 FAM83H	pS647 ** ** ** * 4
SAMD4B	seq:	260	-	291		+	Phospho	(ST) *** ** *** * *** *** 4 FAM83H	seq:	923	-	934		+	Phospho	(ST) * * *** * ** * 4
FAM64A	pS131 * ** * * ** 4 FAM102B	pS350 * *** *** ** 4
IBTK	pS1045 ** *** *** * 4 DIDO1	seq:	1231	-	1274		+	2	Phospho	(ST) * * *** * * 4
LPHN2	seq:	1428	-	1439		+	Phospho	(ST) ** ** *** *** 4 BTF3	pS30 * * *** ** 4
EDC3	pS131 * *** * ** 4 RBMXL1	pS208 *** 4
PVRL4	pS444 ** *** * * * ** 4 HIST3H2A	seq:	101	-	119		no	mod ** 4
BRAF	seq:	444	-	462		+	Phospho	(ST) * ** ** * 4 TBX2	seq:	379	-	395		+	Phospho	(ST) ** * ** * 4
HMGXB4	pS497 ** *** * ** ** 4 ZFP36L1	seq:	52	-	61		+	Phospho	(ST) * ** ** 4




























































































TNRC18	pS1857 * ** 4 PPM1H	pS221 ** *** ** * * *** *** 4
ZMYND8	pS490 ** * *** ** ** 4 ATXN2	pS784 ** * *** * 4
COPB2	seq:	847	-	875		+	Phospho	(ST) * *** * *** * 4 CHD1	seq:	89	-	98		+	Phospho	(ST) * ** * ** 4
TRAM1	pS365 *** 4 NUMA1	seq:	1990	-	2004		+	Phospho	(ST) * *** ** ** 4
MARK2	seq:	607	-	627		+	Phospho	(ST) * * *** ** *** ** ** 4 AKAP11	seq:	419	-	438		+	Phospho	(ST);	Phospho	(Y) * *** 4
TMX1	pS247 ** *** * * 4 DVL3	seq:	106	-	143		+	Phospho	(ST) ** * ** * 4
ACTN4	seq:	217	-	233		no	mod * ** * * 4 MARK3	seq:	387	-	404		+	Phospho	(ST) ** 4
NUMB	seq:	292	-	297		+	Phospho	(ST) ** 4 H1FX	pS31 * * * ** * 4
CLIC1	seq:	120	-	131		no	mod ** ** ** * 4 MAP7D1	pS460 * * * * * ** 4
CEP55	pS436 * * * ** 4 TIAM1	pS231 ** *** ** ** 4
LARP1	pS143 *** *** *** ** *** 4 MARCKS	seq:	157	-	161		+	Phospho	(ST) * *** * * *** 4
TJP3	pS164 *** ** ** * 4 RPB4_HUMAN	seq:	71	-	75		+	Phospho	(ST) * *** * * *** 4
CAD	pS1859 * *** ** 4 NOP2	pS786 * *** * * ** * ** 4
LMNA	seq:	628	-	644		+	Phospho	(ST) ** * *** *** * 4 VDAC1	pS104 * * ** 4
MARCKS	pS159 *** ** 4 LRRC16A	seq:	966	-	980		+	Phospho	(ST) *** * *** 4
RRBP1	seq:	1263	-	1291		+	Phospho	(ST) * ** * ** 4 SDE2	seq:	269	-	291		+	Phospho	(ST) ** 4
CAMSAP3	seq:	429	-	444		+	Phospho	(ST) * ** ** ** * * ** 4 LARP4	pS583 * * ** ** ** * 4
PUM2	pS82 ** * * ** 4 KLHDC4	seq:	400	-	432		+	Phospho	(ST) * *** * ** 4
SUV39H1	pS391 ** 4 GAL	pS116 * * ** 4
BTF3	pS30 *** *** ** *** ** ** 4 RBM33	pS41 * *** ** 4
CTTN	seq:	399	-	428		+	Phospho	(ST) * *** 4 LDHB	seq:	8	-	23		no	mod *** * *** * *** ** 4
KIF23	pS902 * *** * ** 4 C12orf45	pS178 *** * ** *** ** 4
SLC9A3R1	pS280 * ** * *** ** ** 4 MTDH	pS568 * *** * ** 4
TMPO	seq:	49	-	86		+	Phospho	(ST) ** *** ** 4 ANKRD13D	pS465	pT469 ** * *** * 4
MLF2	seq:	230	-	241		+	Phospho	(ST) ** ** ** * ** 4 CLASP1	pS600 *** 4
LMNA	pS392 ** ** * * 4 KLC1	seq:	521	-	531		+	Phospho	(ST) ** ** 4
EMSY	pS209 ** ** *** ** * ** * 4 DBN1	seq:	589	-	615		+	Phospho	(ST) ** *** ** 4
TOM1	seq:	453	-	478		+	Phospho	(ST) ** ** ** ** *** *** 4 ATXN2L	pS111 *** * *** ** 4
NOTCH2	pS2081 ** 4 MTMR12	pS564 *** *** * 4
MARCKS	pS170 * *** * *** 4 CTTN	seq:	415	-	428		+	Phospho	(ST) ** ** ** *** ** *** 4
BCL7C	seq:	110	-	142		+	Phospho	(ST) ** ** * * * * 4 MARCKSL1	pS93 * *** ** * 4
TOR1AIP1	seq:	149	-	174		+	2	Phospho	(ST) ** ** 4 NCOA3	pS857 * * ** 4
YWHAB	seq:	130	-	140		no	mod * *** ** ** *** * 4 ANKRD17	seq:	4	-	44		+	Phospho	(ST) * * ** * 4
RBM15	seq:	763	-	783		+	Phospho	(ST) ** * * 4 NAA30	pS89 * *** * 4
LSR	pS643 * * ** 4 PKN2	seq:	524	-	550		+	Phospho	(ST) * * ** * 4
LRRC47	seq:	508	-	542		+	Phospho	(ST) *** * 4 BICD2	pS582 ** *** *** * * 4
KIAA1522	seq:	969	-	984		+	Phospho	(ST) *** * * * *** 4 GAPVD1	pS902 *** ** * * *** ** 4
AIF1L	pS134 * * ** ** 4 KIAA1522	pS862 ** * ** * 4
BCL2L11	seq:	85	-	91		+	Phospho	(ST) ** * ** ** ** 4 ERBB3	pS982 *** ** * ** ** 4
HNRNPK	seq:	222	-	247		no	mod ** ** * 4 SCRIB	pS1486 ** * ** 4
EIF2AK3	pS715 *** ** 4 CTNND1	pS349 * ** *** ** 4
AHNAK	seq:	5834	-	5858		+	Phospho	(ST) ** ** ** 4 CSRP1	pS192 *** ** *** ** * *** * 4
BAG6	seq:	1073	-	1087		+	Phospho	(ST) * *** ** *** * 4 KRT8	seq:	134	-	148		+	2	Oxidation	(M) ** ** ** 4
GORASP2	seq:	421	-	452		+	Phospho	(ST) *** * *** * 4 JPH1	pS185 ** ** ** 4
YWHAQ	seq:	128	-	138		no	mod ** * ** * ** 4 ILF3	seq:	475	-	523		+	Phospho	(ST) * * ** 4
LARP1	pS90 * *** * 4 FAM91A1	seq:	340	-	376		+	Phospho	(ST) ** 4
FAM83H	pS1003 * *** *** * * 4 UTP3	pS37 ** ** ** 4
USP15	seq:	241	-	256		+	Phospho	(ST) ** 4 NOP56	seq:	561	-	578		+	Phospho	(ST) * ** 4
FAM83H	pS936 * * ** ** 4 ARFGAP2	pS146 ** 4
CTTN	seq:	397	-	428		+	2	Phospho	(ST) * * *** ** ** ** 4 CCDC86	seq:	30	-	53		+	Phospho	(ST) ** * 4
C10orf12	seq:	288	-	297		+	Phospho	(ST) * ** * ** 4 KRT8	seq:	274	-	295		no	mod *** 4
LMNA	seq:	29	-	41		no	mod *** ** ** *** *** *** 4 URI1	seq:	370	-	386		+	Phospho	(ST) * *** *** 4
BAG3	seq:	283	-	294		+	2	Phospho	(ST) ** *** * * *** ** 4 KRT18	seq:	383	-	407		+	Oxidation	(M) ** *** *** ** * 4
ACIN1	pS657 ** *** ** * ** *** 4 ABCF1	pS140 ** * *** 4
PPP1R37	seq:	557	-	564		+	Phospho	(ST) ** *** ** * ** *** 4 PDAP1	seq:	76	-	88		no	mod *** * ** * 4
NUFIP2	pS629 ** * ** * * ** 4 FAM102B	seq:	226	-	235		+	Phospho	(ST) *** ** * *** ** * 4
MISP	pS575 ** *** * *** 4 RPL19	seq:	22	-	38		no	mod ** *** 4
SCRIB	pS1348 ** ** * * 4 ABCF1	pS109 * * ** *** 4
SLC9A3R1	pS280 ** ** ** ** ** ** 4 NUMB	seq:	4	-	9		+	Phospho	(ST) * * *** 4
IRS1	pS1101 * ** ** ** 4 EIF3G	seq:	33	-	65		+	Phospho	(ST) * ** 4
LMNA	pS390 *** *** *** *** *** * 4 MAPKAP1	seq:	508	-	515		+	Phospho	(ST) * *** * ** * 4
KRT80	pS45 ** * *** *** *** 4 IGF2R	pS2409 ** ** 4
LMNA	seq:	387	-	397		+	Phospho	(ST) ** * ** *** * * 4 ROCK2	seq:	977	-	995		no	mod ** * ** 4
NDRG3	pS331 * * * *** * 4 KRT19	seq:	254	-	264		+	Oxidation	(M) * ** ** 4
TP53BP1	seq:	1459	-	1490		+	Phospho	(ST) *** *** 4 CTNND1	seq:	847	-	858		no	mod ** * * 4
ADD3	pS693 ** * ** *** * 4 SSMM1_HUMAN	seq:	240	-	244		+	Phospho	(ST) * * * ** * 4
FOXA1	pS307 ** * * * ** * ** 4 MARCKSL1	seq:	91	-	95		+	Phospho	(ST) * * * ** * 4
PPP1R10	pS313 *** * *** ** ** 4 AHNAK	pS5110 *** * * ** *** * 4
CTNND1	pS349 * *** * *** * 4 RGL4	seq:	418	-	423		+	Phospho	(ST) *** 4
UBAP2L	seq:	602	-	618		+	Phospho	(ST) * * ** 4 TOP2A	seq:	1239	-	1259		+	Phospho	(ST) ** 4
RBM7	seq:	134	-	143		+	Phospho	(ST) * ** 4 FASN	pS207 * * ** *** 4
SCRIB	pS1348 * *** * * 4 HSPD1	seq:	97	-	121		no	mod * *** * 4
RBMXL1	seq:	204	-	217		+	Phospho	(ST) *** 4 KPNA2	seq:	52	-	68		+	Phospho	(ST) * ** 4
CEP170	seq:	836	-	858		+	Phospho	(ST) ** 4 MYH9	pS1943 ** * * ** ** 4
PRRC2C	pT2673 * *** ** 4 RSL1D1	pS361 *** ** * 4
MTDH	pS568 * * * ** 4 HSPD1	seq:	97	-	121		no	mod * *** ** 4
ALDOA	seq:	29	-	43		+	Phospho	(ST) *** * ** * 4 FAM102B	pS228 *** *** *** ** *** *** *** 4
EEF1D	pS162 *** * * ** * 4 PPM1H	seq:	122	-	134		+	Phospho	(ST) ** 4
EEF1D	pS162 *** * ** * 4 KIAA1522	pS862 ** * *** * 4
FAM134C	seq:	433	-	464		+	Phospho	(ST) ** ** 4 HSP90B1	seq:	435	-	448		no	mod ** * *** 4
TCOF1	seq:	571	-	591		+	Phospho	(ST) ** * ** ** * 4 UBQLN4	seq:	88	-	136		+	Phospho	(ST) ** ** ** *** 4
TRIM28	seq:	592	-	629		+	Phospho	(ST) * ** *** 4 FLNB	pS2478 * ** 4
ANLN	pS182 *** *** *** 4 MYBBP1A	seq:	1156	-	1167		+	Phospho	(ST) *** * * * * * ** *** 4
GIGYF2	seq:	17	-	35		+	Phospho	(ST) * ** ** 4 CTTN	seq:	399	-	428		+	2	Phospho	(ST) ** * * * *** * * 4
ABCF1	seq:	103	-	121		+	Phospho	(ST) * * * * ** ** 4 BAIAP2	pT360 *** * ** * * *** 4
MAPK3	pY204 *** * * * 4 KPNA2	seq:	52	-	68		no	mod *** ** * *** ** 4
RBBP6	pS1179 ** ** * 4 SLTM	seq:	549	-	564		+	Phospho	(ST) * ** 4
NIPBL	seq:	290	-	308		+	Phospho	(ST) *** *** ** 4 CAMSAP3	pS368 * ** 4
AFAP1	seq:	661	-	672		+	Phospho	(ST) ** ** * *** ** *** 4 PPM1H	seq:	122	-	134		+	Phospho	(ST) * * ** * *** ** 4
SLC9A3R1	seq:	113	-	138		no	mod ** * *** ** 4 CLCC1	pS438 *** *** *** ** * *** ** * 4
COPB2	seq:	847	-	872		+	Phospho	(ST) *** 4 CDCA5	pS21 * ** 4
OCIAD1	pS108 ** ** * 4 AKT1S1	seq:	202	-	223		+	Phospho	(ST) ** 4
CCDC86	seq:	30	-	53		+	Phospho	(ST) ** * 4 LAD1	seq:	266	-	282		+	Phospho	(ST) *** ** ** 4
AHNAK	pS5731 * *** * ** ** ** 4 RAD23B	pS160 ** * 4
AHNAK	pS5731 *** * ** ** ** * 4 KRT8	seq:	19	-	32		+	2	Phospho	(ST) ** 4
FXR2	pS601 * * *** ** 4 EIF2A	seq:	503	-	520		+	Phospho	(ST) ** * *** *** * 4
ZBTB7A	seq:	330	-	354		+	Phospho	(ST) ** *** * 4 TMPO	pS424 ** * ** 4
AKAP11	pS422	pS433 * *** 4 EPB41L4A	seq:	309	-	316		+	Phospho	(ST) * * * ** ** *** *** 4
TP53BP1	pS552 *** ** *** *** ** *** 4 MARCKSL1	pS104 * * * ** ** *** *** 4
USP6NL	pS680 * *** ** * 4 RPS3	seq:	202	-	227		+	Phospho	(ST) *** * 4
EIF4B	pS406 ** * 4 MAPK8IP3	seq:	362	-	373		+	Phospho	(ST) * *** ** *** *** 4
CCNYL1	pS344 *** * ** 4 LARP1	pS90 * * ** 4



























































































GAPDH	seq:	235	-	248		no	mod * *** ** 4 ZFYVE19	seq:	338	-	366		+	Phospho	(ST) *** * 5
EPCAM	seq:	34	-	44		no	mod * ** ** 4 KRT8	seq:	187	-	198		no	mod *** ** 5
YWHAZ	seq:	140	-	157		no	mod *** 4 AHNAK	pS5110 *** * 5
PRRC2C	pS2105 ** 4 SRRM2	seq:	1129	-	1158		+	Oxidation	(M);	Phospho	(Y) ** 5
JPH1	pS216 ** ** * ** * 4 HSP90B1	seq:	76	-	84		no	mod ** * * 5
CTTN	seq:	399	-	428		+	Phospho	(ST) ** * 4 MCM2	seq:	34	-	79		+	2	Phospho	(ST) ** ** ** 5
DNAJC5	seq:	8	-	24		+	Phospho	(ST) ** ** 4 RECQL4	seq:	319	-	329		+	Phospho	(ST) *** 5
YY1	pS247 ** * 4 KRT18	seq:	270	-	301		no	mod ** * 5
YY1	seq:	231	-	258		+	Phospho	(Y) ** * 4 PTGES3	seq:	49	-	65		no	mod *** 5
NOP56	seq:	511	-	534		+	Phospho	(ST) * ** * * 4 SRRT	seq:	527	-	559		+	Phospho	(ST) * *** 5
SEPT9	pS30 ** *** ** * 4 ACTG1	seq:	255	-	284		no	mod ** 5
GRIP1	pS43 ** 4 MPRIP	seq:	540	-	559		+	Phospho	(ST) ** 5
SEC31A	pS1163 * ** *** 4 KRT18	seq:	51	-	90		+	Phospho	(ST) ** * 5
WDR44	seq:	342	-	360		+	Phospho	(ST) ** 4 ALDOA	seq:	154	-	173		no	mod ** 5
NT5C	pS182 ** * * ** 4 PKP2	seq:	147	-	171		+	2	Phospho	(ST) * ** * 5
MDC1	pS168 ** * ** 4 SRRT	seq:	527	-	559		+	Phospho	(ST) ** * 5
USP6NL	seq:	698	-	718		+	Phospho	(ST) * *** *** * ** * * 4 KRT18	seq:	51	-	90		+	Oxidation	(M);	Phospho	(ST) *** * 5
USP6NL	seq:	698	-	718		+	Phospho	(ST) ** * * 4 PURB	seq:	85	-	116		+	Phospho	(ST) ** ** * 5
ANLN	seq:	656	-	677		+	Phospho	(ST) *** 4 HSP90AB1	seq:	625	-	639		no	mod ** ** 5
PDS5B	pS1358 * ** 4 KRT18	seq:	51	-	90		+	2	Oxidation	(M);	Phospho	(ST) *** ** ** * 5
KRT18	pS399 *** * 4 NPM1	pS70 * * ** 5
SH3BP4	pS246 ** * *** * 4 AHNAK	seq:	5780	-	5814		+	Phospho	(ST) *** *** 5
MVD	pS96 ** ** * * ** 4 SAFB	seq:	173	-	216		+	Phospho	(ST) *** * ** *** *** *** 5
FAM102B	pS320 ** * 4 KRT8	seq:	226	-	252		no	mod *** ** *** * 5
GAPDH	seq:	67	-	84		no	mod *** ** * 4 KRT2	seq:	189	-	197		no	mod *** ** * 5
SSR1	pS268 * ** 4 TPD52	seq:	170	-	185		+	Phospho	(ST) ** * *** 5
PNN	seq:	374	-	397		+	Phospho	(ST) ** 4 KRT19	seq:	371	-	381		no	mod ** ** 5
SQSTM1	pS272 ** *** * 5 PFN1	seq:	76	-	89		no	mod ** 5
FUS	seq:	270	-	306		no	mod *** *** 5 MFAP1	pT267 *** *** ** * 5
GTF2I	seq:	671	-	702		+	Phospho	(ST) ** * *** * 5 TPD52	pS176 *** 5
MCM2	seq:	34	-	79		+	Phospho	(ST) *** * * 5 HSP90AA1	seq:	346	-	355		no	mod ** * * 5
FUS	seq:	275	-	306		no	mod * ** ** 5 HSP90AA1	seq:	346	-	355		no	mod ** 5
PPP6R3	pS617 * ** 5 ZCRB1	seq:	140	-	177		+	Phospho	(ST) ** * * 5
TUBA8	seq:	85	-	105		no	mod *** * * * 5 GPSM2	pS565 * *** * ** ** *** * *** 5
MAP4	pS280 *** ** * * 5 NPM1	pS70 ** * 5
G6PD	seq:	408	-	427		no	mod ** 5 CTNNB1	pS675 ** ** 5
TUBA8	seq:	85	-	105		no	mod *** * 5 GAPDH	seq:	163	-	186		no	mod * ** 5
PTPN13	seq:	906	-	919		+	Phospho	(ST) *** ** 5 KRT18	seq:	263	-	300		no	mod ** * ** 5
AKAP11	pS433 *** *** 5 GIT1	seq:	410	-	431		+	Phospho	(ST) * ** 5
AHNAK	seq:	204	-	225		+	Phospho	(ST) *** 5 NPM1	pS125 *** 5
ZNF687	pS1057 * * * * *** 5 PUM2	seq:	85	-	110		+	Phospho	(ST) ** ** 5
SRRM1	seq:	870	-	888		+	Phospho	(ST) *** 5 HSF1	seq:	297	-	336		+	2	Phospho	(ST) * ** * 5
REPIN1	seq:	19	-	33		+	Phospho	(ST) *** 5 FAM177A1	seq:	56	-	82		+	2	Phospho	(ST) ** ** * 5
TRIM28	pS501 ** * * 5 NCL	seq:	487	-	508		no	mod ** ** * 5
KRT74	seq:	380	-	392		no	mod ** 5 NPM1	seq:	55	-	80		+	Phospho	(Y) *** * ** * 5
NUMA1	seq:	1223	-	1239		+	Phospho	(ST) ** 5 GAPDH	seq:	272	-	309		no	mod ** *** ** 5
JPH1	seq:	157	-	190		+	2	Phospho	(ST) ** ** ** ** 5 GAB2	pS210 ** *** *** *** *** 6
SIPA1L1	pS255 ** ** 5 AARS	seq:	730	-	747		no	mod ** 6
TPT1	seq:	39	-	85		+	Phospho	(ST) ** * 5 SNRPD3	seq:	9	-	29		no	mod *** *** 6
GTF2I	pS823 *** * ** * * 5 PRPF4B	seq:	381	-	390		+	Phospho	(ST) ** ** *** *** *** 6
HMGB1	seq:	30	-	44		no	mod *** 5 AKT1S1	seq:	244	-	251		+	Phospho	(ST) *** ** *** *** *** *** *** ** 6
SHANK2	seq:	718	-	741		+	Phospho	(ST) *** ** * ** 5 CHAMP1	seq:	498	-	509		+	Phospho	(ST) * * ** ** 6
NONO	pT450 ** ** * 5 ZNF592	seq:	683	-	705		+	Phospho	(ST) * * ** * 6
DNAJC5	seq:	8	-	33		+	Phospho	(ST) *** ** 5 SYNPO2	pS902 ** *** *** *** *** ** 6
DNAJC5	seq:	8	-	33		+	Phospho	(Y) *** ** 5 RPL7A	seq:	197	-	217		no	mod *** 6
ALDOC	seq:	140	-	149		no	mod ** * * 5 SCD	seq:	2	-	26		no	mod ** ** 6
HNRNPU	seq:	463	-	484		no	mod ** 5 PKM	seq:	279	-	294		no	mod ** ** 6
TPD52L1	seq:	149	-	162		+	Phospho	(ST) *** 5 KRT8	seq:	226	-	252		+	Gln->pyro-Glu	(N-term	Q);	Oxidation	(M) ** 6
C2CD5	pS643 ** 5 INF2	seq:	322	-	340		no	mod ** ** 6
TUBA8	seq:	215	-	229		no	mod ** *** 5 RCC2	seq:	152	-	170		no	mod * ** * *** * 6
ASAP2	pS701 *** ** * * ** ** 5 ENO1	seq:	307	-	326		no	mod * ** ** 6
PLEKHA5	seq:	408	-	419		+	Phospho	(ST) *** * ** ** * 5 SLC9A3R1	seq:	59	-	78		no	mod ** ** * *** 6
KRT18	seq:	176	-	187		no	mod ** 5 SLC9A3R1	seq:	59	-	78		no	mod * * ** * *** 6
RRM2	seq:	6	-	41		+	Phospho	(ST) ** 5 HSP90AA2	seq:	154	-	173		no	mod ** 6
PRKCI	pT564 ** 5 HSP90AA1	seq:	465	-	483		no	mod *** * 6
MYH10	seq:	1944	-	1976		+	Phospho	(ST) *** *** 5 HSPD1	seq:	494	-	516		no	mod ** 6
HNRNPK	seq:	103	-	139		+	Phospho	(ST) ** ** * 5 HSP90AB1	seq:	457	-	475		no	mod * *** ** ** 6
SRPK1	pS51 *** * 5 ACKR3	seq:	343	-	362		+	Phospho	(ST) *** *** *** ** *** *** * *** 6
TSEN54	seq:	225	-	272		+	2	Phospho	(ST) *** * * 5 RBM14	seq:	616	-	625		+	Phospho	(ST) * ** * 6
KRT8	seq:	134	-	149		+	2	Oxidation	(M) ** ** * 5 NCL	seq:	17	-	52		+	2	Phospho	(ST) *** 6
SEC24C	seq:	320	-	340		no	mod *** 5 RPL6	seq:	227	-	246		no	mod ** ** 6
GTF2I	seq:	807	-	826		+	Phospho	(ST) ** * ** 5 ALDOA	seq:	260	-	289		no	mod ** * 6
CRTC2	seq:	64	-	96		+	Phospho	(ST) ** * 5 ATXN2	pS758 ** ** 6
GPSM2	seq:	481	-	498		+	Phospho	(ST) ** * 5 CCT6A	seq:	80	-	104		no	mod * ** 6
PPP6R3	pS617 *** ** 5 PPHLN1	seq:	203	-	216		+	Phospho	(ST) * ** *** * * ** 6
THRAP3	pS248 ** 5 CTSD	seq:	393	-	403		no	mod *** *** *** *** *** * 6
GREB1	seq:	1136	-	1164		+	Phospho	(ST) ** 5 ENO1	seq:	307	-	326		no	mod * ** 6
PPP6R3	pS617 *** * * 5 SEC16A	pS136 * ** 6
SEC24C	seq:	320	-	340		no	mod ** 5 GAPDH	seq:	87	-	107		no	mod ** * 6
MDC1	pS168 ** * * ** 5 ERCC5	pS341 * ** * 6
SSRP1	seq:	429	-	455		+	Phospho	(ST) *** *** 5 HNRNPA3	seq:	168	-	187		no	mod * * *** ** 6
NPM1	seq:	25	-	45		no	mod *** ** 5 HNRNPA1L2	seq:	147	-	166		no	mod * * *** ** 6
UTP3	seq:	18	-	55		+	Phospho	(Y) ** * * 5 HNRNPA3	seq:	168	-	187		no	mod * * * ** 6
SDAD1	pS585 ** 5 HNRNPA1L2	seq:	147	-	166		no	mod * * * ** 6
HNRNPA1	seq:	4	-	15		+	Phospho	(ST) * *** ** ** * ** * 5 KIF1A	pS1548 ** ** *** ** ** 6
ARHGEF16	pS107 ** ** * ** 5 CTSD	seq:	393	-	403		no	mod *** *** *** *** *** 6
KRT18	seq:	51	-	81		+	Oxidation	(M);	Phospho	(ST) ** * * ** 5 KRT8	seq:	226	-	252		+	Gln->pyro-Glu	(N-term	Q) ** 6
EIF4G1	seq:	1194	-	1205		+	Phospho	(ST) *** * * * * * 5 GAPDH	seq:	87	-	107		no	mod ** 6
SUGP1	seq:	475	-	501		+	Phospho	(ST) ** 5 HNRNPH2	seq:	151	-	167		no	mod * ** * 6
KRT18	seq:	51	-	81		+	Phospho	(ST) ** 5 TPT1	seq:	39	-	85		no	mod ** * 6
TTLL12	seq:	10	-	40		+	Phospho	(ST) ** * 5 PSMA5	seq:	169	-	187		no	mod * * ** ** * 6
MCM6	seq:	230	-	256		no	mod * *** 5 NUMA1	pT2000 ** * *** * 6
DYNC1LI2	pS194 *** * ** 5 YWHAB	seq:	141	-	160		no	mod * ** ** * * 6
EPS15L1	seq:	560	-	591		+	Phospho	(ST) ** ** ** ** 5 VGLL4	seq:	46	-	55		+	Phospho	(ST) ** * * 6
ZFP36L2	seq:	482	-	494		+	Phospho	(ST) *** 5 ATXN2	pS758 ** ** 6
ATRX	seq:	1517	-	1536		+	Phospho	(ST) *** * ** ** 5 PRRT3	seq:	880	-	909		+	Phospho	(ST) ** * *** *** * ** ** * 6
ING5	pS118 *** * 5 ZFAND3	seq:	117	-	135		+	Phospho	(ST) * ** 6
KIAA0101	pS72 ** 5 PA2G4	seq:	34	-	51		no	mod * ** * 6
NACA	pS166 *** ** * 5 AHNAK	seq:	103	-	123		no	mod * ** 6
HSPA2	seq:	303	-	314		no	mod ** 5 HSP90AB4P	seq:	156	-	171		no	mod ** * 6
NPM1	pS125 *** *** * 5 ZNF185	pS64 *** *** *** *** *** ** *** * 6
PURB	seq:	85	-	116		+	Phospho	(ST) ** ** * 5 CASKIN2	seq:	798	-	831		+	Phospho	(ST) * *** 6
NPM1	pS125 ** * * 5 HSPA9	seq:	369	-	391		no	mod ** * * * 6
RPS6KB1	pS447 ** * 5 HSP90AB4P	seq:	156	-	171		no	mod ** ** 6
NPM1	seq:	55	-	73		no	mod *** 5 PRRC2C	pS2105 * ** ** 6
AHNAK	seq:	5780	-	5814		+	Phospho	(ST) ** ** 5 CFL1	seq:	128	-	146		no	mod ** ** 6
RPIA	seq:	96	-	114		+	Phospho	(ST) *** 5 PRRT3	pS854 * * * *** ** 6
KDM1A	seq:	151	-	182		+	Phospho	(ST) *** 5 RANBP1	seq:	6	-	39		+	2	Phospho	(ST) ** ** 6
EPS15L1	seq:	560	-	591		+	Phospho	(Y) ** ** ** 5 IDH3A	seq:	147	-	169		no	mod * * ** * * 6
YTHDC1	seq:	415	-	437		+	Phospho	(ST) ** * 5 PPP1R8	seq:	197	-	221		+	Phospho	(ST) ** ** * ** * 6
HSP90AA1	seq:	633	-	647		no	mod ** 5 HSP90AB1	seq:	457	-	475		+	Oxidation	(M) * ** ** ** 6
PLEKHA5	seq:	53	-	72		+	Phospho	(ST) ** ** ** 5 RAB5C	seq:	143	-	166		no	mod ** 6
PKP2	seq:	80	-	101		+	Phospho	(ST) ** 5 HSPA5	seq:	307	-	324		no	mod * * *** * * 6
PRKRA	seq:	6	-	25		+	Phospho	(ST) ** * 5 KRT18	seq:	223	-	241		no	mod ** ** 6









ALB	seq:	500	- 508		no	mod ALB	seq:	500	- 508		no	mod
ALB	seq:	438	- 452		no	mod ALB	seq:	438	- 452		no	mod
ALB	seq:	258	- 264		no	mod ALB	seq:	258	- 264		no	mod
ALB	seq:	287	- 298		no	mod ALB	seq:	287	- 298		no	mod
ALB	seq:	162	- 168		no	mod ALB	seq:	162	- 168		no	mod
PRDX2	seq:	17	- 26		no	mod TP53	seq:	307	- 319		+	Phospho (ST)
PRDX6	pT44 SOD1	seq:	11	- 24		no	mod
PRDX6	seq:	42	- 53		no	mod SOD1	seq:	81	- 116		no	mod
PRDX3	seq:	84	- 91		no	mod S100A13	seq:	30	- 39		+	Phospho (ST)
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change Mutation type Sift_Score Sift_Prediction Poly_Score Poly_Prediction
1 113237484 G A MOV10 coding 529 G>D nonsyn 0 DAMAGING 1 PROBABLY DAMAGING
1 152328809 C G FLG2 coding 485 G>R nonsyn 0.07 TOLERATED 0 UNKNOWN
1 153909116 C A DENND4B coding 792 A>S *nonsyn 0.23 TOLERATED 0 BENIGN
1 185931672 G T HMCN1 coding 617 M>I nonsyn 0.18 TOLERATED 0 BENIGN
1 242511431 T A PLD5 coding 101 E>D nonsyn 0.41 TOLERATED 0.002 BENIGN
10 15008531 G C MEIG1 coding 22 E>Q nonsyn 0.01 DAMAGING 0.404 POSSIBLY DAMAGING
10 25273776 A T ENKUR coding 218 I>K nonsyn 0.4 TOLERATED 0.862 PROBABLY DAMAGING
11 6898572 G A OR10A4 coding 232 A>T nonsyn 0.28 TOLERATED 0.062 BENIGN
12 20787953 C T PDE3A coding 655 A>V nonsyn 0.34 TOLERATED 0 BENIGN
14 105517794 T G GPR132 coding 227 K>T nonsyn 0.47 TOLERATED 0.703 POSSIBLY DAMAGING
14 32561316 G T ARHGAP5 coding 481 E>* nonsyn:stop-gain na na na na
14 59961938 C A JKAMP coding 166 P>T nonsyn 0 DAMAGING 0.999 PROBABLY DAMAGING
14 74388787 G A ZNF410 coding 400 S>N nonsyn 0.01 DAMAGING 0.07 BENIGN
14 94528701 C A DDX24 coding 329 A>S nonsyn 0.76 TOLERATED 0.004 BENIGN
15 50303116 T G ATP8B4 intronic (splice_site) na na na na na
16 68156591 T C NFATC3 coding 269 S>P nonsyn 0 DAMAGING 0.996 PROBABLY DAMAGING
17 37884010 C T ERBB2 coding 1161 R>* nonsyn:stop-gain na na na na
17 7412449 C T POLR2A coding 1218 R>W nonsyn 0 DAMAGING 1 PROBABLY DAMAGING
19 56155962 C A ZNF581 coding 9 P>T nonsyn 0.38 TOLERATED 0.265 POSSIBLY DAMAGING
19 7975396 TG T MAP2K7 coding 211 V>Vframeshift:stop-gain na na na na
2 168114614 G A XIRP2 coding 553 E>K nonsyn 1 TOLERATED 0.003 BENIGN
2 179623854 G T TTN coding 3387 S>Y nonsyn 0.01 DAMAGING 0.998 PROBABLY DAMAGING
2 219204617 C A PNKD coding 116 F>L nonsyn 0.51 TOLERATED 0 BENIGN
20 29628233 A G FRG1B coding 84 M>V *nonsyn 0.64 TOLERATED 0.223 POSSIBLY DAMAGING
22 21991190 C A CCDC116 coding 558 P>H nonsyn 0.08 TOLERATED 0.553 POSSIBLY DAMAGING
22 32215016 G C DEPDC5 coding 559 E>Q nonsyn 0.44 TOLERATED 0.953 PROBABLY DAMAGING
3 118621782 G A IGSF11 coding 294 S>F nonsyn 0.05 DAMAGING 0.996 PROBABLY DAMAGING
3 180327887 T A TTC14 coding 624 S>T nonsyn 0.01 DAMAGING 0.993 PROBABLY DAMAGING
3 7188352 G T GRM7 coding 245 A>S nonsyn 0.77 TOLERATED 0.136 BENIGN
4 103682008 C A MANBA coding 15 G>V nonsyn 0.07 TOLERATED 0 UNKNOWN
4 20736354 A T KCNIP4 coding 145 F>Y nonsyn 0 DAMAGING 0.957 PROBABLY DAMAGING
4 56865526 A G CEP135 coding 690 K>E nonsyn 0.98 TOLERATED 0.92 PROBABLY DAMAGING
4 6052337 G A JAKMIP1 coding 626 L>F nonsyn 0.04 DAMAGING 0.889 PROBABLY DAMAGING
4 995878 G T IDUA coding 301 D>Y nonsyn 0.1 TOLERATED 1 PROBABLY DAMAGING
5 178392214 A G ZNF454 coding 270 K>R nonsyn 0.07 TOLERATED 0.63 POSSIBLY DAMAGING
5 78602211 C T JMY coding 632 A>V nonsyn 0.24 TOLERATED 0.953 PROBABLY DAMAGING
7 47945538 A T PKD1L1 coding 475 F>Y nonsyn 0.09 TOLERATED 0.203 POSSIBLY DAMAGING
8 109796491 G C TMEM74 coding 279 N>K nonsyn 0.01 DAMAGING 0.832 POSSIBLY DAMAGING
8 110497292 T A PKHD1L1 coding 3199 I>K nonsyn 0 DAMAGING 0.979 PROBABLY DAMAGING
8 22273343 AG A SLC39A14 coding 271 E>Eframeshift:stop-gain na na na na
8 65493351 G A BHLHE22 coding 2 E>K nonsyn 0.01 DAMAGING 0.953 PROBABLY DAMAGING
8 94767182 TG T TMEM67 coding 14 W>C frameshift:stop-gain na na na na
8 94767184 G T TMEM67 coding 14 W>C nonsyn 0.08 TOLERATED 0.33 POSSIBLY DAMAGING
9 123591456 C T PSMD5 coding 198 E>K nonsyn 0.4 TOLERATED 0.071 BENIGN
9 12702410 TACAA T TYRP1 coding 351 STN>STVframeshift:stop-gain na na na na
9 13188797 C A MPDZ coding 784 A>S nonsyn 0.19 TOLERATED 0.994 PROBABLY DAMAGING
9 139735084 C G RABL6 coding 409 C>W nonsyn 0 DAMAGING 0 UNKNOWN
9 8499826 G T PTPRD coding 715 P>T nonsyn 0.07 TOLERATED 1 PROBABLY DAMAGING
X 122551485 C T GRIA3 coding 578 P>L nonsyn 0 DAMAGING 0.955 PROBABLY DAMAGING




	 	 	 	
	











change Mutation type Sift_Score Sift_Prediction Poly_Score Poly_Prediction
1 114340234 G T RSBN1 coding 376 Y>* nonsyn:stop-gain na na na na
1 114340235 T G RSBN1 coding 376 Y>S nonsyn 0.04 DAMAGING 0.978 PROBABLY DAMAGING
1 16891340 T A NBPF1 coding 1046 R>S nonsyn na na na na
1 171121155 G T FMO6P coding 312 V>L nonsyn 0.5 TOLERATED 0.002 BENIGN
1 19513935 C A UBR4 coding 498 K>N nonsyn 0.25 TOLERATED 0.021 BENIGN
10 25273776 A T ENKUR coding 218 I>K nonsyn 0.4 TOLERATED 0.862 PROBABLY DAMAGING
11 34156760 G T NAT10 coding 650 M>I nonsyn 0.06 TOLERATED 0.003 BENIGN
11 4903392 G A OR51T1 coding 115 W>* nonsyn:stop-gain na na na na
12 108686583 G A CMKLR1 coding 53 L>F nonsyn 0.1 TOLERATED 0.983 PROBABLY DAMAGING
12 130855792 A G PIWIL1 coding 798 Y>C nonsyn 0.01 DAMAGING 0.977 PROBABLY DAMAGING
12 20787953 C T PDE3A coding 655 A>V nonsyn 0.34 TOLERATED 0 BENIGN
12 8281876 T G CLEC4A coding 72 Y>* nonsyn:stop-gain na na na na
14 105417602 G A AHNAK2 coding 1396 L>F nonsyn 0.23 TOLERATED 0.99 PROBABLY DAMAGING
14 105517794 T G GPR132 coding 227 K>T nonsyn 0.47 TOLERATED 0.703 POSSIBLY DAMAGING
14 38092061 G T TTC6 coding 264 W>C nonsyn na na na na
14 59961938 C A JKAMP coding 166 P>T nonsyn 0 DAMAGING 0.999 PROBABLY DAMAGING
14 74388787 G A ZNF410 coding 400 S>N nonsyn 0.01 DAMAGING 0.07 BENIGN
15 101605839 C T LRRK1 coding 1733 P>S nonsyn 0.07 TOLERATED 0.998 PROBABLY DAMAGING
15 51510816 T G CYP19A1 coding 222 D>A nonsyn 0.12 TOLERATED 0.911 PROBABLY DAMAGING
16 31447264 G A ZNF843 coding 303 P>S nonsyn 0 DAMAGING 0 UNKNOWN
16 67914641 C G EDC4 coding 760 A>G nonsyn 0.34 TOLERATED 0.001 BENIGN
16 68156591 T C NFATC3 coding 269 S>P nonsyn 0 DAMAGING 0.996 PROBABLY DAMAGING
16 84494366 G A ATP2C2 coding 843 A>T nonsyn 0.23 TOLERATED 0 BENIGN
16 88706241 C T IL17C coding 119 R>C nonsyn 0 DAMAGING 1 PROBABLY DAMAGING
17 37884010 C T ERBB2 coding 1161 R>* nonsyn:stop-gain na na na na
17 39881291 A C HAP1 coding 560 F>V nonsyn 0.02 DAMAGING 0 BENIGN
17 71197935 A C COG1 coding 657 T>P nonsyn 0.32 TOLERATED 0.046 BENIGN
19 19741303 T A GMIP coding 839 D>V nonsyn 0.17 TOLERATED 0.975 PROBABLY DAMAGING
19 45419479 T C APOC1 coding 31 S>P nonsyn 0.02 DAMAGING 0.956 PROBABLY DAMAGING
19 7975396 TG T MAP2K7 coding 211 V>V frameshift:stop-gain na na na na
2 152514561 T C NEB coding 2040 Y>C nonsyn 0.05 DAMAGING 0.999 PROBABLY DAMAGING
2 215839556 G C ABCA12 coding 1805 S>* nonsyn:stop-gain na na na na
2 50758554 T C NRXN1 coding 760 S>G nonsyn 0.09 TOLERATED 0.997 PROBABLY DAMAGING
2 55077223 G T EML6 coding 438 A>S nonsyn 0.59 TOLERATED 0.16 BENIGN
2 62449947 C A B3GNT2 coding 198 L>M nonsyn 0.03 DAMAGING 0.402 POSSIBLY DAMAGING
21 38525331 A G TTC3 coding 832 K>E *nonsyn 0 DAMAGING 0.965 PROBABLY DAMAGING
22 21991190 C A CCDC116 coding 558 P>H nonsyn 0.08 TOLERATED 0.553 POSSIBLY DAMAGING
3 10251344 A G IRAK2 coding 166 R>G nonsyn 0.51 TOLERATED 0.047 BENIGN
3 180327887 T A TTC14 coding 624 S>T nonsyn 0.01 DAMAGING 0.993 PROBABLY DAMAGING
3 62355885 G C FEZF2 coding 418 T>R nonsyn 0.2 TOLERATED 0.759 POSSIBLY DAMAGING
4 103682008 C A MANBA coding 15 G>V nonsyn 0.07 TOLERATED 0 UNKNOWN
4 20736354 A T KCNIP4 coding 145 F>Y nonsyn 0 DAMAGING 0.957 PROBABLY DAMAGING
4 56865526 A G CEP135 coding 690 K>E nonsyn 0.98 TOLERATED 0.92 PROBABLY DAMAGING
4 6052337 G A JAKMIP1 coding 626 L>F nonsyn 0.04 DAMAGING 0.889 PROBABLY DAMAGING
5 52097480 G T PELO coding 322 D>Y nonsyn 0.04 DAMAGING 0.284 POSSIBLY DAMAGING
5 78602211 C T JMY coding 632 A>V nonsyn 0.24 TOLERATED 0.953 PROBABLY DAMAGING
5 837524 C T ZDHHC11 coding 286 V>M nonsyn 0.17 TOLERATED 0.84 POSSIBLY DAMAGING
6 39513406 C A KIF6 coding 414 V>F nonsyn 0.4 TOLERATED 0.83 POSSIBLY DAMAGING
6 44224171 C T SLC35B2 coding 90 D>N nonsyn 0.34 TOLERATED 0.095 BENIGN
8 103845356 A G AZIN1 coding 278 S>P nonsyn 0.01 DAMAGING 0.992 PROBABLY DAMAGING
8 10465962 C A RP1L1 coding 1882 E>D nonsyn 0.37 TOLERATED 0 UNKNOWN
8 10465990 T C RP1L1 coding 1873 D>G nonsyn 0.41 TOLERATED 0 UNKNOWN
8 10466031 A C RP1L1 coding 1859 D>E nonsyn 1 TOLERATED 0 UNKNOWN
8 110497292 T A PKHD1L1 coding 3199 I>K nonsyn 0 DAMAGING 0.979 PROBABLY DAMAGING
8 94767182 TG T TMEM67 coding 14 W>C frameshift:stop-gain na na na na
8 94767184 G T TMEM67 coding 14 W>C nonsyn 0.08 TOLERATED 0.33 POSSIBLY DAMAGING
9 139735084 C G RABL6 coding 409 C>W nonsyn 0 DAMAGING 0 UNKNOWN
9 6014884 C A RANBP6 coding 242 D>Y nonsyn 0.01 DAMAGING 0.998 PROBABLY DAMAGING
9 8499826 G T PTPRD coding 715 P>T nonsyn 0.07 TOLERATED 1 PROBABLY DAMAGING
X 118108966 G T LONRF3 coding 75 D>Y nonsyn 0.07 TOLERATED 1 PROBABLY DAMAGING
X 119388178 C G ZBTB33 coding 303 P>R nonsyn 0.06 TOLERATED 0.001 BENIGN
X 131762534 C T HS6ST2 coding 552 R>Q nonsyn 0.29 TOLERATED 0.966 PROBABLY DAMAGING
X 131762535 G A HS6ST2 coding 552 R>* nonsyn:stop-gain na na na na
X 22132634 A T PHEX coding 411 E>V nonsyn 0 DAMAGING 0.818 POSSIBLY DAMAGING




	 	 	 	







change Mutation type Sif t_Score Sif t_PredictionPoly_Score Poly_Prediction
1 144220807 A C NBPF8 coding 3576 D>A nonsyn 0.54 TOLERATED 0.817 POSSIBLY DAMAGING
1 152083578 C A TCHH coding 705 Q>H nonsyn 0.3 TOLERATED 0 UNKNOWN
1 169541554 T G F5 coding 93 E>A nonsyn 0 DAMAGING 0.7 POSSIBLY DAMAGING
1 171511168 G T PRRC2C coding 1521 L>F nonsyn 0.17 TOLERATED 0 UNKNOWN
1 89449390 T C RBMXL1 coding 40 I>M nonsyn 1 TOLERATED 0 BENIGN
10 75276253 C A USP54 coding 1311 D>Y nonsyn 0 DAMAGING 0.998 PROBABLY DAMAGING
12 56221541 C A DNAJC14 coding 301 W>L nonsyn 0.03 DAMAGING 0.96 PROBABLY DAMAGING
14 106320630 C A IGHM coding 394 A>S nonsyn 0.2 TOLERATED 0.139 BENIGN
15 75763112 C T PTPN9 coding 423 R>Q nonsyn 0.54 TOLERATED 0.004 BENIGN
16 77242422 G A SYCE1L coding 81 R>K nonsyn 0.85 TOLERATED 0.217 POSSIBLY DAMAGING
16 78064626 G T CLEC3A coding 170 G>V nonsyn na na na na
17 39240627 T C KRTAP4-7 coding 57 S>P nonsyn 1 TOLERATED 0 UNKNOWN
17 62271174 G C TEX2 coding 641 Q>E nonsyn 0.72 TOLERATED 0 BENIGN
18 6264019 TG T L3MBTL4 coding 49 S>Q|K *nonsyn|f rameshif t:stop-gain na na na na
19 51535325 G C KLK12 coding 88 H>Q nonsyn 0.39 TOLERATED 0.061 BENIGN
3 121383364 T G GOLGB1 coding 3258 H>P nonsyn 0 DAMAGING 0.996 PROBABLY DAMAGING
5 74364388 G T ANKRD31 coding 1917 Q>K nonsyn 0.04 DAMAGING 0.066 BENIGN
6 111912772 C T TRAF3IP2 coding 182 G>D nonsyn 0.46 TOLERATED 0.013 BENIGN
6 155451057 C T TIAM2 coding 234 R>C nonsyn 0.1 TOLERATED 0.004 BENIGN
6 35087005 C A TCP11 coding 440 D>Y nonsyn 0.07 TOLERATED 0.988 PROBABLY DAMAGING









Appendix	 15.	 (A)	 Quantification	 of	 total	 area	 under	 the	 chromatographic	 peaks	 contained	 in	 72	
phosphoproteomics	MS	runs.	Two	samples	(15min_lactic_acid_5mM_B2_T2	and	30min_HCl_0.97mM_B2_T2)	
were	run	with	an	incorrect	method,	which	resulted	in	chromatograms	which	intensity	was	below	the	detection	
threshold.	 (B)	Number	of	MS	and	MS2	 scans	quantified	by	RawMeat.	 (C)	Number	of	 identified	peptide	 ions	
(FDR<0.05)	that	generate	the	database	created	from	the	72	MS	runs.	The	two	samples	that	did	not	contribute	







	 	 	 	
Appendix	16	
Summary	 of	 modulated	 phosphopeptides	 associated	 to	 structural	 constituents	 of	 cytoskeleton,	













































































































































MAP4	seq:	786	- 798		+	Phospho (ST) ** ** 2 GO:0005200;	F:structural	constituent	of	cytoskeleton;	GO:0005198;	F:structural	molecule	activity
TBC8B	seq:	487	- 493		no	mod * * * ** ** *** * 2 GO:0005200;	F:structural	constituent	of	cytoskeleton
LEO1	pS205 * 5 GO:0005200;	F:structural	constituent	of	cytoskeleton;	GO:0005198;	F:structural	molecule	activity
HSP90AA1	seq:	387	- 400		no	mod * * 5 GO:0005200;	F:structural	constituent	of	cytoskeleton;	GO:0005198;	F:structural	molecule	activity
ENO1	seq:	222	- 228		no	mod * 5 GO:0005200;	F:structural	constituent	of	cytoskeleton;	GO:0005198;	F:structural	molecule	activity
HNRNPC	pS260 * ** 5 GO:0005200;	F:structural	constituent	of	cytoskeleton
HNRNPK	seq:	397	- 405		no	mod * * 5 GO:0005200;	F:structural	constituent	of	cytoskeleton
HSPB1	seq:	80	- 89		no	mod ** * * 5 GO:0005200;	F:structural	constituent	of	cytoskeleton
BRAF	seq:	147	- 158		+	Phospho	(ST) * * 5 GO:0005198;	F:structural	molecule	activity
ACTBL2	seq:	41	- 51		no	mod ** * 5 GO:0005198;	F:structural	molecule	activity
ATP5A1	seq:	150	- 161		no	mod * ** * * * 5 GO:0005198;	F:structural	molecule	activity
STIP1	seq:	154	- 160		no	mod * ** * 5 GO:0005198;	F:structural	molecule	activity
RPLP0	seq:	17	- 26		no	mod * * * 5 GO:0005198;	F:structural	molecule	activity
PPP1R12A	seq:	414	- 424		+	Phospho	(ST) ** ** ** * * * 5 GO:0005198;	F:structural	molecule	activity
TPI1	seq:	71	- 90		no	mod * * * ** 5 GO:0005198;	F:structural	molecule	activity
INTS1	seq:	11	- 33		+	Phospho	(ST) * ** * * ** 5 GO:0005198;	F:structural	molecule	activity
PRDX2	seq:	111	- 119		no	mod * 5 GO:0005198;	F:structural	molecule	activity
EPPK1	seq:	2713	- 2732		+	Phospho (ST) * * ** * ** 5 GO:0005198;	F:structural	molecule	activity
PFN1	seq:	128	- 136		no	mod * * * 5 GO:0005198;	F:structural	molecule	activity
GRP75_HUMAN	seq:	647	- 653		no	mod * 5 GO:0005198;	F:structural	molecule	activity
RPS27	pS78 * * * * * * * ** 6 Arf6	trafficking	events
KRT19	pS46 * * *** 6 Arf6	trafficking	events
HNRNPA3	seq:	355	- 376		+	Phospho	(ST) * * ** * 6 GO:0032319;	P:regulation	of	Rho	GTPase activity
NIPBL	seq:	274	- 289		+	Phospho (ST) *** ** * * *** 6 GO:0032319;	P:regulation	of	Rho	GTPase activity
ARHGAP17	seq:	674	- 699		+	2	Phospho (ST) * ** * * ** * ** 6 GO:0032319;	P:regulation	of	Rho	GTPase	activity
HNRNPU	pS59 * * * ** * 6 GO:0032319;	P:regulation	of	Rho	GTPase activity
RB1	seq:	788	- 798		+	2	Phospho (ST) * * 6 GO:0032319;	P:regulation	of	Rho	GTPase activity
HSP90AB2P	seq:	172	- 188		+	Phospho (ST) * 6 GO:0032319;	P:regulation	of	Rho	GTPase activity
PCNP	pS119 * * * * 7 RAC1	signalling	pathway
HNRNPCL4	seq:	30	- 39		no	mod * * ** * 7 RAC1	signalilng pathway
Fold vs control (log2, n=4)
-5 -4 -3 -2 -1 0 1 2 3 4 5
-5 -4 -3 -2 -1 0 1 2 3 4 5


















(left	 panel)	 and	 histogram	 distribution	 of	 the	 correlation	 between	 the	 alignment	 of	 retention	 times	 of	 all	
experimental	 samples	 (right	 panel).	 (E)	 Box	 plots	 demonstrating	 the	 distribution	 of	 log2-transformed	
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ABRAL * * HSP74 * * ZO3 *
TFP11 * KRT38 ** * ** PTH2 *
SDC4 * 1433E * TKT ** **
ROCK2 * ADK * RLA0 *
IGS21 * ** PFD4 * * SSA27 *
KS6C1 * IDHP *** * PSMD1 **
TMC3 * * STPG1 * CY1 * **
SPAT5 * * H90B4 * * P5CR2 *
CNKR2 * DR4L2 * GDIA ** *
PINX1 * SC31A * * * ANM5 * **
CASP6 * ** SYIC * NP1L4 *
GLYR1 * STAU1 * FUCO ** **
AGRIN * * U2AF2 * WDR61 *
KT3K * CPSF7 * SHOT1 **
CHMP3 * SYAP1 * EI2BA ** **
K1324 * * RABP2 ** *** ANX11 **
IQEC3 ** MT1H ** DYLT1 *
TMED3 ** SCOT1 * DNJA1 *
SYMM * IF1AY * IF4G1 ** **
BOLA1 * TYB4 * ** HNRL1 *
LRRF1 * UGGG1 * NUCB1 * **
NDKB * * NPC2 * SUGP2 *
NIPS1 *** ** TBC8B * * EF1A3 *
IBP2 * ATPG * ** HSBP1 *
VDAC1 ** MA7D2 * KTN1 *
EFTS * * EWS * * SCRN1 ** ***
HS902 * * ** ** XRCC1 ** * DYN3 * *
ATPD * IGSF3 * * ABHDB *
GORS1 * CADH1 * CATB * * *
RS27 * UBA6 * * H1FOO * ** **
GMPR2 * DD19A ** TRA2B *
MTPN * ** ENPL * RPIA *
PCBP3 *** * DNPEP * * FRYL * *
PTBP2 * ** * GLU2B ** MOD5 * *
FA83H * RL30 * ARI3B ** *
GNAO * * G6PD * * Sep-02 *
CPSF5 * ACINU * * CSN5 **
DDTL * PNO1 ** STML2 *
DREB ** HN1L * ** * CLH2 *
PLST * GFPT2 * CKAP4 *
GBLP ** * TCPD ** PP4R2 * *
PRDX2 * *** MCM4 ** * PFKAP **
ADHX ** YBOX1 ** RASH * *
DLDH * RCN1 * SPTB2 *
ACLY * RADI * * NDUBA * * *
LITAF ** * RHG01 * PSMD6 * *
OTOAN * SFXN1 * H13 *
H90B2 * * * TCPW * ANXA2 ** *
RAN ** SRRM2 * ** * GANAB ** ** *
MTCH2 * ACHA9 ** SAFB2 * *
NDRG1 * FEN1 * TF65 *
SMD3 * * RTCB * CSK *
PLEC * * SMD1 ** * PTMS *
ARL3 * XRCC5 * * ENSA *
TCRG1 * FUMH * SYK * **
EEA1 * * CRK * * TFG **
ATLA3 * CATIN ** * ESPNL **
LYAR * SMCE1 * GATA3 * *
CHM2A * FA84B ** CAND1 * *
CPNE3 * * * DENR ** ** * EPCAM ** *
DDX1 * PPT1 * CHM4B * *
U5S1 * NASP ** * LIS1 ***
CNDP2 * DHSO ** FAH2B *
RUVB1 * CPNE1 ** AP1B1 **
LPPRC * ANXA4 * ** LYAG *
PSMD7 ** * K1C25 * * KYNU * *
RL18A ** GFPT1 * THIOM *
RAD21 ** TPM2 * DCNL1 ** ***
CASP5 * CENPE * UBP10 *
LTOR2 * DCTN3 ** * * SF3B3 * *
IMDH2 * ACTS *** * ICAL *
COR1C ** QCR2 * SF3B1 *
PRP4 * FA98B ** * PDLI5 *
ACTN4 * * NDUS6 ** CLIC5 *
ROA0 * * S30BP ** LRBA *
CDV3 * RLBP1 * * P5CR1 * *
GDIB ** * *** PUR9 * LAT1 **
UBA1 * PSMD2 * * * ALBU ** *
YBOX3 * * HEXB * CNN2 **
UBR7 * AIF1L * SND1 *
ACTN1 * * NIT2 * ** AKT1 * *
PP14B * SARNP * RAB6A * *
RL9 * F10A5 ** * ZW10 *
RS16 * CBS * * AT1A1 ** *
RL1D1 * TR150 * 3MG **
TATD1 ** AIMP2 * NUCKS * *
PSMD3 * * SATT ** * WEE2 *
TPR * DDX6 ** ZRAB2 * *
CLH1 * * TOM7 ** ** UBP2L *
Appendix	18	
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ARP19 * ** SYQ * TF3C1 *
EF2 ** PP1R7 * COPZ1 * **
ARAP2 ** RLA1 * ERLN2 ** *
HS90A * CALR ** * * GSHR *
MYH10 * BRK1 * ASPM *
PPP6 * SAFB1 * AGFG1 *
SQSTM * UCRI *** * SNX5 *
TCPH *** RAVR1 * GNAT3 *
DDX3Y * RMXL3 * H4 ***
GELS ** MYL3 * ANXA3 *
DPY30 * RL14 * SK2L2 * *
ACPM ** COPB * *** NC2B *
QCR6 * ERF3A ** ** CFA99 *
TPM3 * MYH9 * MAP11 *** *
HS90B * * GOGA2 *** GPDM *
ALDOC * EIF3B * ** UN45A *
SEPT_7 * DC1L1 * * PDLI7 **
SPB6 * MYL6 ** HBA *** ***
EIF3H ** ** * PSDE * * PLAK * *
TRAD1 * BICD2 * CLGN *
AL4A1 * * * TNPO1 * * KAD2 *** **
HINT2 * PAR6B * * PCBP2 *
NCOR2 * TMX1 * PSA1 *
CPNE6 * APLP2 ** UBP14 *
UGPA ** H2B1A * * KS6B1 *
EIF3C * * IPO5 * *** PAPS1 * *
LMA2L ** * * HXK2 * ** MPPA *
ENAH ** *** * BAZ2A * IST1 *
SKIV2 * PPIG * TSN *
NOP2 * PP2BB * ** * ELAV1 * **
GNS * USH2A * ** ANXA5 **
UBXN1 * TES ** DESM **
HPS3 * K1C23 * PP4C *
CPSF2 * PDS5A ** PPAC *
AT2A3 * * PARVA * MYO1B *
GMFG * GPD1L * EBP2 *
RRBP1 * *** TNPO2 * NUBP1 ***
RM39 ** S10A9 ** *** DX39B *
PPM1A ** GABP1 ** BZW1 *
MRP *** ** NDUA3 * * ANXA6 **
PRP16 * U119B * COPG1 ***
ATOX1 * * T2FA ** ARL8A *
KATL2 * ** OVCA2 * PPM1G *
TRPS1 ** * CP013 * ACBP *
TRIP6 * CARM1 ** LDHB *
NOG1 *** * * ** ATPK ** CTBL1 *
GMPPA * SSDH * ATPO *
ZN326 ** * VATA ** ** DHE4 **
FXR1 * CHM1B * * FLII **
NOP56 ** ARFP1 * CCS *
FAF2 * RP1BL * EF1G ***
ZCCHL ** ATP5H ** * GIPC2 *
DSRAD ** ** F162A * VPS35 **
IF2G * TRAK2 * RS15 *
UBP13 * TCF25 * * 2AAB **
SPCS2 ** ** PGM2 * PA24D *
NUP93 * CCD47 * DNPH1 *
EXOS5 * ** * K0100 * RS4Y2 *
PLRG1 * RAP1A * RBM39 *
GCDH * K22E * GSTM3 *
RBM23 * DCXR * * AK1A1 *
NAGAB * PPGB ** SCRIB * *
UFC1 * UBF1 * * H2A3 **
EXOC4 * * SAP30 * NLTP **
NP1L2 * PABP4 * * CSN4 *
NPY6R ** EIF3G * * PAP1L *
DICER * MTA2 * * ARC1B **
SETD3 * VA0D1 * RBBP4 * *
REQU ** * S12A2 * * OTUB1 *
ITSN2 ** RB * TIGAR *
DYN2 * * RALB * * PSA2 *
NUDC2 * * ARMT1 ** * TADBP ***
AMOT * * * ** SH3L3 * SYHC * *
SPT5H * ** EST4A * ** MCM6 *
CPNE9 *** ILF2 * HPLN1 ** *
CC122 * RL22 *** HNRL2 *
CIKS * ** * *** *** RBM42 ** * PCTL *
AKP8L * JKIP3 * * LAP2B *
PIAS4 * * SNUT1 * HSPB1 * *
NT5C * MOFA1 * IF5AL ** *
FABP5 * PMVK * HPBP1 * *
WDHD1 * DNJC9 * ANM1 *
ASHWN *** FAH2A * RS24 *
RT25 * AP2E * UBC9 *
IMA6 * SRPRB ** IPO4 *
BTBD9 *** ** VPS45 ** RL5 ** *
RL7L * PSB5 * P5CR3 ** *
CDK5 * RCOR1 * * 2AAA ** **
RM22 *** SAHH *** IDH3G **
RBP10 * RB11A * PDCD6 * *
KAP1 * OAT ** PRPS2 *
DDX4 *** * GALK1 ** RL10A * * *
NUP88 * *** CHSP1 * * CAN1 * * *** *
AT2A2 * *** PTPA * PROF1 *
SGSM2 * PPM1H * PP2AA **
NU133 *** *** KAP2 ** RL18 *
R51A1 *** SSU72 * MYH14 *
CWC15 * GLGB * MARE1 *
IF2M *** *** BIEA * IF4A1 *** *
APC1 *** SF3B4 * DPP3 **
PRIPO * ERCC8 * AATC *
MYCPP * *** TWF1 * PP1G *
RTP4 * LTOR5 * ** PP2BC **
NUP50 * SYMC * RASN *
MABP1 * * DBLOH *** RM41 *
PXDNL *** * CUTA * PRDX6 **
DCNL5 * * THTR * VATB2 *
ANFY1 * FPPS * * TRAP1 *
SYNE2 ** ** PRS4 * ARK72 *
MGST1 ** DD19B * METK1 *
PLCD * UB2D3 ** RCC2 *
H32 *** TBA1A ** AIP * *
G3ST4 *** ISCA2 * ** HMCS1 **
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ATP5L * PREP *
BCL9L * SEPT_9 **
VPS25 * AL7A1 *
RFC2 * ** ** UBE2N * **
F161B * SF3B2 **
H2A2B *** *** * PRRC1 * *
RABX5 * * IMB1 *
SIR5 * COMT *
PYRG2 * IF4H *
SMC3 * RL11 * *
EIF3L * GRPE1 *
PKHF1 ** * MOES *
RIR2B * ** SFPQ *
CYLC2 ** *** ** PGAM1 **
RAB13 * ** SPRY4 *
ASC *** * LGI4 ** **
PCKGM ** HMGB2 *
ARPC4 * LMNB2 **
ESRP1 * * HS71B *
FWCH2 * TCPZ *
PP6R3 * HSP7C *
H2BFS * PARK7 *
COR1B * ACADV *
NSMA3 * PPIA *
RBM19 ** *** MAOX ** *
SYSC ** * CTNB1 *
ACTN2 * SPTN5 *
PFD2 * DYHC1 **
ARF4 * DNJA2 **
MVD1 * * RL10 ** *
GCN1L * * * SIAS *
KIF5C * BCAM **
AAMP * H1X * *
SNAA * ABCF1 *
RS30 * PRS10 *
K2C6B * * COPB2 **
CT027 ** K1C17 *
BPNT1 * * KAD4 *
CSRP1 * ARP2 *
DDAH1 ** PRS7 ***
FKBP4 * * SYWC ** *
RMD1 ** EIF3A *
ACTN3 *** RCC1 *
PUR6 * ROAA *
DECR * * NU214 *
OTOG * BAP18 ** *
K1C15 ** *** * NCBP2 *
AMPL * TMTC3 **
MROH8 * * PCNA *
SBDS * C1TC *
RS4Y1 * ** * NOMO1 *
HEAT6 * *** WDR1 *
PP1B * CHTOP ** **
SRS10 * SYNC *
ITPK1 ** AP2B1 *
H2AJ ** PSB4 *
CALU * * SAE2 *
SNW1 * LKHA4 *
SUCA ** TRXR1 *
ITPA * H1T **
RABP1 * * RL24 *
DPYL2 ** COPA *
VPS29 * * KGUA *
DDX3X * SAHH2 *
BTF3 * DDAH2 **
PSA7L * GLSK ***
PFKAL * MP2K2 * *
AHSA1 * HIKES *
FKB1A * NU155 *
CAP1 ** AP3B1 *
AP2A2 *
Fold over control (Log2, n=4)
-1.5 -1 -0.5 0 0.5 1 1.5
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